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Appendix
A bstr a c t
The cDNA encoding the proenzyme of cathepsin C from the parasitic helminth 
Schistosoma mansoni was amplified from a cDNA library using 5’ and 3’ specific 
primers containing sites for SnaBI and Avrll digestion. The full-length cathepsin C 
cDNA was cloned into the Pichia pastoris expression vector, pPIC9K, in frame with 
the initiation codon of the yeast a-factor signal sequence. Sequencing of the 1.3 kb 
cDNA-vector construct revealed a 94.5% identity to the S. mansoni cathepsin C 
sequence in the public database at amino acid level.
A smaller fragment was also amplified from the library and was cloned into the 
pGEM vector and sequenced to characterise its identity. This fragment proved to be 
a truncated version of the cathepsin C cDNA.
Prior to transformation of P. pastoris strain GS115, the pPIC9K-cathepsin C 
construct was linearised with Bglll. Transformants were selected on the basis of 
resistance to the antibiotic G418. PCR revealed that the cathepsin C cDNA had been 
successfully integrated into the yeast genome of transformants.
Protein expression was induced by addition of methanol to a final concentration of
1.0-1.5%, once or twice daily for six days. Recombinant protein was detected by 
SDS-PAGE. Proteins of 58, 55, 47 and 25 kDa were produced but a western blot and 
ELISA did not detect the presence of the hexahistidine tag fused to the COOH 
terminus of the recombinant enzyme. Protease assays were performed to determine 
if the enzyme was active against the fluorogenic cathepsin C substrate H-Gly-Arg- 
NHMec. Activity proved low in all instances relative to positive controls.
Biochemical characterisation of Fasciola hepatica cathepsin C was undertaken. The 
enzyme was demonstrated to exhibit similar properties to its S. mansoni counterpart 
such as enhancement of activity by the reducing agent DTT and halide ions. A peak 
of activity was seen at pH 5.5 but also at pH 8.5, which proved to be unique to F  
hepatica cathepsin C.
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A b b r e v ia t io n s
Amp Ampicillin
A0X1 Alcohol Oxidase Promoter
Asp Asparagine
cDNA Complementary DNA
Cys Cysteine
DMF Dimethylformamide
DPPI Dipeptidyl peptidase I
DTT Dithiothreitol
EDTA Ethylene Diamine Tetra Acetic Acid
E-64 Trans-epoxysuccinyl-L-leucylamide
(4-guanidinol)-butane 
FhCC Fasciola hepatica cathepsin C
GAP Glyceraldehyde-3-Phosphate Dehydrogenase
GRAS Generally Regarded As Safe
GST Glutathione-S-Transferase
Hb Haemoglobin
HBsAg Hepatitis B Surface Antigen
H-Gly-Arg-NHMec H-Glycine-Arginine-NHMec
His Histidine
Hr Hour(s)
IL Interleukin
IPTG Isopropyl beta-D-thiogalactopyranoside
kb Kilobase
kDa Kilodalton
LB Luria-Bertani Medium
mA Milliamps
Min Minute(s)
Mut+ Methanol Utilisation Plus
Muts Methanol Utilisation Slow
Mw Molecular Weight
NEM N-ethyl-malelimide
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NHMec (AMC) 7-amino-4-methyl-coumarin
Ni-NTA Nickel Nitrilo Acetic Acid
OD Optical Density
PAGE Polyacrylamide Gel Electrophoresis
PBS Phosphate Buffered Saline
PCR Polymerase Chain Reaction
PEG Polyethylene Glycol
Pmy Paramyosin
PMSF Phenylmethylsulfonylfluorid
rSmCC Recombinant Schistosoma mansoni cathepsin C
RBCs Red Blood Cells
RT Room Temperature
Sec Second(s)
SDS Sodium Dodecyl Sulfate
SjCC Schistosoma japonicum  cathepsin C
Sj pmy Schistosoma japonicum  paramyosin
SmCB Schistosoma mansoni cathepsin B
SmCC Schistosoma mansoni cathepsin C
SmCLl Schistosoma mansoni cathepsin LI
SmCL2 Schistosoma mansoni cathepsin L2
Sm28 GST Schistosoma mansoni Glutathione-S-Transferase
WHO World Health Organisation
X-Gal 5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside 
Z-Phe-Arg-NHMec H-Phenylalanine-Arginine-NHMec
Z-Phe-Ala-NH2 Z-Phenylalanine-Alanine-NH2
Z-Phe-Phe-OH Z-Phenylalanine-Phenylalanine-OH
V Volts
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• • Introduction
1 :  I n t r o d u c t i o n
1.1: P a r a sit e s
Parasitism is defined as an intimate and obligatory relationship between two 
organisms during which the parasite, usually the smaller of the two partners, is 
metabolically dependent on the host (Cheng et ah, 1986). Parasitism is 
described as being “the most common life style on Earth” and parasites by far 
outnumber the free-living species (Windsor, 1998). Parasitism is a way of life 
that transcends all phylogenetic boundaries. Parasites are considered 
ubiquitous among all plant and animal groups and it has been estimated that at 
least 50% of all plant and animals are parasitic at some stage during their life 
cycles (Bush et ah, 2001). The World Health Organisation (WHO) has stated 
that of the six major unconquered human diseases, five of them, namely 
filariasis, leishmaniasis, malaria, schistosomiasis and African trypanosomiasis 
are parasitic in the traditional sense. At least 500 million people on Earth - one 
living person in ten - is afflicted by one or more of the eight major tropical 
diseases in which parasites are implicated (Godal, 1996).
Typically parasites can be endoparasites that reside within their hosts, in the gut, 
body cavity, lungs or other tissues. Endoparasites nearly always live a 
completely parasitic existence. Conversely, ectoparasites are organisms such as 
fleas, lice and ticks, which live outside their hosts usually attached to skin, 
feathers or hair. They can never attain a completely parasitic existence as they 
utilise oxygen from outside the host (Smyth, 1976). A parasite that has an 
absolute dependence on the host during some or all of its life cycle is referred 
to as an obligatory parasite. Alternatively a parasite can be a facultative 
parasite, which does not solely depend on the parasitic way of life but can adapt 
to it if placed in such a relationship (Smyth, 1976; Cheng, 1986). A parasite 
can have many different types of host during its life cycle. A host in which a
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parasite produces progeny by sexual means is referred to as the definitive host. 
An intermediate host is needed by the parasite to complete its life cycle and the 
parasite will undergo physiological and morphological change in this host. 
However, despite the fact that asexual reproduction may occur in the 
intermediate host, sexual reproduction will not occur within this host 
(Fernandez and Esch, 2001).
Parasitic infections can be classified into two groups, those that are caused by 
protozoa and those attributed to the presence of helminths. Three hundred and 
forty-two helminth parasite species have been detected in humans (Bush et al., 
2001). Helminths infections result in morbidity as opposed to mortality with 
disease severity related to worm burden (Maizels et al., 1993). The phylum 
Platyhelminthes is a large and diverse group. The class Trematoda (flukes) to 
which the genus Schistosoma belongs, also referred to as digeneans or digenetic 
trematodes, generally possess a complex life cycle. Most flukes are 
hermaphrodites, the schistosomes being the exception. Those that infect man 
are found typically in the bile ducts, lungs, intestine and blood depending on 
the species (Seaton, 1979).
1 .1 .1 :  P a r a s i t e  V a c c i n e s
To date no vaccines against any eukaryotic parasite of man are available 
although several highly effective vaccines against parasites of veterinary 
importance exist (Vercruysse et al., 2001). Vaccines to protect against human 
parasitic infections are not yet available for a number of reasons. The use of 
attenuated organisms, which where viral infections are concerned have proven 
to be the most successful approach, is not feasible for parasites owing to the 
impracticability of culturing large numbers of parasites (Ada, 1993). Parasites 
cannot be cultured in vitro as easily as prokaryotic organisms can. Most of the 
successful veterinary vaccines currently available contain live parasites whose 
virulence has been attenuated by irradiation, in vitro culture or in vivo passage.
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They are difficult to produce, have a short shelf life and must be kept 
refrigerated, which makes large-scale application difficult to install (Vercruysse 
et al., 2001). By virtue of the fact that parasites possess a multi-stage life cycle 
producing distinct antigens at each stage, in order for a vaccine to be effective 
it would have to evoke protection against more than one infectious stage. Many 
parasites are capable of manipulating immune responses to their favour 
(Mulcahy et al., 1999) and possess an efficient means for evading host immune 
responses. Some of the ways in which this is accomplished include:
• Molecular mimicry: The possession of endogenously produced host-like 
or host acquired molecules, which confers “self’ status upon the parasite.
• Genetic complexity: Parasites have larger genomes than their eukaryotic 
counterparts and this is expressed in the variety of complex methods by 
which parasitic organisms are able to avoid or subvert the host’s immune 
defences (Vercruysse et al., 2001).
• Antigenic variation: Stage specific antigen presentation. For example, 
the tegumental membrane is periodically sloughed off in schistosomes 
and so too are any bound immunoglobulins.
• Innate lack of immunogenicity of relevant epitopes.
• Subversion of immune responses e.g., by cleaving bound 
immunoglobulins (Newport and Colley, 1993).
In the case of any infectious disease, if it can be demonstrated that immunity to 
reinfection occurs after a natural infection then hope exists that a suitable 
vaccine can be developed. Schistosomes can live in humans for up to thirty 
years (Bush et al., 2001) and establish a long-term relationship with their host. 
Chronic parasitic infections, in which the immune responses are incapable of
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effecting long lasting immunity to continuing infection or re-infection are the 
norm rather than the exception in parasitic diseases (Vercruysse et al., 2001). 
Protective immunity may occur only after many years or decades of exposure to 
the parasite (Maziels et al., 1993). Irrefutable evidence exists which shows that 
people living in endemic areas do develop various degrees of immunological 
protection against re-infection (Hagan et al., 2000). The nature of immunity in 
humans is thought to involve an IgE production mediated mechanism which 
could prove problematic since a vaccine designed to promote IgE production 
could elicit undesirable side-effects such as exacerbation of allergy (Wilson and 
Coulson, 1998). In the case of some helminth infections “concomitant 
immunity” may occur where an initial infection is not eliminated but becomes 
established and the host then acquires resistance to invasion by new worms of 
the same species (Bradley, 2001). Another obstacle to the successful 
development of a parasite vaccine is the fact that animal models of disease do 
not correlate with human diseases. Cell mediated immunity involves helper T 
cells, which are phenotypically divided into Thl and Th2 subsets that differ in 
the cytokines they produce. An over simplification is that Thl responses 
mediate in the killing of intracellular parasites and that Th2 responses eliminate 
extracellular ones. Thl and Th2 subsets have contrasting and cross-regulating 
cytokine profiles (Bradley, 2001). It is generally accepted for example that in 
humans, primates and rats protective immunity to schistosomes is associated 
with Th2 responses involving the production of interleukin (IL) 4, 5, IgE and 
eosinophils. In murine schistosomiasis immunity is associated with a Thl 
response involving IL 2 and 12 and interferon-gamma (IFN-y). However, 
different responses have been observed within the same host species, which is 
indicative of the complex interaction between the parasite and the host (Capron,
2001). It has been argued that the Th2 subset (IgE) has evolved to help combat 
helminth infections. Therefore, perhaps helminths have evolved mechanisms 
that allow them to counteract Th2 responses (Maizels et al., 1993).
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Aided by recombinant DNA technology, many novel parasite proteins have 
been and will continue to be isolated and cloned and this will undoubtedly 
contribute enormously to the pool of information that already exists about these 
parasites. It is only as a result of much research into the basic cell biology and 
immunology of parasites that advances can be made in attaining the goal of 
producing an efficacious parasite vaccine.
1.2: Sc h ist o so m ia sis
Schistosomiasis (bilharzia) is one of the world’s most prevalent parasitic 
infections and has significant economic and public health consequences. It is 
caused by digenetic blood trematodes that belong to the family 
Schistosomatidae (Smyth, 1976). First identified in 1851 by Theodor Bilharz to 
be the cause of African schistosomiasis, schistosomiasis is considered to be an 
ancient disease of man (Jordan, 2000; Ross, 2002). Old papyrus records from 
Egypt depict the incidence of the disease around 2,000 B.C. and calcified 
schistosome ova from two mummies dating from 1,250-1,000 B.C have also 
been discovered. Around 600 million people are at risk in 74 countries 
particularly in urban areas, refugee camps and where water resources are being 
developed (Godal, 1996; Ross, 2002). It is estimated that 200 million people 
are infected, 120 million are symptomatic and 20 million have severe disease 
(Chitsulo, 2000).
1 .2 .1 :  C a u s a t i v e  S p e c i e s  a n d  G e o g r a p h i c a l  l o c a t i o n
The major forms of human schistosomiasis are attributable to five species of 
blood fluke:
Schistosoma mansoni: Causes intestinal schistosomiasis in 53 countries in 
Africa, the East Mediterranean, the Caribbean and South America.
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Schistosoma iaponicum : (including Schistosoma mekongi in the Mekongi river 
basin) causes oriental or Asiatic intestinal schistosomiasis. This species is 
endemic in seven countries in South East Asia and in the Western Pacific region.
Schistosoma intercalatum : Also causes intestinal schistosomiasis and has been 
linked to ten central African countries.
Schistosoma haem atobium : Gives rise to urinary schistosomiasis endemic in 54 
countries in Africa and the Eastern M editerranean.
(Adapted from WHO fact sheet)
Figure 1: Geographical Distribution of S. mansoni
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Figure 2: Geographical Distribution of S. japonicum  
1.2.2: S c h i s t o s o m e  l i f e  c y c l e
An alternation o f generations occurs during the schistosome life cycle, with 
asexual reproduction taking place in a susceptible freshwater snail host and 
sexual reproduction occurring in a warm blooded vertebrate (Newport and 
Colley, 1993).
• All schistosoma infections occur as a result o f direct contact with fresh 
water that harbours free-living larval forms o f the parasite known as 
cercaria (Ross, 2002).
• A muscular tail mediates locomotion of cercaria. When a suitable host is 
contacted the cercaria penetrates the skin and looses its tail. It is thought 
that cercariae possess a number o f external sensory structures which 
regulate a number o f tropisms that attracts them to areas where the 
definitive host is likely to be located (Newport and Colley, 1993).
• Cercariae, now called schistosomulae, reach the venous circulation either 
directly or via the lymph vessels. In the venous system schistosomulae
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are carried to the lungs within 4 days and reach their highest 
concentration at 7-9 days.
• By the 15th day the schistosomules can be found in the liver where they 
feed on portal blood and undergo rapid growth (Smyth, 1976; Cheng, 
1986).
Liver and intestine
Urinary bladder
Migration'
I M aturation in liver 
ij? > circulationCercaria wïhout tail during „„¡e 
penetration of skin
Cercaria in water
INTERÆDIATE HOSTS
.. (Snails) Schistosoma
haematobium
Biompkataria *p .
(’ Sp°i°cyst
Miracidium
LIFE CYCLE of SCHISTOSOMA spp.
A d a p ted  a n d  redraw n from  NCDC
Ba linns sp.
Figure 3: Schistosome life cycle
• Depending on the species, the worms then migrate to the superior 
mesenteric veins (S. mansoni), the inferior mesenteric and superior 
haemorrhoidal veins (S. japonicum ) or the vesical plexus and veins 
draining the ureters (S. haematobium). Egg production commences 4-6 
weeks after infection and will continue for the life o f the worm which is 
usually 3-5 years although some worms can live for up to 30 years (Bush
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et al., 2001; Ross, 2002). The mature female will lay between 200-300 
eggs per day depending on the species (Newport and Colley, 1993). 
Fertilisation will occur when spermatozoa from the male are introduced 
into the female. The male is broader than the female and its body is 
curved to form a groove, called the gynecophoral canal, in which the 
female is snugly held (Cheng, 1986).
• Eggs will pass from the lumen of the blood vessels into adjacent tissues. 
Many will exit the body through the intestinal or bladder mucosa and are 
shed in the faces (S. mansoni and S. japonicum) or urine (S. 
haematobium) (Ross, 2002).
• The eggs will hatch upon contact with water releasing free-living ciliated
miracidia. Successful miracidia penetrate the soft tissues of the 
intermediate snail host. S. mansoni will infect Biomphalaria species, S. 
japonicum  infects Oncomelania species and S. haematobium infects 
Bulinus species of freshwater snails. Inside the host asexual
reproduction will occur resulting in the generation of mother sporocysts, 
which in turn give rise to several generations of daughter sporocysts 
(Cheng, 1986; Newport and Colley, 1993; Ross, 2002).
Daughter sporocysts will eventually produce large numbers of cercaria which 
will exit the snail and the cycle will be repeated when the cercaria come into 
contact with the skin of a suitable human host (Cheng, 1986).
1 .2 .3 :  DISEASE SYMPTOMS AND PATHOLOGY
Schistosomiasis brings about intermittent morbidity and chronic infections, 
which may be potentially fatal. After initial skin penetration by cercaria, 
“swimmer’s itch” a characteristic rash or dermatitis develops. This condition is 
also attributable to skin penetration by cercaria of blood flukes that usually
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infect only avian species. The cercaría will be eliminated by the human host’s 
immune system in a matter of days (Seaton, 1979; Bush et al., 2001).
The onset of early schistosomiasis is characterised by an explosive rise in 
temperature known as katayama fever. The most common manifestations are 
fever, chills, weakness, weight loss, headache, nausea, vomiting, diarrhoea, 
hepatomegaly, splenomegaly and marked eosinophilia (Lambertucci, 2000). 
However, in some cases the acute phase of infection may prove to be 
asymptomatic. Chronic schistosomiasis results from the immune response of 
the host to schistosome eggs and the granulomatous reaction evoked by the 
antigens they secrete (Ross, 2002). As a direct result of frequent re-infection 
repeated penetration of the intestinal and bladder walls results in extensive scar 
formation which prevents migration of the eggs through these structures. 
Because of this many eggs will be transported to the liver and occasionally to 
other sites such as the brain and spinal cord (Cheng, 1986). Wherever the eggs 
become lodged local inflammation, fibrosis and necrosis will occur. 
Hepatosplenic schistosomiasis is the most usual manifestation of chronic 
disease, which is characterised by enlargement of the liver and spleen 
(Lambertucci, 2000). As the disease progresses the liver recedes and becomes 
contracted and cirrhotic but the spleen will continue to enlarge, resulting in a 
bloated abdomen. If eggs become lodged in the blood vessels congestive heart 
failure and aneurysms may result (Smyth, 1976).
1 .2 .4 :  T r e a t m e n t
Due to the fact that no effective schistosomiasis vaccine is available, to date the 
most significant step towards control has been the availability of a safe and 
efficacious drug, praziquantel. Discovered in the mid 1970’s praziquantel’s 
precise mode of action on adult worms is unknown although it is believed to 
cause tetanic contractions and tegumental vacuoles causing the worm to detach 
from the wall of the vein and die (Ross, 2002). Praziquantel is active against
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all five schistosome species that can infect humans. Another drug, artemeter, 
commonly used in the treatment of malaria has also been shown to possess anti- 
schistosomal properties by acting on the juvenile stages of the parasite. It has 
been reported that combined therapy using high doses of both praziquantel and 
artemeter showed very high worm reduction rates of 90% and above (Utzinger,
2001). From 1976-1979 the Brazilian government implemented an ambitious 
programme of schistosomiasis control known as PECE (Special Programme for 
Schistosomiasis Control), which recommended the use of integrated control 
measures such as education, construction of sanitary facilities and mass 
chemotherapy. Mass chemotherapy prevailed as the most successful control 
strategy. The morbidity of schistosomiasis decreased since the wide spread use 
of chemotherapy and a decrease of 47% in mortality rate between 1977-1994 
was observed (Lambertucci, 2000).
Evidence is now emerging of resistance to praziquantel. There are already reports of 
low efficacy of the drug in Egypt and Senegal (Wilson and Coulson, 1998). Similarly 
in regions of Kenya where there has been heavy exposure to praziquantel there are 
reports of S. mansoni and S. haematobium infections that are not responsive to multiple 
courses of treatment (Ismail et al., 1999; William et al., 2001), Another drug, 
oxamniquine has also proved efficacious in the treatment of schistosomiasis, but as is 
the case for artemeter, its limited availability means that there is essentially only one 
drug widely available for the treatment of schistosomiasis. Therefore resistance to 
praziquantel would have serious implications for schistosomiasis control (Hagan et al., 
2000). Rapid re-infection often follows chemotherapy and drug delivery itself requires 
a substantial infrastructure to cover all parts of an endemic area regularly (Capron, 
1998). Another problem with chemotherapy as a control measure is that in a minority 
of individuals with a high worm burden, transition to severe and irreversible pathology 
is usually diagnosed at too late a stage for chemotherapy to affect the outcome (Wilson 
and Coulson, 1998).
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By virtue of the fact that chemotherapy only provides a short-term solution to the 
problems posed by schistosomiasis it is vital to explore all other avenues in attempts to 
find a suitable means of controlling the disease such as vaccination. A vaccination 
programme would be cheaper in the long term and would produce less strain on services 
than drugs, which have to be constantly re-distributed in endemic areas (Hagan et al., 
2000). However developing a schistosomiasis vaccine is by no means a simple task. 
Efforts are hindered by the long-term relationship helminths establish with their hosts. 
Mature schistosomes inhabit the bloodstream, potentially the most hostile environment 
in the body yet they are long lived parasites primarily due to their highly evolved 
evasion mechanisms (refer to 1.1.1). To date at least 100 different schistosome antigens 
have been partially or fully characterised. Among the antigens selected on the basis of 
their immunogenicity, a significant proportion are muscle proteins or enzymes (Capron, 
1998).
1 .2 .5 :  P o t e n t i a l  S c h i s t o s o m i a s i s  V a c c i n e  C a n d i d a t e s
Progress in identifying and synthesising potential immunogens by recombinant 
DNA technology together with advances in immunology and cell biology have 
prompted a feeling of optimism among parasitologists that effective vaccines 
for parasites of medical and clinical importance, including schistosomiasis are 
within reach. With regards to schistosomiasis, in the mid 1990’s six vaccine 
candidate molecules were selected by the WHO Special Programme for 
Research and Training in Tropical Diseases (WHO/TDR) for independent 
testing. These were:
• 28 kDa glutathione S-transferase
• 97 kDa paramyosin
• 62 kDa Irv-5, an irradiated larva associated vaccine derived from a 200 kDa 
molecule with extensive sequence homology with human myosin.
• 28 kDa triose phosphate isomerase
• 23 kDa integral membrane antigen
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• 14 kDa fatty acid binding protein
Two of the most promising of the above candidates have proven to be 
glutathione S-transferase and paramyosin (Doenhoff, 1998; Bergquist, 2002).
Glutathione-S-Transferases (GSTs) are multi-functional enzymes that play an important 
role in the detoxification of xenobiotics and function as intracellular binding proteins 
(Scott and McManus, 2000). In parasitic helminths it has been proposed that GSTs help 
protect the parasites from host immune attack and could play a key role in the passive 
detoxification of antihelminthic compounds and hematin, the end product of 
haemoglobin digestion by blood flukes (Howell et al, 1988; Brophy and Barrett, 1990). 
Early reports of a significant level of protection of rats and mice immunised with an S. 
mansoni antigen of molecular mass 28 kDa against a natural challenge infection with 
live cercaria stimulated much in depth study of this antigen, later shown to be a GST 
(Balloul 1987 a and b). In the case of Sm28 GST a reduction in worm burden of 38% 
was observed in baboons on receiving three vaccinations of rSm28 GST. When two 
vaccinations with Sm28 GST in aluminium hydroxide and Bordtella pertussis were 
administered, female schistosoma fecundity was reduced by 33% with a more 
pronounced effect (66%) on faecal egg output (Boulanger, 1991). Protection was 
attributed to specific IgA antibody responses to rSm28 GST which lead to impaired 
schistosome fecundity by limiting both the egg laying of mature worms and the 
hatching capacity of schistosome eggs into viable miracidia (Grzych et al., 1993). 
Phase I clinical trials in normal human volunteers in endemic areas have been 
undertaken on a S. haematobium GST called Bilhvax (Capron, 1998; Hagan et al, 
2000; Ross, 2002). The vaccine was deemed safe and proved to be an excellent 
immunogen (Hagan et al., 2000). S. haematobium was the species of choice for this 
trial because it has been proven that resistance to S. haematobium is associated strongly 
with immune mediated inhibition of fecundity. Secondly, the methods of qualitative 
evaluation of eggs in urine are reliable and easier to handle than stool examination and, 
finally, disease progression in urinary schistosomiasis can be easily followed by non-
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invasive methods such as bladder and urinary tract ultrasound tomography (Capron,
1998).
Paramyosin is a 97 kDa myofibrillar protein located in the muscle layers and 
tegument of schistosomes (Ramirez et a l,  1996). Immunisation of mice with 
native paramyosin from S. mansoni or a partial recombinant fragment of 
paramyosin with Bacille Calmette Guerin (BCG) reduced worm burden by 39% 
and 26% respectively (Pearse et a l, 1988). Also, it has been shown that mice 
immunised with paramyosin without adjuvant were protected by 24-53% against 
cercarial challenge (Flanigan et a l., 1989). A murine monoclonal IgE antibody 
that recognised S. japonicum  paramyosin (Sj pmy) was shown to confer 19-58% 
protection against S. japonicum  cercarial challenge following passive transfer 
into mice (Kojima et al., 1987). This prompted further evaluation of Sj pmy as 
a vaccine candidate. Unlike the African schistosomes, of which humans are the 
sole definitive hosts, Asian schistosomes can also infect buffaloes, cattle, dogs, 
pigs and sheep, which poses an additional problem for the implementation of 
control measures (Kalinna et al., 1997; McManus et al., 2002). However, a 
unique control opportunity exists, by immunising reservoir farm animals, in 
particular the water buffalo, a known culprit in the transmission of Asian 
schistosomiasis. Subsequently, it was illustrated by the use of a bacterially 
expressed Sjpmy that high levels of specific anti-pmy IgG antibodies, 
significant reduction in worm burden and liver eggs could be obtained 
(McManus et al., 2002). Limitations to the widespread use of rSj pmy are costs 
of scale-up and the fact that the low expression levels of bacterially produced Sj 
pmy make large-scale trials impossible. Nevertheless, solutions to these 
problems are under investigation and if these obstacles can be surmounted then 
it is feasible that a rSj pmy vaccine could control Asian schistosomiasis.
Nucleic acid vaccines have been tested as potential vaccine candidates in the 
fight against schistosomiasis. A nucleic acid vaccine has been used to induce 
protective immune responses to S. mansoni integral membrane protein Sm23
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(Da’dara et al., 2002). Sm23 is a member of the “tetraspanin” family of 
proteins, which possess four hydrophobic trans membrane domains. It is 
expressed in all stages of the schistosome life cycle. In a recent trial, on 
cercarial challenge of mice immunised with a plasmid carrying cDNA for Sm23, 
a 21-44% reduction in worm burden was observed (Da’dara et al., 2002). 
Another study employing a cocktail DNA vaccine comprising four plasmids 
encoding four different S. japonicum antigens, namely Sj62, Sj28, Sj23 and 
Sj 14-3-3 showed significant resistance (34-45%) against S. japonicum cercarial 
challenge infection (Zhang, 2002). A DNA vaccine containing the cDNA 
coding for S. mansoni legumain, asparaginyl endopeptidase (Sm32) cloned in a 
mammalian expression vector under the control of the CMV promoter/enhancer 
was shown to have an anti-fecundity effect on immunisation of mice. Female 
worms of a challenge infection produced 37% less eggs than those grown in 
naïve or non-vaccinated mice (Chlichlia, 2002).
Vaccines derived from radiation attenuated cercaria have to date been the most 
effective of all schistosomiasis vaccine candidates tested. In rodents and mice 
vaccination with radiation attenuated cercaria resulted in a 50-80% reduction in 
challenge worm burden (Coulson, 1997). In a small scale study using non­
human primates (chimpanzees), the protective effect of vaccination with 
radiation attenuated S. mansoni cercaria was manifested as an amelioration of 
acute disease and overall morbidity and a 38% reduction in faecal egg output 
upon challenge infection (Eberl, 2001). Radiation attenuated cercarial vaccines 
could form the basis for the development of a recombinant vaccine if the 
relevant immune mechanisms and protective antigens were known.
The aforementioned schistosomiasis vaccine candidates together with the 
haemoglobin degrading proteinases, also potential vaccine candidates (refer to 
1.2.6), illustrate the concentration of international effort that has been invested 
into the development of a vaccine against schistosomiasis. Given the 
encouraging results, along with advances in immunology and parasitology, the
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prospect of a future schistosomiasis vaccine appears to be both feasible and 
attainable (Wilson and Coulson, 1998; Ross, 2002).
1 .2 .6 :  D i g e s t i o n  o f  H a e m o g l o b i n  b y  S c h i s t o s o m e s
Developing and mature schistosomes are obligate blood feeders. It has been 
estimated that male and female S. mansoni ingest 39,000 and 330,000 red blood 
cells (RBCs) per hour respectively (Dalton et al., 1995). The host haemoglobin 
(Hb) is degraded into usable amino acids by a number of proteases present in 
the alimentary tract of the worm and is used by the parasite for its growth, 
development and reproduction. Evidence for this comes from the discovery of 
haematin, a dark pigment from the end product of Hb digestion in the digestive 
tract of adult worms (Brindley et al., 1997).
• In the oesophagus of the schistosome, ingested RBCs are lysed by the 
action of haemolysin.
• Hb released from the RBCs flows into the caecum and gastrodermis of 
the schistosomes where it is degraded further by endopeptidases such as 
cathepsin B, cathepsin LI and cathepsin D, which cleave the protein into 
polypeptides.
• Next, these polypeptides are acted on by exopeptidases such as cathepsin
C, which break them into dipeptides or free amino acids that are 
metabolised by the gastrodermal cells.
• Haematin, the end product of Hb digestion will be regurgitated by the 
parasite and will accumulate in the liver of infected hosts.
(Brindley et al., 1997)
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Figure 4: The digestion of haemoglobin by schistosomes (taken from Tort et 
at., 1999)
S c h is t o s o m e  l e g u m a i n  a ls o  p l a y s  a n  i n d i r e c t  r o l e  i n  t h e  d i g e s t i o n  p r o c e s s .  I t  is  
t h o u g h t  t h a t  i t  m a y  p l a y  a  r o l e  i n  t h e  a c t i v a t i o n  o f  t h e  p r o t e o l y t i c  e n z y m e s  
p i v o t a l  t o  t h e  d i g e s t i o n  o f  H b  s u c h  a s  c a t h e p s i n  C ,  D a n d  L .
I t  is  b e l i e v e d  t h a t  i m m u n e  r e s p o n s e s  d i r e c t e d  a g a i n s t  a n y  o f  t h e s e  d i g e s t i v e  
e n z y m e s  c o u l d  b l o c k  t h e  d i g e s t i v e  p r o c e s s  t o  t h e  d e t r i m e n t  o f  t h e  p a r a s i t e  t h u s  
p r o v i d i n g  a n  e f f e c t i v e  v a c c i n e  a g a i n s t  s c h i s t o s o m ia s is .  S u c h  a  v a c c i n e  c o u l d  
s u c c e e d  w h e r e  o t h e r s  h a v e  f a i l e d  b e c a u s e  i t  w o u l d  b e  t a r g e t i n g  o n e  o f  t h e  m o s t ,  
i f  n o t  t h e  m o s t ,  v i t a l  p r o c e s s  i n  t h e  l i f e  c y c l e  o f  t h e  p a r a s i t e .  B y  p r e v e n t i n g  t h e  
f l u k e  f r o m  f e e d i n g ,  i t s  l i f e  s u p p o r t  w i l l  e f f e c t i v e l y  b e  c u t  o f f  a n d  i t  w i l l  d i e  
b e f o r e  e g g s  c a n  b e  p r o d u c e d  a n d  b e f o r e  i t  c a n  c a u s e  a n y  d a m a g e  t o  t h e  h o s t .
20
1.3: P a r a s i t e  P r o t e i n a s e s
Proteolytic enzymes or proteinases are enzymes that catalyse the cleavage of 
peptide bonds in other proteins (Neurath, 1984). It is accepted that proteolytic 
enzymes have their origins very early in evolution as they are required by all 
organisms even the most primitive for digestion and metabolism of their own 
proteins. Although proteinases of all the four major groups of peptidases: 
serine, aspartic, cysteine and metalloproteinases, have been characterised in 
parasitic helminths, by far the largest number reported to date belong to the 
papain superfamily of cysteine proteinases (Tort et al., 1999).
1 .3 .1 :  C y s t e i n e  P r o t e i n a s e s
Cysteine proteinases are widely distributed among living organisms. Cysteine 
proteinases play numerous indispensable roles in the biology of parasitic 
organisms. Thought to play a key role in parasite immunoevasion, 
excystment/encystment, digestion, exsheating and cell and tissue evasion, 
proteinases comprise approximately 2% of all expressed genes with little 
variance between organisms (Sajid and McKerrow, 2002). Cysteine proteinases 
may be subdivided into groups on the basis of their primary structure. The two 
major superfamilies have diverged from different ancestral genes: the papain 
superfamily consisting of papain, cathepsin B, C, H, L and calpain, and the 
superfamily that includes viral cysteine proteinases (Ishidoh et al., 1991). The 
majority of cysteine proteinases belong to the papain family (clan CA, family 
Cl). The papain superfamily consists of papain and related plant proteinases 
such as chymopapain, caricain, bromelain, cruzipain and related parasite 
proteases and of lysosomal cathepsins (Turk et al., 2000). The papain like 
proteases consists of 2 domains, the L- (left) and R- (right) domains. The 
central helix of about 30 residues in length is the most prominent feature of the 
L-domain whereas the fold of the R-domain is based on the P-barrel motif. The 
two-domain interface opens on top to form a “V” shaped active site cleft. The
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two active site residues Cys 25 and His 159 are located in the middle of the 
cleft, Cys being positioned at the N-terminus of the central helix from the L- 
domain and His 159 as part of the R-domain (3-barrel structure (Sajid and 
McKerrow, 2002).
Mode of Action
The mechanisms by which cysteine proteinases hydrolyse peptide bonds are as 
follows (Sajid and McKerrow, 2002):
• Prior to hydrolysis of a peptide bond, the proteinase binds the protein or 
peptide substrate in its active site.
• An essential cystidine Cys 25 is found at the active site. The thiol group 
is enhanced as a nucleophile because of its close proximity to the active 
site histidine, which acts as a proton donor/general base. Sequences that 
directly flank the active site cystidine and histidine are highly conserved 
to maintain catalytic register.
• The sulfhydryl (SH) of the cystidine side chain and the imidazole of 
histidine give rise to a thiolate-imidazolium charge relay diad. This is 
stabilised by a highly conserved asparagine residue.
• A highly conserved glutamine forms the oxyanion hole, which is crucial 
to the formation of an electrophilic centre to stabilise the tetrahedral 
intermediate during hydrolysis.
The evolutionary history of proteinase families may be regarded as the 
evolution from a single, general-purpose ancestral proteinase to multiple, 
increasingly specific paralogous enzymes through the process of repeated gene
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duplications. This process has resulted in at least 12 paralogous cysteine 
proteinases and possibly many more (Neurath, 1984; Berti and Storer, 1995).
1 .3 .2 :  L y s o s o m a l  C y s t e i n e  P r o t e i n a s e s
Lysosomal cysteine proteinases, also known as cathepsins were discovered in 
the first half of the 20th century. There are 11 human cathepsins (B, C, F, H, K, 
L, O, S, V, W, X) (Sajid and McKerrow, 2002). Cathepsin C (dipeptidyl 
peptidase I) was the first pure lysosomal cathepsin to be isolated in the 1940’s 
(Gutman and Fruiton, 1948). It wasn’t until the 1970’s that more cathepsins (B, 
H and L) were isolated and the first amino acid sequences of mammalian 
cathepsins did not appear until the 1980’s when the sequences of rat cathepsin 
C and H were published (Barrett et al., 1998). The principal function of the 
lysosomal proteases is considered to be the non-selective degradation of 
proteins inside lysosomes. Occasionally, cathepsins have been found outside 
the lysosomes, most often resulting in a pathological condition (Turk et al., 
2000). Lysosomal cysteine proteinases are optimally active at a slightly acidic 
pH. Inactivation at neutral pH is common to all lysosomal cysteine proteinases 
an exception being cathepsin S. The enzymes are monomers of ~ 30 kDa with 
the exception of cathepsin C which is a tetramer of 200 kDa (Turk et al., 2001 
and 2002). Catalysis can be initiated either within a polypeptide chain 
(endopeptidases) or from amino or carboxyl ends (exopeptidase). All 
cathepsins are initially synthesised as inactive zymogens or preproenzymes 
consisting of a pro-region, which may serve as an intramolecular chaperone to 
assist in protein folding and as an endogenous inhibitor to regulate protease 
activity. Additionally a leader or signal sequence composed of 15-22 
hydrophobic amino terminal sequences will target the protease to its 
intracellular compartment or will act as a secretion signal (Sajid and McKerrow,
2002).
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1.3.2.1: C a t h e p s in  C , Dip e p t id y l  P e p t id a s e  I (D PP I)
In humans cathepsin C (DPP I) serves a vital role in the activation of a number 
of granule serine proteases such as granzyme A and B exclusively expressed in 
the granules of activated cytotoxic lymphocytes (Pham and Ley, 1999), in cell- 
mediated apoptosis, inflammation and connective tissue remodelling (Olsen et 
al., 2001). It has been suggested that cathepsin C may be essential for 
establishing and maintaining the structural organisation of the epidermis of the 
extremities and the integrity of the tissue surrounding the teeth and may 
participate directly in the processing of proteins such as keratins (Nuckolls and 
Slavkin, 1999). Recently a mutation in the cathepsin C gene was shown to be 
implicated in Papillon-Lefevre syndrome, an autosomal recessive disorder that 
manifests as severe peridontitis and palmoplantar keratosis. Peridontitis leads 
to premature tooth loss whereas keratosis affects the knees and elbows (Toomes 
et al., 1999; Hart et al., 2000). Spleen and kidney provide the richest sources 
of cathepsin C in humans. Serum levels of cathepsin C were highest in hepatic 
diseases, peripheral arterial disease, thromboembolism, myocardial infarction, 
diabetes mellitus and prostatic hypertrophy (Dolenc et al., 1995). Cathepsin C 
has also been suggested to play a role in chronic airway diseases such as asthma 
(Turk et al., 2001).
Cathepsin C functions in the removal of dipeptides from the amino terminus of 
peptide and protein substrates and is active in the pH range of 3.5-8,0. It is an 
exopeptidase with broad specificity. Only peptides with a basic residue at the 
N-terminus, a blocked amino group at the N-terminus, or a proline on either 
side of the scissile bond are not hydrolysed (Paris et al., 1995; Lauritzen et al., 
1998 and Cigic and Pain, 1999). The enzyme’s requirement for halide ions and 
sulfhydryl reagents such as dithiothreitol (DTT) is well known. Cathepsin C is 
inhibited by rat stefin A and chicken cystatin, two inhibitors of cysteine 
proteinases from the cystatin family and also by general cysteine protease 
inhibitors such as leupeptin and NEM (Dolenc et al., 1995).
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Cathepsin C is unusual in that it has a very long pro-peptide of ~ 200 amino 
acids due to extension at the N-terminus. A large part of this pro-region, called 
the residual propart remains attached in the mature enzyme, which is unique to 
cathepsin C (Cigic and Pain, 1999; Horn et al., 2002). The N-terminal portion 
of the propeptide bears no sequence similarity to any of the other cysteine 
proteases. However, the C-terminal portion of the propeptide is homologous 
with propeptides of other cysteine proteases (Hola-Jamriska et al., 1998),
Cathepsin C is the only member of the papain superfamily to exist as a tetramer 
of four identical subunits. During activation the structure of cathepsin C 
undergoes a series of transformations, from the monomeric form of the 
preproenzyme via a dimeric form of proenzyme to the tetrameric form of the 
mature enzyme (Muno et al., 1993). Each subunit or monomer consists of an 
N-terminal fragment, a heavy chain and a light chain. The N-terminal fragment 
also called the residual pro-part or exclusion domain is suggested to be 
involved in the formation of the tetramer (Dolenc et al., 1995; Turk et al., 
1995; Cigic et al., 2000; Dahl et al., 2001). The C terminal part of the 
propeptide functions as the activation peptide and is liberated from the enzyme 
during maturation (Dahl et al., 2001). Procathepsin C is not capable of 
autoactivation despite the fact that many members of the papain superfamily 
such as cathepsin B and papain possess this quality. The dimeric cathepsin C 
precursor, which can be activated 2000 fold with papain can also be activated 
by cathepsin L and S (Dahl et al., 2001).
The cDNA sequences encoding bovine, canine, human, murine, rat and 
schistosome cathepsin Cs have been determined (Ishidoh et al., 1991; Butler et 
al., 1995; Paris et al., 1995; McGuire et al., 1997; Hola-Jamriska et al., 1998; 
Wolters et al., 1998; Frye et al., 2000). From the deduced sequence of all 
cathepsin Cs, a distinct tyrosine is found adjacent to the active site cysteine. 
This tyrosine motif appears to be unique to the papain superfamily in which 
tryptophan usually occupies the position adjacent to the active site residue. The
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conservation of this tyrosine motif among all cathepsin Cs suggests that it plays 
a role in the determination of substrate specificity (McGuire et al., 1997). 
Phylogenetic analysis of cathepsin C sequences has also revealed that the 
closest evolutionary relation to cathepsin C is cathepsin B (Berti and Storer, 
1995; Tort et al., 1999).
1 .3 .3 :  PROTEASES OF SCHISTOSOMES
Cysteine proteases such as cathepsins B, C, D and L and asparaginyl 
endopeptidases (legumain) are all implicated in the digestion of haemoglobin 
by schistosomes (refer to Section 1.2.6). The main proteases involved in this 
process will be discussed briefly:
1 .3 .3 .1 : C a t h e p s in  B
Cathepsin B belongs to the papain superfamily of cysteine proteases and is 
localised in the lysosome. Cathepsin B is synthesised as a preproenzyme of 340 
amino acids with the processed mature enzyme containing 250 residues 
(Brindley et al., 1997). It has a molecular mass of 31 kDa, which is larger than 
its predicted molecular mass of 28 kDa due to N-linked glycosylation of the 
mature form (Tort et al., 1999). S. mansoni cathepsin B (SmCB) was revealed 
to be 70% similar to mammalian cathepsin B (Klinkert et al., 1989). SmCB, 
expressed in an insect system was demonstrated to be able to hydrolyse the 
cathepsin B specific substrate Z-Arg-Arg-NHMec (Gotz and Klinkert, 1993). 
Recombinant S. mansoni procathepsin B has also been expressed in 
Saccharomyeces cerevisiae (Lipps et al., 1996). The enzyme could not be 
activated in vitro, which suggests that autoprocessing does not occur but 
implies that another enzyme could be responsible for activation. This theory 
was confirmed when it was shown that porcine pepsin could activate 
recombinant SmCB. However, in our laboratory Pichia pastoris expressed
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cathepsin B was shown to autoactivate at low pH (Cunneen, M, unpublished 
data).
1.3.3.2: C a t h e p s i n  C
S. mansoni cathepsin C (SmCC), which is the focus of this thesis, shares many 
of the characteristics of mammalian cathepsin C referred to in Section 1.3.2. 
Butler et al., 1995, first reported the cDNA sequence of SmCC. The deduced 
amino acid sequence of preprocathepsin C is 454 amino acids in length, which 
comprises a signal peptide of 24 amino acids, a long propeptide of 193 amino 
acids and a mature enzyme of 237 residues (Brindley et al., 1997). Using the 
cathepsin C specific substrate H-Gly-Arg-NHMec, cathepsin C from 
schistosome extracts was observed to have a pH optimum of 5.5 (Hola-Jamriska 
et al., 1999). The cDNA sequence of S. japonicum  cathepsin C (SjCC) was 
reported by Hola-Jamriska et al. 1999. The preproenzyme shared only 59% 
identity with SmCC, which suggested that they were discrete enzymes rather 
than species homologues. Phylogenetic analysis using the mature enzyme 
sequence illustrated the common ancestry shared by cathepsin C and B. The 
proenzyme of SjCC was expressed in a baculovirus expression system. The 
purified recombinant enzyme resolved in reducing SDS-PAGE gels as three 
forms of 55, 39 and 38 kDa all of which were reactive with antiserum raised 
against bacterially expressed SjCC (Hola-Jamriska et al., 2000).
1.3.3.3: C a t h e p s i n  L
Two cathepsin L proteinases are expressed and secreted by adult schistosomes, 
cathepsin LI and cathepsin L2. Analysis of the primary structure revealed that 
both enzymes are only 44% similar and cathepsin L2 showed more identity 
(52%) with human cathepsin L than with schistosome cathepsin L (Dalton et al., 
1996). Differences in their active sites, propeptide region and potential 
glycosylation sites would indicate that each enzyme has a separate function.
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When the dominant protease activity in soluble extracts and ES products of Sm 
and Sj was examined, cathepsin L was seen to be the dominant proteases at pH
4.0-6.0 (Brindley et ah, 1997). The specific activity for cathepsin L substrates 
was observed to be 60 fold greater than that for cathepsin B specific substrates 
(Dalton et ah, 1995). S. mansoni cathepsin LI (SmCLl) full-length transcript 
encodes a preprocathepsin LI of 319 amino acid residues inclusive of a signal 
peptide. After processing the mature enzyme is 215 amino acids with an 
apparent molecular mass of ~24 kDa. SmCL2 preprocathepsin consists of 330 
amino acids including a signal peptide of 18 residues, a propeptide of 97 and a 
mature enzyme of 215 amino acids. Active site labelling and immunoblotting 
revealed SmCL2 to have a molecular mass of 31 kDa (Brindley et ah, 1997).
1 .3 .3 .4 :  S c h i s t o s o m e  L e g u m a i n
Asparaginyl endoproteinases (Sm32 in S. mansoni) or legumains are members 
of a family of proteinases characterised predominately from legumes (Dalton et 
ah, 1995). These enzymes cleave peptide bonds on the carboxyl side of Asn 
residues except where the Asn occurs at the N-terminus or at the second 
position from the N-terminus of the polypeptide or where the Asn is 
glycosylated (Brindley, 1997). Legumains function in the post-translational 
modifications of storage proteins in legume seeds by cleaving asparaginyl 
peptide bonds between propeptides and mature proteins. As in plant legumains, 
schistosome legumain may process other proteins (Dalton and Brindley, 1996). 
The mRNA of S. mansoni legumain encodes a 50 kDa single chain protein of 
429 amino acids, The S. mansoni and S. japonicum  legumains are 73% 
identical and are 30-40% identical to plant legumains (Brindley et al., 1997). A 
second gene was shown to encode an active legumain as prior to this only 
inactive legumain had been identified that had the Cys 197 replaced by an 
asparagine residue. Isolation and sequencing of a number of clones derived 
from Sm mRNA identified a second gene for Sm32 with the active site Cys 
present. This was expressed in P. pastoris and autocatalysis was shown to
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occur at acid pH which resulted in the production of mature, active Sm32 
accompanied by the removal of the C-terminal extension and possibly of the N- 
terminal pro domain (Caffrey et al., 2000).
1.3.3.5: CATHEPSIN D
Aspartic protease or cathepsin D, an integral endopeptidase in schistosomes is optimally 
active at pH 3.0-4.0. It has been suggested that aspartic protease plays a more crucial, 
perhaps even the principal role in the process of haemoglobin (Hb) digestion by 
schistosomes than cysteine proteases (Brindley et al., 1997). It cleaves Hb into 
numerous tripeptides, tetrapeptides and other fragments. Schistosome cathepsin D 
expressed in insect cells was demonstrated to autoactivate at pH 3.6 to a -40 kDa form 
that cleaved the substrates o-aminobenzoyl-Ile-Glu-Phe-nitro-Phe-Arg-LeuNH2 and Hb 
(Brindley et al., 2001). S. mansoni preprocathepsin D consists of a signal peptide of 14 
residues, a propeptide of 37 amino acids and a mature enzyme of 377 amino acids with 
a predicted molecular mass of 41 kDa. Schistosome cathepsin D is expressed in the 
gastrodermal cells of adults and activity is blocked in the presence of pepstatin, a 
general inhibitor of aspartic proteases (Tort et al., 1999). It has been suggested that 
schistosomes express at least two forms of cathepsin D like aspartic proteases, one form 
with a COOH extension and another without this extension (Wong et al., 1997). In a 
recent study, mice were vaccinated with recombinant Sj cathepsin D aspartic protease 
expressed in both insect cells and bacteria in order to evaluate vaccine efficacy. 
Although vaccination did not reduce fecundity mean total worm burdens were 
significantly reduced in vaccinates by 21-38%. High levels of antibodies, 
predominantly IgGl, IgG2 and IgG2b were present in vaccinates but no correlation was 
seen between antibody levels and protective efficacy (Verity et al., 2001).
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1 .4 : H e t e r o l o g o u s  P r o t e in  P r o d u c t io n
Over the past few decades’ scientists have learned how to manipulate DNA to 
identify, excise, move and place genes into a myriad of organisms that are 
genetically quite different to the original organism from which the gene was 
taken. Due to these biotechnological advances it is not surprising that hundreds 
of recombinant proteins have been produced to date in a wide variety of 
expression systems. Heterologous protein expression refers to the expression of 
recombinant proteins in cells where they do not naturally occur (Walsh and 
Headon, 1994).
Four steps are employed in the production of a recombinant protein (Cereghino 
and Cregg, 1999):
1) The DNA sequence coding for the protein of interest is cloned into a 
vector (e.g., a plasmid) containing a promoter and transcriptional 
termination sequences.
2) The next step involves the transformation and stable maintenance of this 
DNA fusion in the host.
3) Synthesis of the foreign protein will occur when specialised culture 
conditions are employed.
4) The final step involves the purification of the heterologous protein and 
comparison with its native counter part.
When a host is been selected for heterologous protein production the following 
criteria should be satisfied in order to obtain optimum expression of the 
recombinant protein (Nicaud et a!., 1986):
• The desired protein should be produced as a major proportion of the total 
cell protein.
• The active protein should be secreted at the level of several grams per L.
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• Post-translational modifications should be carried out in the host, in 
particular if the protein is for human use.
• The host should be easy to culture on a large scale, preferably on cheap 
substrates.
• The host should be free of toxic factors (e.g., endotoxins, pyrogens) 
especially where the production of therapeutics are concerned.
Early successes in the commercial production of heterologous proteins were 
achieved using the well-characterised bacterium Escherichia coli as a host. 
However, E. coli proved to be inadequate where the production of complex 
proteins for therapeutic uses was concerned (Buckholz and Gleeson, 1991). To 
date the majority of therapeutic proteins have been produced in mammalian cell 
culture systems such as Chinese Hamster Ovary (CHO) cells (Andersen and 
Krummen, 2002). An extensive choice of expression systems are available each 
with its own limitations and successes. The choice of expression system is 
dependent on the final use of the recombinant protein. Some of the common 
expression systems currently available will now be discussed:
1.4.1: E . COLI EXPRESSION SYSTEMS
Despite its limitations the gram negative bacterium E. coli still remains one of 
the most attractive systems for the production of heterologous proteins because 
of its ability to grow rapidly to a high density on inexpensive substrates, its 
well characterised genetics and the availability of an increasingly large number 
of cloning vectors and mutant host strains (Baneyx, 1999). Although E. coli 
has proven useful for the production of recombinant proteins of modest size 
containing not more than two or three disulfide bridges, it has many limitations 
where the production of proteins with more complex structures is concerned, 
particularly those requiring post-translational modifications for biological 
activity (Hockney, 1994). By virtue of the fact that E. coli has no intracellular 
protein-processing compartment such as endoplasmic reticulum or golgi, it has
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no capacity to glycosylate proteins in either N-or O-linked conformations. 
Glycosylation is the most extensive of all post-translational modifications and 
has important functions in the secretion, antigenicity and clearance of 
glycoproteins (Jenkins et al., 1996). N- and O-linked oligosaccharides differ in 
the sugar residues they contain. For instance, in O-linked sugars, N- 
acetylgalactosamine is invariably linked to serine or threonine. In all N-linked 
oligosaccharides, N-acetylglucosamine is linked to asparagine. O-linked 
oligosaccharides are generally short, most containing only one to four sugar 
residues. The N-linked oligosaccharides, in contrast, have a minimum of five 
sugars and always contain mannose in addition to N-acetylglucosamine (Lodish 
e ta ! . ,  1995).
Many proteins expressed in E. coli, particularly those that are over expressed, 
can accumulate intracellularly in the form of insoluble, biologically inactive 
inclusion bodies. Biologically active protein may be recovered from these 
inclusion bodies by denaturation and refolding, which adds to the expense and 
complexity of downstream processing (Hockney, 1994). Another obstacle to 
the use of microbial systems such as E. coli for the production of therapeutic 
proteins is the presence of the lipopolysaccharide cell wall (endotoxin), which 
is highly immunogenic. Its presence in a therapeutic protein would have a 
detrimental effect on the recipient. Nevertheless, attempts are continually been 
made to circumvent many of the problems associated with the use of E. coli as 
an expression system. For example, research has illustrated that many proteins 
do not attain their natural conformation spontaneously but require the assistance 
of accessory proteins like molecular chaperones and foldases to achieve their 
final biologically active state (Hockney, 1994). Coexpression of these 
chaperones and foldases with the heterologous protein has been shown to 
reduce inclusion body formation in some cases (Weickert et al., 1996; Baneyx,
1999). Generally inclusion bodies tend to form only at temperatures above 
30°C. It has been shown that growth of cultures at temperatures lower than 
30°C lead to the production of active, soluble protein whereas when growth
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proceeded at 37°C most of the produced protein was insoluble and inactive 
(Schein, 1989). Although the aforementioned solutions exist for some of the 
problems associated with the use of E. coli, the production of fully functional, 
active protein in this system still remains quite a challenge. Because of the 
safety issues concerning the use of gram negative bacteria for the production of 
a recombinant vaccine, it is necessary to use alternative expression systems that 
have attained GRAS (generally regarded as safe) status which are capable of 
performing post-translational modifications similar to those present in higher 
eukaryotes.
1 .4 .2 :  FUNGAL SYSTEMS
In recent years techniques for transforming many filamentous fungi have 
evolved which allow for heterologous proteins to be produced in established 
fungal systems. Many of the industrially important species currently used such 
as Aspergillus niger, Aspergillus oryzae, Trichoderma reesei and Penicillium 
chrysogenum have GRAS status and are considered safe for use in the 
production of recombinant proteins for human use (Radzio and Kuck, 1997). 
The type of vectors used to transform filamentous fungi integrate heterologous 
DNA into the host genome by means of homologous or heterologous 
recombination and the resulting transformants usually have a high mitotic 
stability. Secretion of the recombinant protein can occur if the appropriate 
secretion signal is present. One special feature of protein secretion in 
filamentous fungi is that proteins are secreted mainly at the tips of growing 
hyphae (Punt et al., 1994). Post-translational modifications such as disulfide 
bond formation and glycosylation are all known to occur in filamentous fungi. 
Glycosylation patterns similar to those which occur in yeast systems like 
Saccharomyeces cerevisiae have been reported but in contrast to S. cerevisiae 
where hypermannosylation occurs, the glycosylation patterns in filamentous 
fungi are more similar to those found in higher eukaryotes (Jenkins et al., 1996). 
Nevertheless, certain problems with the use of this system serve as a barrier to
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its widespread acceptance. Due to the fact that filamentous fungi secrete an 
abundance of proteases, yields of heterologous proteins can be quite low. 
Despite the fact that protease deficient strains have been developed even the 
best strains have shown residual levels of protease activity which under certain 
conditions can result in substantial losses in protein yield (Punt et al., 2002).
1 .4 .3 :  INSECT (BACULOVIRUS) EXPRESSION SYSTEMS
The baculovirus-infected insect cell expression system has become a popular 
route for recombinant protein synthesis because of its short process 
development time and potentially high yields (Jenkins et al., 1996). The 
majority of evidence to date suggests that the N-glycosylation capabilities of 
this system are limited to the production of only simple oligomannose type 
oligosaccharides (Jarvis and Finn, 1995). However, this isn’t always the case, a 
secreted alkaline phosphatase produced in Trichoplusia ni has been reported 
that has both galactose and terminal sialic acids present (Jenkins et al., 1996). 
Over expression of the appropriate galactosyltransferases and sialyltransferases 
have led to some success in generating sialylated oligosaccharides on insect 
derived proteins (Andersen and Krummen, 2002). Proenzyme S. japonicum 
cathepsin C was expressed in a baculovirus expression system utilising 
Trichoplusia ni (High Five) strain host insect cells (Hola-Jamriska et al., 2000). 
Approximately 1 mg of affinity purified schistosoma cathepsin C was obtained 
per litre of insect cell culture supernatant. One of the polypeptides produced in 
this system was seen to have a molecular mass of 55 kDa, which is larger than 
the predicted molecular mass of 51 kDa. This indicated that the recombinant 
protein was glycosylated.
1 .4 .4 :  TRANSGENIC ANIMALS AS EXPRESSION VECTORS
The combination of large daily protein output, excellent post-translational 
modification capabilities, ease of access to the recombinant protein (milking)
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and low capital costs of production plants (farms) as compared to high volume 
fermenters have made the transgenic mammary gland an excellent candidate for 
the production of recombinant proteins. Regulatory sequences of the major 
milk protein genes have been used with variable successes to direct the 
expression of an array of heterologous proteins in the milk of transgenic mice, 
rats, rabbits, pigs, sheep, goats and cows (Echelard, 1996). In some instances it 
has been difficult to obtain protein yields superior to 1 mg/ml with cDNA 
derived constructs and sometimes transgenes have proven to be 
transcriptionally silent. Transgenically produced human protein C (hPC) from 
mouse and swine is well characterised. Analysis of transgenic mouse and pig 
mammary gland derived hPC as compared to that derived from plasma showed 
reduced anticoagulant activity in addition to high proportions of single chain 
unprocessed precursors indicating that post-translational modifications were 
carried out inefficiently (Lee et al., 1995; Medved et a l, 1995). However, at 
least two products, namely sheep derived human a-antitrypsin and goat derived 
antithrombin III have entered phase I clinical trials and the number of 
heterologous proteins being produced in transgenic animals continues to grow 
rapidly.
1 .4 .5 :  Y e a s t  E x p r e s s i o n  S y s t e m s
Yeasts are attractive hosts for the production of heterologous proteins. Having 
been the basis of biotechnology for over the last 4,500 years the safety of this 
organism is assured (Spier, 2000). Yeast expression systems offer considerable 
advantages over alternative eukaryotic and prokaryotic systems. Post- 
translational modification can be efficiently carried out resulting in the 
production of authentic biologically active molecules (Buckholz and Gleeson, 
1991; Cereghino and Cregg, 1999; Gellissen, 2000). Yeast offers the ease of 
microbial growth and genetic manipulation associated with bacterial systems 
along with the advantage of rapid growth to high densities on inexpensive 
media. In 1984, the first recombinant vaccine to be granted FDA approval, the
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human hepatitis B vaccine, was produced in Saccharomyeces cerevisiae. A 
vector was constructed carrying the DNA sequence for hepatitis B surface 
antigen (HBsAg) and this was expressed within the yeast (McAleer et al., 1984). 
Prior to the availability of this recombinant vaccine, HBsAg had to be purified 
from the blood of carrier individuals for use in the vaccine, which required the 
implementation of stringent processes to purify the antigen and eliminate any 
pathogens present. Disadvantages still exist with the use of yeasts for the 
expression of some heterologous proteins, which are mostly related to their 
inability to perform certain complex post-translational modifications such as 
prolyl hydroxylation (refer to 1.4.5.2) and amidation as well as some some 
types of phosphorylation and glycosylation (Cereghino and Cregg, 1999).
1 .4 .5 .1 :  S a c c h a r o m y e c e s  c e r e v i s i a e
Although a wealth of information exists detailing the genetics and cell biology 
of this yeast species, it is sometimes not viewed favourably as a host for 
recombinant protein expression because of the perception that it has a lower 
secretory capacity relative to other yeasts such as Pichia pastoris (Cereghino 
and Cregg, 1999). In some cases yields of heterologous proteins have been 
shown to only reach a maximum of 1-5% of the total protein even under the 
influence of a strong promoter. Plasmid stability can be poor, which results in 
difficulties in scale-up. Hyperglycosylation of recombinant proteins can occur. 
This can result in changes in immunogenicity, diminished activity and 
decreased serum retention of the heterologous protein product (Moir and 
Dumais, 1987). Many secreted proteins produced in S. cerevisiae are found in 
the periplasmic space in a cell-associated form. This leads to problems during 
purification and decreased yields of the purified product (Smith et al., 1985). 
Nevertheless, S. cerevisiae has GRAS status, it possesses well-characterised 
auxotrophic markers and strong promoters and a high-copy number mitotically 
stable plasmid has been identified (Buckholz and Gleeson, 1991). While much 
work has been carried out in an attempt to modify and improve S. cerevisiae as
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an expression system for the production of recombinant proteins, alternative 
yeast hosts have been developed and are being employed by many laboratories 
for stable high level expression of appropriately modified recombinant proteins.
1.4.5.2: PlC H IA  PAST ORIS
Among yeasts a limited number of species belonging to the genera Hansenula, 
Candida, Torulopsis and Pichia are capable of growth on methanol as a sole 
carbon source. Initially these yeasts were considered ideal candidates for the 
production of single-cell protein (SCP) but nowadays the scope of these yeasts 
has been extended, culminating in their use as powerful expression systems for 
a growing number of biotechnological applications (Gellissen, 2000). Pichia 
pastoris is a single celled organism that can easily be grown and manipulated. 
However, it is a eukaryote capable of undertaking many of the post- 
translational modifications performed by higher eukaryotes such as proteolytic 
processing, folding, disulfide bond formation etc., (Higgins and Cregg, 1998; 
Cereghino and Cregg, 2000). Since 1984 P. pastoris has been used to produce 
over 300 foreign proteins. Its wide acceptance is attributed to many factors. 
The techniques used for the molecular genetic manipulation of P. pastoris are 
similar to those of S. cerevisiae, one of the most well characterised 
experimental systems in modern biology (Higgins and Cregg, 1998). Extremely 
high yields of both intracellular and secreted proteins have been reported using 
P. pastoris (Romanos, 1995). By virtue of the fact that P. pastoris secretes 
only very low levels of endogenous proteins, the secreted heterologous protein 
constitutes the vast majority of total protein in the medium which will greatly 
simplify any subsequent purification steps (Cereghino and Cregg, 2000). 
Protein expression in P. pastoris is under the control of the tightly regulated 
alcohol oxidase promoters AOX1 and AOX2. The AOX1 gene is responsible 
for the vast majority of alcohol oxidase activity in the cell. The first step in the 
metabolism of methanol is the oxidation of methanol to formaldehyde, 
generating hydrogen peroxide in the process, by the enzyme alcohol oxidase
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(Higgins and Cregg, 1998). This has to occur within the peroxisome to avoid 
hydrogen peroxide toxicity. The peroxisome is a specialised organelle, which 
is massively induced in cells growing on methanol. Peroxisomes also function 
as storage compartments for the foreign protein, which would be of particular 
benefit if the protein of interest is highly susceptible to proteolytic degradation 
or if it is toxic to the host (Faber et a l., 1995). The AOX1 promoter is tightly 
repressed by glucose and most other carbon sources but is induced >1000-fold 
in cells shifted to methanol as a sole carbon source (Cereghino and Cregg, 1999 
and 2000). P. pastoris vectors are designed for homologous integration into 
either the AOX1 locus or the HIS4 locus (Hollenberg and Gellissen, 1997). 
Cleavage of a P. pastoris vector within a sequence shared by the host genome 
stimulates homologous recombination events that efficiently target integration 
of the vector to that genome locus (Cereghino and Cregg, 2000). Homologous 
recombination will maximise the stability of expression strains. The vector is 
restricted at a unique site in the marker gene (e.g., HIS4) or the AOX1 promoter 
fragment and is subsequently transformed into the appropriate auxotrophic 
mutant, for example, in this project P. pastoris strain GS115 was used, The 
vector of choice for this project was pPIC9K supplied by Invitrogen, which 
contains the bacterial kanamycin gene that allows for the selection of 
transformants on plates containing the antibiotic G418. The level of G418 
resistance can be roughly correlated to the vector copy number. If the 
recombination event results in the replacement of the AOX1 gene, such strains 
will have to rely on the transcriptionally weaker AOX2 gene for growth on 
methanol. These strains are referred to as Muts (Methanol utilisation slow), 
which utilise less methanol and sometimes express higher levels of foreign 
protein than wild type (Mut+) strains, particularly in shake flasks. Typically, 
transformed strains are initially grown in a defined medium containing glycerol 
as its carbon source. During this time biomass will accumulate but 
heterologous gene expression will be fully repressed. Upon depletion of 
glycerol a transition phase will be initiated during which additional glycerol 
will be fed to the culture at a growth-limiting rate. Finally, methanol or a
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mixture o f glycerol and methanol will be fed to the culture to induce expression 
(Cereghino and Cregg, 2000).
(www.invitrogen.com)
Figure 5: A diagrammatic representation of the pPIC9K expression vector
pPIC9K contains the S. cerevisiae a-m ating factor, which will allow the foreign 
protein to be secreted in P. pastoris.
Many factors will affect recombinant protein production in P. pastoris 
including the following:
• The copy number o f the expression cassette. A strain that contains 
multiple integrated copies o f an expression cassette can sometimes yield 
more heterologous protein than single copy strains (Clare et al., 1991a). 
In a detailed optimisation study o f tetanus toxin fragment C expression it 
was shown that protein levels increased with increasing copy number 
(Clare et al., 1991 b, Romanos, 1995). Another such study compared the 
expression levels o f a single-copy vector encoding HBsAg to those
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obtained using increasing copies of the heterologous gene expression 
cassette created using an in vitro multimerisation approach. A 
systematic investigation of the resultant clones demonstrated that the 
increase in copy number results in a proportional elevation in the steady- 
state levels of the HBsAg-specific mRNA, which in turn is closely 
paralleled by a corresponding increase in the total levels of HBsAg 
protein (Vassileva et al., 2001). For secreted proteins, the effects of 
gene dosage are not so simple. Although there are many reports showing 
that product yield has been improved using multiple vector copies, in 
some cases it has been discovered that a too-high copy number reduces 
yield i.e., an optimal rather than maximal copy number is required 
(Romanos et al., 1998). Optimisation studies should always be carried 
out using single and multi-copy transformants to determine the exact 
copy number required for optimum protein production before any 
expression project is undertaken.
• The site and mode of chromosomal integration of the expression cassette. 
In some instances it has been shown that strains with AOX mutations 
(i.e., those that occur as a result of gene transplacement) are better 
producers of foreign proteins than wild-type strains (Cregg et al., 1987; 
Tschopp et al., 1987).
• The fermentation parameters, including media and growth conditions 
(see “Recommendations”, Section 4.7). Expression levels in shake 
flasks are generally low relative to what is obtainable in fermenter 
cultures. Fermenters provide a more controlled environment relative to 
shake flasks where factors such as oxygen concentration, pH and 
temperature can be closely monitored. Methanol concentration in the 
media also has an effect on expression levels and it has been shown that 
the level of transcription initiated from the AOX1 promoter can be 3-5 
times greater in P.pastoris cells fed methanol at growth limiting rates
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relative to cells grown in excess methanol (Higgins and Cregg, 1998). 
Optimisation of the pH medium is crucial especially for yeast-secreting 
protein because they can grow over a wide pH range. P. pastoris, for 
instance is capable of growth between pH 3.0-7.0 (Thiry and Cingolani,
2002). P. pastoris can produce proteases that could have a detrimental 
effect on the recombinant protein. Adjusting the pH to one that is not 
optimal for a problem protease will remedy that problem. Temperature 
is another factor, which may be controlled in a fermenter that has a 
marked effect on both the solubility and productivity of the expressed 
protein. Lowering the temperature from 30 to 25°C during the methanol 
induction phase results in a four-fold increase in yield production of 
galactose oxydase cloned in P. pastoris (Whittaker, 2000).
Active S. mansoni cathepsin B has recently been produced in a P. pastoris 
expression system using the pPICZa vector (Caffrey et ah, 2002). Induction 
was carried out for 48 hours in 1% methanol and yields of the purified enzyme 
were in the range of 40-60 mg/L of culture medium. An earlier study by 
Caffrey et ah, from 2001 used pPICZa to produce rhodesain, the major cysteine 
protease of Trypanosoma brucei rhodesiense, which causes African sleeping 
sickness, to a final yield of 20-40 mg/L.
In a high-density fermentation an expression level of 1.5g/L of human insulin 
precursor was achieved using the pPIC9K vector in P. pastoris. High-copy 
number transformants were generated and BgUI was used to linearise the 
plasmid because it is considered more efficient in the generation of high-copy 
number transformants than SacI or Sail (Wang et ah, 2001).
Human cystatin C, a cysteine proteinase inhibitor was produced in a fed-batch 
fermentation system. Muts transformants were used in this fermentation. 
During the induction phase it was found that addition of glycerol together with 
methanol increased the growth rate of the cells, which increased the production
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rate of the recombinant protein. Typically, using a methanol-only feed results 
in long incubation times and low productivity. However, it was observed that 
the maximum concentration of expressed protein was much lower with the 
higher glycerol feed rate. Lower glycerol levels lead to higher expression 
levels of cystatin (Files et ah, 2001).
An example of the limitations of yeast systems was seen in a comparative study, 
using the methylotroph Hansenula polymorpha and P. pastoris to produce 
human a l( I)  procollagen. H. polymorpha was capable of secreting recombinant 
human a l( I)  procollagen at a level of 0.6g/L. However, pPICZB was used as 
the vector in P. pastoris, which does not contain the S. cerevisiae a-mating 
factor secretion signal and it was shown that the human procollagen 
preprosegment could not be used to obtain secretion of recombinant collagen in 
P. pastoris. Amino acid analysis illustrated that proline residues of the 
collagen product were not hydroxylated. This is essential for production of 
triple helical collagen. Yeasts appeared to lack the necessary prolyl 4- 
hydroxylase required to produce recombinant triple helical collagen (de Bruin 
et ah, 2000).
Generally, when a recombinant protein is being expressed in P. pastoris 
expression is under the control of the inducible AOX promoter. However, 
constitutive promoters, namely the glyceraldehyde-3-phosphate dehydrogenase 
(GAP) promoter have been developed for the P. pastoris expression system. 
These vectors allow for the continuous production of the desired recombinant 
protein without methanol induction. This system is more desirable for large- 
scale production because the hazard and cost associated with the storage and 
delivery of large volumes of methanol are eliminated. Using the GAP promoter 
continuous production at levels of 300 mg/L of human chitinase was observed 
in a fed-batch fermentation using either glucose or glycerol as the carbon 
source (Goodrick et ah, 2001).
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In conclusion, P. pastoris has been widely employed over the past decade to 
produce a myriad of recombinant proteins. P. pastoris has intrinsic features 
that make it pre-eminently suitable for specific commercial and scientific 
applications (Faber et al., 1995). However, there are certain proteins, which 
simply cannot be expressed by this system (Cereghino and Cregg, 2000). 
Nevertheless, many of the problems encountered in protein expression can be 
overcome by due consideration of the factors that influence protein expression. 
Each and every expression project is different and many parameters of the 
process may need to be manipulated before optimum expression of a 
heterologous protein can occur. The widespread use of this system will 
undoubtedly expand our knowledge of the intricacies and limitations of the 
system.
1.5: P r o j e c t  A i m s
The aim of this project was to isolate the cDNA encoding Schistosoma mansoni 
cathepsin C (SmCC) using primers that were designed based on the sequence 
that was available in the public database (Genbank accession no. Z32531). 
Secondly, this cDNA was cloned into a vector that could be used to transform 
the yeast Pichia pastoris with a view to obtaining functional recombinant 
enzyme.
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• • Materials and  M ethods
2 .1 : M a t e r i a l s
The following materials were obtained from the suppliers listed below:
Amresco
Ethidium bromide was obtained from Amresco Inc., 30175 Solon Industrial 
Parkway, Solon, Ohio 44139, USA.
Bachem
Synthetic peptides H-Gly-Arg-NHMec and Z-Phe-Arg-NHMec and inhibitors Z- 
Phe-Ala-NH2 and Z-Phe-Phe-OH were supplied by Bachem (UK) Ltd., 69 High 
Street, Saffron Walden, Essex CB10 IAA UK.
BDH
Silicone anti-foam Silcorel AFP20 and sucrose were supplied by BDH 
Laboratory Supplies, Poole, UK.
Becton Dickinson
Difco Bacto Agar, Bacto Peptone, Bacto Yeast Extract, Yeast Nitrogen Base 
without amino acids and 3 ml Luer-Lok syringes were all obtained from Becton 
Dickinson Microbiology Systems, Sparks, MD, USA.
Bio-Rad
30% Acrylamide/Bis solution, Goat Anti-Mouse IgG (H + L)-HRP conjugate 
and Trans-Blot SD Semi-Dry Transfer Cell and Power Pac 200 were provided 
by Bio-Rad Laboratories, 2000 Alfred Nobel Drive, Hercules, CA 94547, USA.
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Biotrin
TMB was supplied by Biotrin International, 93 The Rise, Mount Merrion, Co 
Dublin, Ireland.
Chivers
Dried skimmed milk (Marvel) was supplied by Chivers, Ireland Ltd., Coolock, 
Dublin.
Cornell University
A Schistosoma monsoni cDNA library cloned in pB42AD (BD Biosciences) was 
obtained from Dr. Sharon McGonigle, Cornell University, Ithaca, New York.
Fisher Scientific
100% Methanol was supplied by Fisher Scientific (UK) Ltd., Bishop Meadow 
Road, Loughborough, Leics, LEI 1 5RG, UK.
Genosys Biotechnologies (Europe)
All oligonucleotide primers were obtained from Genosys Biotechnologies 
(Europe), London Road, Pampisford, Cambridge, CB2 4EF, UK.
Invitrogen
E. coli Top F’ cells, Multi-Copy Pichia Expression Kit (Version E) and Pro 
Bond Resin 50% slurry in 20% ethanol were all supplied by Invitrogen 
Corporation, 1600 Faraday Avenue, Carlsbad, CA 92008, USA.
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New England Biolabs
The restriction enzymes Avrll, PstI and SnaBI and prestained protein marker, 
broad range were obtained from New England Biolabs, 32 Tozer Road, Beverly, 
MA 01915-5599, USA.
Oswel
DNA sequencing was performed by Oswel Research Products Ltd, Lab 5005, 
Medical and Biological Services Building, University of Southampton, 
Boldrewood, Bassett Crescent East, Southampton, S0167 PX, UK.
Pall Gelman
Acrodisc 32mm syringe filters with 0.2 (xm Supor Membrane were supplied by 
the Pall Corporation, 600 South Wagner Road, Ann Arbour, MI 48103-9019 
USA.
Pierce
The BCA protein assay kit was acquired from Pierce Biotechnology Inc., 
Rockford, II 61105, USA.
Promega
Promega, 2800 Woods Hollow Road, Madison, WI 57311-5399, USA supplied 
the following materials: Agarose, LE analytical grade and low melting point, 
blue/orange loading dye, 1 kb DNA ladder, 87% glycerol, IPTG (isopropyl- 
beta-D-thiogalactopyranoside), PCR Master mix, pGEM -T Easy Vector System, 
pGEM -T Vector System, PMSF (phenylmethylsulfonylfluorid) and restriction 
enzymes A v a il and Vspl.
46
Roche
Anti-His6 antibody was provided by Roche Diagnostics Ltd., Bell Lane, Lewes, 
East Sussex, BN7 1LG.
Schleicher & Schuell
Protran nitrocellulose transfer membrane was supplied by Schleicher & Schuell 
Inc., 10 Optical Avenue, Keene, MH 03431, USA.
Sigma-Aldrich
Sigma-Aldrich PO Box 14508, St. Louis, Missouri, 63178, USA, also the 
supplier of Fluka and Riedel-de-Hiien materials supplied the materials detailed 
in Table 1:
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Table 1: Materials supplied by Sigma-Aldrich
Sigma Fluka Riedel-de-Haen
-Acetic acid -Agar -Calcium Chloride
-Bovine Seram Albumen -Ammonium persulfate -Glycine
-Brilliant blue R250 -Buffer standard solution, -Natrium-acetat-3 -hydrat
-Chloroform colour coded pH 4.0, 7.0 & -2-propanol
-DMF 10.0 -Sodium Hydroxide Pellets
-EDTA -Phenol -Tween 20
-Sigma Fast ™ 3 ,3 ’- -Sodium Carbonate
Diamino benzidine tablet -Sodium Chloride
set (DAB peroxidase -Tryptone media
substrate) -Yeast extract
-Ethyl alcohol
-Glass beads
-X-Gal
-5U/|iL Lyticase
-Lauiyl Sulfate -(Sodium
Dodecyl Sulfate solution)
-Mineral oil
-Nuclease free H2 O
-Red Taq ™ DNA
Polymerase & 10 X
reaction buffer, 25 mM
MgCl2 & 12.5 M dNTPs
-Sodium Phosphate
-TEMED
-Tetracycline
-Trizma base -(Tris
[hydroxymethyl] amino
methane)
disodium salt
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Tulane University
Anti-cathepsin C antibody, purified baculovirus-expressed S. mansoni cathepsin 
C and Schistosoma japonicum  worms were provided by Professor Paul Brindley, 
Department of Tropical Medicine, SL29A, Tulane University, Health Sciences 
Centre, 1430 Tulane Avenue, New Orleans, Louisiana 70112-2699, USA.
Qiagen
Nickel-nitriloacetic acid agarose (Ni-NTA) in 50% ethanol, polypropylene 1 ml 
columns and the QIAexpressionist ™ kit were supplied by Qiagen Inc., 28159 
Avenue Stanford, Valencia, CA 91355, USA.
Equipment
• Anthos 2001 plate reader
• Beckman centrifuge J2-MC
• Consort power supply pac
• Eppendorf centrifuge 5417C
• Hybraid electrophoresis apparatus
• Hybraid omni gene thermal cycler
• Image master ®-VDS transilluminator
• Janke and Kunkel Homogeniser
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• Jeio-Tech Shaker SK-71
• Kodak polaroid film
• Neubauer hemocytometer
• Olympus CK2 microscope
• Perkin Elmer fluorimeter
• Sonics and Materials, Inc., Vibra Cell ™ Sonicator
• Thermohybraid PCR express thermal cycler
• Thermo orion pH meter
• Tomy autoclave
• Uni cam HeîUos Spectrophotometer
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2.2: M e th o d s
2.2.1: C lo n in g  o f  S c h i s t o s o m a  m a n s o n i  c a th e p s in  C  (SmCC) c D N A  
P rim e r  Design
The full-length cDNA sequence of Schistosoma mansoni cathepsin C (SmCC) 
was retrieved from the Genbank (accession no: Z32531). This sequence was 
used to design primers to amplify the pro and mature segments of SmCC. 
SnaBI and A v r ll  restriction enzyme recognition sequences were incorporated 
into the 5 ’ and 3’ ends respectively of the primers that were initially designed 
(SmCCF and SmCCR). A hexahistidine tail was included in the design of 
SmCCR for purification of recombinant SmCC (rSmCC) on a Ni-NTA column 
(see below)
SmCCF: 5’- GCGGCTACGTAGCTGATACTCCTGCTAACTG -  3’
SmCCR: 5 ’-GCGCCTAGGTTAGTGGTGGTGGTGGTGG 
TGGTGGGC C C T A AC AC C GG AT C A A A AC G- 3 ’
SnaBI and A v r ll  recognition sequences are underlined and the hexahistidine tail 
is in italics.
Several sets of primers were designed before the 1.3 kilobase (kb) SmCC cDNA 
was successfully amplified (refer to 3.1.1). Tables 2 and 3 depict the primers 
that were used to amplify the SmCC cDNA, their sequence and the regions of 
the SmCC cDNA they amplified.
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Table 2: Forward Primers
Primer name Sequence Location on SmCC
SmCCF GCGGCTACGTAGC
TGATACTCCTGCT
AACTG
base 82-101
SmCCF2 GCTGATACTCCTG 
CT AACTGT ACTTA 
TG
base 82-101
SmCCF4 GCATTGGGTGTTC
CACTG
base 27-44
SmCCMF CATTAACTGGAAA
TCTTCCTTTGG
base 662-685
SmCCMF2 GTTTCGGTAGAAC
TCTCTAC
base 461-480
SmCCMF3 GGTTATTATGGCG
CTACTAATG
base 1042-1063
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Table 3: Reverse Primers
Primer name Sequence Location on 
SmCC
SmCCR GCGC CT AGGTT AGT GGT GGT GGT
GGTGGTGGGGCCCTAACACCGG
ATCAAAACG
base 1369-1389
SmCCR2 TTATAACACCGGATCAAAACGTA
CACC
base 1369-1389
SmCCR3 GATTTTATAACACCGGATCA base 1374-1393
SmCCR4 CCAATATCCGGCTCTATTC base 1400-1420
SmCCR5 CGGATCAAAACGTACACCTAAA
CTTTCTAC
base 1351-1380
SmCCR6 TAACACCGGATCAAAACGTACA
CCTAAACTTTCTAC
base 1351-1386
SmCCMR C C A A AGG A AG ATTT C C AGTT A AT 
G
base 662-685
SmCCMR3 CCATAACCAACCAATAAAAC base 1222-1241
SmCCMR4 CATCAATAGCTATATCCGGG base 210-230
SmCCMR5 TCTTC AT AT ACTTC AA AACCC base 1110-1130
A 500 pmol stock of each primer was prepared and from this a working stock of 
lOpmol/pL was made.
For example, in the case of SmCCF: Mw = 9487 g
nmoles = 33.5 = 33,500 pmoles
stock = 500 pmol = 33.500 = 67 pL RNAse
500 free water
53
Therefore to make a 500pmol stock 67 jiL of RNAse free water was added to 
the primer. The 10 pmol/^iL working stock was made by performing a 1:50 
dilution of this.
Template DNA
When SmCC was amplified by PCR the template DNA used was S. mansoni 
cDNA library in pB42AD, unless stated otherwise.
Polymerase Chain Reaction (PCR)
A ready-made PCR master mix (Promega) was employed for the majority of 
PCR reactions carried out.
Table 4: PCR Reaction (Promega Master Mix)
Component Volume (25 ^.L rxn.) Final
concentration
PCR master mix, 2X 12.5 (J.L IX
5’ primer 1 nL 10 pmole/|xL
3’ primer 1 \iL 10 pmole/(xL
DNA template 2.5 [iL < 250 ng
Nuclease free H20 8 |xL N/A
2X master mix was composed of 50 units/ml of Taq DNA polymerase in a 
proprietary reaction buffer (pH 8.5), 3 mM MgCh, 400 dATP, 400 (xM 
dCTP, 400 nM dGTP and 400 [iM dTTP.
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Where ready-made master mix was not used it was necessary to make up a mix 
by adding all the individual components of the PCR reaction.
Table 5: PCR Reaction
Component Volume (25 |iL rxn) Final concentration
10X buffer 2.5 (iL IX
25 mM MgCh 2.5 [ih 2.5 mM
12.5 mM dNTPs 0.8 |xL 0.2 mM
Taq (IU /jiL) 2.5 [lL 2.5 U
RNAse free H2O 12.2 ¡¿L N/A
1 [iL of SmCCF and SmCCR primers and 2.5 (xL of template DNA were added 
to each tube.
By virtue of the fact that some primers failed to successfully amplify the SmCC 
cDNA different PCR cycling conditions were implemented. Other conditions in 
the PCR reaction such as MgCh concentration were altered in an attempt to 
amplify the cDNA.
A standard PCR cycle used is detailed below:
Denaturing 94°C/5 min (1st cycle)
Denaturing 94°C/1 min 30 sec 
Annealing 55°C/1 min 30 sec 40
Extension 72°C/1 min 30 sec cycles
Extension 72°C/10 min (last cycle)
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Analysis of PCR Product
Amplified fragments were electrophoretically separated in a 1% agarose-Tris- 
acetate gel. The gel was stained with ethidium bromide and visualised under 
ultra-violet light.
DNA Purification
The 1.3 kb band was excised using a sterile blade. For DNA purification, a 1% 
agarose low melting point gel was used. DNA was purified from the gel using 
the Wizard DNA Purification System (Promega) according to the protocol 
provided by the manufacturer. The purified band was concentrated by ethanol 
precipitation. 0.1 volumes of 3 M sodium acetate pH 5.0-6.0 were added to the 
DNA sample, followed by mixing. Then 2-3 volumes of 100% ethanol were 
added. Brief vortexing ensued and the sample was placed at -80°C for 15 min 
Afterwards centrifugation at 1,807 x g for 10 min was carried out. Excess 
ethanol was allowed to evaporate and the pellet was resuspended in 20 
RNAse free H2O.
Determination of DNA concentration
The concentration of SmCC cDNA was determined on a spectrophotometer by 
measuring absorbance at 260 nm.
The concentration of DNA was determined by implementation of the following 
formula:
ng/(xL DNA = 50 ng/fiL x (OD26o measured) x (dilution factor)
1
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2.2.2: C lo n in g  o f  SmCC cDNA i n t o  t h e  pGEM v e c t o r
The SmCC cDNA was successfully amplified with SmCCF2 and SmCCR6 
primers. It was then decided to clone the purified SmCC fragment into the 
pGEM vector in order to increase the concentration of SmCC template present 
for the re-amplification of SmCC with SmCCF and SmCCR primers containing 
the restriction sites for cloning into pPIC9K. By virtue of the fact that Taq 
polymerases add a single deoxyadenosine to the 3’ ends of the amplified 
fragments in PCR and because the pGEM vector contains single 3’-T overhangs 
at the insertion site ligation of the gene to the vector can, in theory, be swiftly 
performed.
Ligation into pGEM
For ligation of DNA to pGEM the molar ratio of vector: insert DNA was 3:1. 
The following equation was used to determine the quantities of vector and 
insert to be used:
Molar ratio: ng vector x kb size of insert x_3
kb size of vector 1
The vector was supplied at a concentration of 50 ng/(xL
A sample ligation set-up is outlined in Table 6 in accordance with the 
guidelines provided by the manufacturer (Promega).
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Table 6: Sample Ligation Procedure
Component Sample Background control Positive
control
1 OX buffer 1 pL 1 pL 1 pL
vector 3 pL 1 pL 1 pL
insert 1 pL N/A N/A
control insert N/A N/A 2 pL
ligase 1 pL 1 pL 1 pL
h 2o 4 pL 7 pL 5 pL
Final volume 10 pL 10 pL 10 pL
All ligation components were provided with the kit. Ligation was performed at 
4°C overnight.
Preparation of Competent Cells
In order for the subsequent transformation steps to be carried out a batch of 
chemically treated E. coli Top F’ cells were prepared.
It was necessary to prepare the following:
• Luria-Bertani broth (LB) (bacto-tryptone lOg/L, bacto-yeast extract 5g/L, 
NaCl lOg/L, pH 7.0, autoclaved for 20 min)
• 0.1 M calcium chloride
• 80% filter-sterilised glycerol
• 10 mg/ml tetracycline stock prepared in ethanol
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An overnight culture of E. coli Top F’ cells were grown at 37°C in 2 ml of LB 
broth (lOpg/ml tetracycline). Four hundred ml of LB broth (10 pg/ml 
tetracycline) was inoculated with this overnight culture and cells were grown to 
an OD600 of 0.4-0.5, which took 2-2.5 hrs. Cells were then chilled on ice for 1 
hr, followed by centrifugation at 200 x g for 10 min. Resuspension of the cells 
followed in 10 ml per 50 ml starting culture of 0.1 M CaCh. Cells were once 
again chilled on ice, this time for 40 min. The second centrifugation step was 
implemented as for the first except the resultant pellets were resuspended in 2 
ml per 50 ml starting culture 0.1 M CaCl2. 80% glycerol was added to the cells 
to a final concentration of 10%. Cells were stored at -80°C until use.
Transformation
Once the overnight ligation step was performed, transformation of competent E. 
coli cells with the vector containing the ligated SmCC cDNA could proceed 
(Figure 6).
The following media was needed for the transformation process (Table 7).
Table 7: Media for Transformation Process
Luria-Bertani broth/X IA  plates • *15g/L  agar
• 5g/L NaC l
• lOg/L tryptone
• 5g/L yeast
pH 7.0, autoclave 20 min
* agar for X IA  plates only
The relevant antibiotics and supplements listed in Table 8 were added when the 
autoclaved media had cooled to room temperature. Only ampicillin was added 
to the LB media.
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The transformation procedure is outlined in Figure 6
competent E. coli cells were removed from  
-80°C & thawed on ice 
*
50 |iL competent cells & 2 (xL ligation  m ix were 
resuspended & left on ice for 30 min
4
Heat shock at 42°C for 2 min
2 min on ice
4
Add to 2 ml LB-Amp broth 
2hrs at 37°C with shaking
4
100 |il aseptically spread onto X IA  plate, 
overnight incubation at 37°C
Figure 6: Overview of the transformation procedure
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Table 8: Supplements to be added to media in Table 7
Ampicillin Stock 100 mg/ml 
Want 60 pg/ml 
—*■ 600 pL/L added
IPTG Stock 0.1 M (0.6 g IPTG + 25 
ml diLO, filter sterilised)
Want 0.2 pM 
^  2 ml IPTG/L added
X-Gal Stock 50 mg/ml DMF
Want 40 pg/ml
-* 800 pL X-Gal/L added
Only ampicillin was added to LB media 
Screening of Colonies
After 24 hrs transformed colonies appeared on the plates. An advantage of 
using the pGEM system is that blue/white colour screening can be employed. If 
transformed colonies do not contain the fragment of interest blue colonies will 
appear on the plates because a functional P-galactosidase will be produced by 
the plasmid resulting in metabolism of the X-Gal substrate present in the media 
giving the colonies a blue colour. If the insert is successfully incorporated into 
the pGEM vector, the gene encoding (3-galactosidase will be interrupted and a 
functional enzyme will not be produced. The X-Gal substrate will not be 
broken down and colonies on the plate will be white. White colonies were 
selected and grown up overnight in LB-ampicillin (LB-Amp) broth.
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Plasmid Purification
Plasmids were purified from an overnight bacterial culture by employing either 
the Wizard Plus SV Minipreps DNA Purification System using the protocol 
outlined by the manufacturer (Promega) or the alkaline lysis method.
Alkaline Lysis Method
The following reagents detailed in Table 9 were prepared before the procedure 
was carried out:
Table 9: Alkaline Lysis Reagents
Lysis Buffer 9 ml H20 
0.25 ml Tris-HCl 
0.20 ml 0.5 M EDTA 
0.50 ml 20% glucose
SDS/NaOH (1 OX) 8. 8  ml H20 
1 ml 1 0 % SDS 
200 pL NaOH(lON)
Ammonium acetate 7.5 M Filter sterilised
Phenol: Chloroform (1:1) 4 ml phenol
4 ml chloroform
• 1.5 ml of the overnight bacterial culture was centrifuged at 1,807 x g for 1 
min. The supernatant was discarded and the pellet was resuspended in 200 
pL of lysis buffer. This was left at RT for 5 min.
• 400 pL of SDS/NaOH was added, tubes were inverted five times and were 
left on ice for 5 min.
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• 300 (j,L of 7.5 M ammonium acetate was added, tubes were inverted five 
times and left on ice for 10 min followed by centrifugation for 5 min at 
1,807 x g
• The supernatant was kept and the same volume of 1:1 phenolxhloroform 
was addded. Vortexing for two min and centrifugation for 2 min at 1,807 x 
g ensued. The clear top phase was retained and transferred into a clean tube.
• 0.6 volumes of 100% isopropanol were added and tubes were left at RT for 
10 min. Centrifugation at 1,807 x g for 15 min was then carried out.
• The supernatant was removed and the pellet was washed with 70% ethanol. 
Some of the pellets floated when ethanol was added so it was necessary to 
centrifuge these pellets for an additional 3 min.
• The ethanol was discarded but the pellet was not disturbed. It was left to air 
dry for 10  min.
• The pellet was resuspended in 40 [xL of sterile H2O and 1 jiL of sterile 
DNAse free RNAse was added (1 mg/ml).
The success of the plasmid purification process could be ascertained by running 
the sample on a gel in order to see the purified band under UV or also by 
determining the concentration of DNA in the purified sample 
spectrophotometrically (refer to 2 .2 .1)
63
Determination of the Presence of SmCC in pGEM
When the primers in Table 10 are used to amplify pGEM they produce a PCR 
product of 172 bp. If an insert is present the expected size of this PCR product 
will be the size of the insert +172 bp.
Table 10: pGEM Specific Primers
Primer Sequence Location on pGEM
pGEM F CGCATGCTCCC
GGCCGCCAT
base 21-40
PUC/M13 R CAGGAAACAGC
TATGAC
base 176-192
pGEM vector containing the SmCC fragment was used as a template for a PCR 
reaction in which the primers SmCCF and SmCCR were used to amplify SmCC 
with restriction sites for cloning into pPIC9K vector.
2.2.3: C lo n in g  o f  SmCC cDNA i n t o  t h e  PPIC9K v e c t o r
Restriction Digest
A double digest was performed on the purified SmCC cDNA and pPIC9K 
vector. The pPIC9K vector is supplied by Invitrogen at a concentration of 1 
M-g/pL. Table 11 on the next page outlines the set-up of a typical restriction 
enzyme digest.
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Table 11: Digest Set-Up
Component SmCC cDNA pPIC9K
10X Buffer 4 5 nL 5 jiL
BSA 5 n,L 5 |xL
DNA 20  n-L 12.5 nL
H20 15 [iL 15 nL
Avrll 2.5 (iL 2.5 nL
SnaBI 2.5 |iL 2.5 nL
Final volume 50 nL 50 (iL
The digest was performed for 3 hrs at 37°C. Digested DNA was cleaned-up 
using the Wizard DNA Clean-Up System using the protocol supplied by the 
manufacturer (Promega) except when the final elution step was carried out 30 
|j.L of H20 was left on the column for 5 min before eluting. In order to ensure 
that the digest was complete and that the vector DNA had been successfully 
linearised the digest was run on a 1% agarose gel. Ligation and transformation 
protocols were carried out exactly as for pGEM (refer to section 2.2.2), the only 
difference being that LB-Amp plates were used when plating the transformation 
reaction instead of XIA plates. Plasmid DNA was isolated from an overnight 
bacterial culture of the transformed colonies. Due to the fact that blue/white 
colour screening could not be implemented when using pPIC9K, the presence of 
the SmCC cDNA in the vector could be determined only by PCR using SmCC 
specific primers, by visualisation of the plasmid DNA on a gel to see if there 
was a size difference between this DNA and the DNA of pPIC9K alone and by 
carrying out another double digest with SnaBI and A v r ll  to liberate the SmCC 
cDNA from the vector.
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Preparation of Glycerol Stocks
Glycerol stocks of pPIC9K/SmCC expression cassette were made by growing 
up an overnight culture of a colony containing pPIC9K that was shown by PCR 
to contain SmCC in LB-Amp. 0.15 ml of filter sterilised 100% glycerol was 
added to 0.85 ml of this overnight culture, which was stored at -80°C after 
adequate mixing.
2.2.4: DNA SEQUENCING
The complete DNA sequence of the selected recombinant clones was 
determined on a commercial basis by an automated fluorescence based method 
using an ABI 377 Applied Biosciences 96 lane fluorescent DNA sequencing 
machine by Oswel Research Products Ltd., DNA Sequencing and Molecular 
Biology Division, Southampton, UK.
2.2.5: T r a n s f o r m a t io n  o f  P ic h ia  p a s t o r is  w i t h  SmCC
Linearisation of the Plasmid
pPIC9K/SmCC was linearised using the restriction enzyme BgUI prior to the 
transformation process to stimulate recombination when the plasmid is 
transformed into Pichia pastoris. Other enzymes conventionally used for this 
step such as S a il and SacI could not be used as they cut within the SmCC cDNA 
and B g lll was the only enzyme that didn’t.
Pichia pastoris host strain
Pichia pastoris host strain GS115 was used for all transformation procedures. 
This strain has a mutation in histidinol dehydrogenase (his4) that prevents it 
from synthesising histidine. The pPIC9K expression plasmid carries the HIS4
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gene, which complements his4 in the host so transformants are selected for their 
ability to grow on histidine deficient media. GS115 was streaked onto a Yeast 
Extract Peptone Dextrose (YPD) plate (Table 14) and was incubated at 28-30°C 
for 48 hrs. A single colony from this plate was used to inoculate 10 ml of YPD 
in a 100 ml conical flask. Overnight incubation at 30°C/225 r.p.m ensued. 200 
ml of YPD in a 500 ml baffled flask were inoculated with 5, 10 and 20 p.L of 
this overnight culture. Overnight incubation at 30°C/225 r.p.m was once again 
carried out. Cells were harvested when an ODeoo of 0 .2 -0 .3 was reached. Cells 
were centrifuged at 1,500 x g for 10 min. The supernatant was discarded.
Preparation of Spheroplasts
• The pellet from the overnight P. pastoris culture was resuspended in 20 ml 
of sterile water and was transferred to a fresh 50 ml tube.
• The cells were pelleted by centrifugation at 1,500 x g for 5 min. The 
supernatant was discarded.
• The cell pellet was washed once by resuspending in 20 ml of fresh 
Sorbitol/EDTA/DTT (SED) and centrifugation was carried out as before.
• The cells were washed once with 20 ml of 1 M sorbitol and centrifuged.
• Cells were resuspended by swirling them in 20 ml of Sorbitol/Sodium 
Citrate/CaCl2 (SCE) buffer and the suspension was divided into 2 x 50 ml 
conical tubes.
• Zymolyase was removed from -20°C and was placed on ice. The optimal 
time of digestion with zymolyase to make spheroplasts was determined as 
outlined in the manufacturer's manual (Invitrogen). 7.5 ¡iL of zymolyase 
was added to the cells and incubation at 30°C was carried out for the pre-
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determined length of time as suggested by the manual. Cells were then
harvested by centrifugation at 750 x g for 10 min and the supernatant was
decanted and discarded.
• Spheroplasts were washed once with 10 ml of 1 M sorbitol and were
collected by centrifugation at 750 x g for 10 min.
• Spheroplasts were washed once with 10  ml of Sorbitol/Tris-HCl/CaCh
(CaS) and centrifuged as before. They were then resuspended in 0.6 ml of 
CaS for immediate use.
The solutions required for the spheroplast preparation and transformation are
outlined in Table 12.
Table 12: Spheroplasting and Transformation Solutions
Reagent Amount Components
SOS medium 20ml 1 M sorbitol, 0.3 X  YPD, 10 mM CaCl2
Sterile Water 2 x 125 ml Autoclaved, deionised water
SE 2 x 125 ml 1M sorbitol, 25 mM E D T A  pH 8.0
SCE 2 x 125 ml 1 M sorbitol, 10 mM sodium citrate 
buffer, pH 5.8, 1 mM EDTA
1 M sorbitol 2 x 125 ml 22.5 g D-sorbitol/125 ml dH20
CaS 2 x 60 ml 1 M sorbitol, 10 mM Tris-HCL, pH 7.5, 
10 mM CaCl2
40% PEG 25 ml 40% (w/v) PEG 3350 in water
CaT 25 ml 20 mM Tris-HCL, pH 7.5, 20 mM CaCl2
Zymolyase 2 x 20 (xL 3 mg/ml zymolyase in H20 (100,000 
units/g lytic activity)
1 M D TT 1 0 x 1  ml 1.54 g DTT in 10 ml dH20
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Transformation of P.pastoris
Approximately 10 pg of the expression cassette was used incubated with 100 
pL of spheroplasts for 10 min at RT. One ml of a Polyethylene Glycol 
(PEG)/Tris-HCL, CaCl2 (CaT) solution was then added to the cells and DNA, 
followed by gentle mixing and incubation at RT for 10 min. Centrifugation at 
750 x g ensued and the PEG/CaT solution was carefully aspirated. The pellet of 
the transformed cells was resuspended in 150 pL sorbitol/YPD/CaCh (SOS) 
media and was incubated at RT for 20 min. The next step involved the addition 
of 850 pL of 1 M sorbitol. P.pastoris spheroplasts have to be plated in top agar 
to protect them from lysis prior to selection. One-three hundred pL of each 
spheroplast-DNA solution was mixed with 10 ml of molten Regeneration 
Dextrose (RD) agarose, before pouring onto RDB plates. To ensure that the 
spheroplasts were viable, 100 pL of the spheroplasts were mixed with 900 pL of 
1 M sorbitol and 100 pL of this was mixed with 10 ml of molten RDH before 
pouring onto an RDBH plate. The top agarose on all the plates was allowed to 
harden prior to incubation of the plates at 28-3 0°C for 4-6 days.
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Media Components
Table 13: Additives for transformation and plating media
10X YNB (yeast nitrogen base with 
ammonium sulfate without amino 
acids)
134 g YNB with ammonium sulfate without amino 
acids/L, 34 g YNB w/o ammonium sulfate and amino 
acids and lOOg ammonium sulfate/L
500X B (0.02% biotin) 20 mg biotin/100 ml HiO, filter sterilise
100X H (0.4% histidine) 400 mg L-histidine/100 ml H2 O, heat to dissolve, filter 
sterilise
10X D (20% dextrose) 200 g D-glucose/L, autoclave or filter sterilise
10X M (5% methanol) 5 ml methanol in 95 ml H20, filter sterilise
10X GY (10% glycerol) 100 ml o f glycerol/900 ml H20, autoclave or filter 
sterilise
100X AA (0.5% o f each amino 
acid)
500 mg o f L-glutamic acid, L-methionine, L-lysine 
and L-isoleucine/100 ml H20, filter sterilise
1 M potassium phosphate buffer, 
pH 6.0
132 ml 1 M K2HPO,, 868 ml o f 1 M KH2P 0 4, pH to 
6.0 and autoclave
100 mg/ml G418 stock 100 mg/ml in sterile H20, filter sterilise, store at -20°C
Plating of Transformants onto G418
When transformants appeared onto the plates the top agar was removed and the 
cell density was determined for each transformation using a haemocytometer. 
Onto each YPD-G418 plate, with concentrations of G418 from 0.25 mg/ml-1.0 
mg/ml, 10s cells were plated. Cells were also plated onto YPD without 
antibiotic as a control. Plates were incubated at 30°C for 2-5 days. After this 
time, colonies that appeared on the YPD-G418 plates were isolated and streaked 
onto YPD. A second YPD-G418 screening was done 3 days later using the 
colonies on YPD, incubation as before. Table 14 outlines the components of 
the media needed for the transformation process and subsequent plating steps
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carried out during the expression process. The solutions that must be added to 
the media (Table 14) are detailed in Table 13.
Table 14: Media Components
Yeast Extract Peptone Dextrose Medium 
(YPD)
10 g yeast extract, 20 g peptone, (20 g agar for 
plates)/L autoclave, cool, add 100 ml 10X D
YPD-G418 plates YPD plates with 0.25-4.0 mg/ml G418
Regeneration Dextrose Medium + Histidine 
(RD and RDH) Liquid Media
186 g sorbitol/700 ml H20, autoclave, cool and store at 
45 °C, add pre-warmed mixture o f  100 ml o f  10X D, 
100 ml o f  10X YNB, 2 ml o f 500X B, 10 ml o f 100X 
AA to sorbitol
RDB and RDH Agar Plates 186 g sorbitol, 20 g agar/700 ml H20, autoclave, place 
in 60°C water bath, add same pre-warmed mixture as 
for RD and RDH Liquid Media, if  selecting for His+ 
transformants omit histidine, pour immediately
RD and RDH Top Agar 186 g sorbitol, 10 g agar/700 ml H20, autoclave, place 
in 60°C water bath, add the same pre-warmed mixture 
as for RD and RDH Liquid Media, keep at 45°C and 
use during transformation
MD Agar Plates 15 g agar/800 ml H20, autoclave, cool and add 100 ml 
10X YNB, 2 ml o f  500X B and 100 ml 10X D, cool 
and pour
MM Agar Plates 15 g agar/800 ml H20, autoclave, cool, add 100 ml of 
10X YNB, 2 ml o f  500X B and 100 ml 10X M, cool 
and pour
Buffered Glycerol-complex Medium 
(BMGY) and Buffered Methanol-complex 
Medium (BMMY)
10 g yeast extract, 20 g peptone/700 ml H20, 
autoclave, cool, add 100 ml 1 M potassium phosphate, 
pH 6.0, 100 ml 10X YNB, 2 ml 500X B, 100 ml 10X 
GY (BMGY only) and 100 ml 10X M (BMMY only)
Breaking Buffer 6 g monobasic sodium phosphate, 372 mg EDTA and 
50 ml glycerol/900 ml H20, pH to 7.4, store at 4°C,add 
protease inhibitors (e.g., PMSF) before use
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MM/MD Plating
A single colony was picked off the YPD-G418 plate and was dotted onto both 
an MM and MD plate. Extra care was taken to ensure that the MM plate was 
dotted first. Plates were incubated at 30°C for 2 days. The purpose of MM/MD 
plating was to phenotypically differentiate between those colonies that were 
Mut+ (Methanol utilisation plus) and Muts (Methanol utilisation slow). Muts 
phenotype exhibits a reduced ability to metabolise methanol as a result of the 
loss of the AOX1 gene. Mut+ phenotype represents the wild type strain that has 
its full methanol utilising capabilities intact. As the expression cassette had to 
be linearised with the restriction enzyme B g lll prior to transformation, all 
transformants were of the Muts phenotype as the integration event that occurred 
in i’, pastoris was a gene replacement event at the AOX1 locus.
Direct PCR Screening of Pichia pastoris Clones
P. pastoris clones were directly tested for insertion of SmCC by PCR.
A single colony was dissolved in 10 pL H2O. This was followed by the addition 
of 5 pL of a 5U/pL solution of lyticase and incubation at 30°C for 10 min. A 
PCR reaction was set us as follows for each tube:
1 OX Reaction Buffer 
25 mM MgCl2 
25 mM dNTPs
5’ AOX1 primer (10 pmol/pL) 
3’ AOX1 primer (10 pmol/pL) 
Sterile water 
Cell lysate 
Taq
5 pL 
5 pL 
1 pL 
1 pL 
1 pL 
31 pL 
5 pL
1 pL (added after 1st denaturing step) 
50 pL
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Table 15: PCR Screening of P. pastoris Clones
Thirty cycles were carried out
Step Temperature Time
Dénaturation 95°C 1 minute
Annealing 54°C 1 minute
Extension 72°C 1 minute
Final extension 72UC 7 minute
A 10 (j,L aliquot of each PCR reaction was analysed by agarose gel 
electrophoresis.
2 .2 .6 : F u n c t io n a l  E x p re s s io n  o f  SmCC in  .P. p a s t o r i s
The production of rSmCC was under the control of the tightly regulated, 
inducible AOX1 promoter. Recombinant protein production was repressed by 
glucose/glycerol but was induced by growth in the presence of methanol. Only 
clones proven to contain SmCC integrated into the P. pastoris genome were 
used for the induction process.
Standard Methanol Induction
100 ml of BMGY in a 1 L baffled flask were inoculated with a single colony of 
transformed, PCR positive P. pastoris from a YPD plate. Incubation on a 30°C 
shaker at 225 r.p.m ensued until an OD600 2.0-6.0 was reached. Centrifugation 
at 3,000 x g for 5 min followed and the supernatant was decanted. For Muts 
phenotype which all transformants in this instance were, the pellet was 
resuspended in BMMY pH 6.0 using 10-20% of the original culture volume for 
resuspension (10-20 ml). A 1 ml sample of culture (DO) was taken prior to 
incubation on the 30°C shaker at 225 r.pm. A 1 ml sample of culture was taken
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every day for analysis and 1 0 0 % methanol was added to a final volume of 1% 
every day to maintain induction. Each 1 ml sample was spun at 2,460x g for 5 
min and the supernatant was removed. Each pellet and supernatant was stored 
at 4°C until further analysis could be carried out. Variations on this basic 
induction protocol were carried out, for example 1 0 0 % methanol was added to a 
final concentration of 1.5% twice daily for a six-day period. These variations 
on the standard protocol will be discussed in detail in Section 3.3.
Analysis of Protein by SDS Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
Both supernatants and pellets were analysed for rSmCC production by SDS- 
PAGE. A 12% separating gel and 5% stacking gel was used in all cases.
Table 16: SDS-Gel Preparation
Components (for 4 
mini-gels)
Separating Gel 
(12%)
Stacking Gel (5%)
30% Bis Acrylamide 12 ml 1 . 6 6  ml
1 M Tris-HCL 1 1 .2  ml 1.25 ml
dH20 6.7 ml 7.04 ml
10% SDS 300 nL 100 pL
1 0 % ammonium 
persulfate
150 pL 100 pL
TEMED 50 pL 50 i^L
Note: For the separating gel, 1 M Tris-HCL pH 8.8 was used whereas for the 
stacking gel 1 M Tris-HCL pH 6. 8  was used.
Other reagents required for SDS-PAGE are outlined in Table 17;
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Table 17: SDS-PAGE Reagents
Electrophoresis Buffer, pH 8.3 3 g/L Tris
14.4 g/L Glycine
10 ml 10% SDS, pH to 8.3
10% SDS 10 g SDS/100 ml ultra pure H20
10% ammonium persulfate (APS) 0.2 g APS in 2 ml H20
Sample Buffer (4X) 2.5 ml 1 M Tris-HCL pH 6.8 
4 ml 100% Glycerol 
0.8 ml p-mercaptoethanol 
0.04 g Bromophenol Blue 
0.8 g SDS
Make up to 10 ml with dH20
Coomassie Blue Stain 10 g/L 1% Brilliant Blue R 250 
400 ml 40% Methanol/L 
100 ml 10% Acetic Acid/L 
Make up to 1 L with dH20
For analysis, 5 p.L of reducing sample buffer (4X) was added to 10 (J.L of the 
sample. Boiling at 100°C for 3 min ensued. Samples were loaded onto the gel 
(-10-15 nL per well) alongside a protein marker.
Disruption of Pellets
Although supernatants could be directly analysed on the gel, pellets had to be 
disrupted prior to analysis to liberate any protein from within the yeast cells. 
Pellets were first thawed quickly on ice. For each 1 ml sample 100 (.iL of 
breaking buffer was added to the cell pellet, which was resuspended. An equal 
volume of acid washed glass beads were added to the sample. Vortexing for 30 
sec was followed by incubation of the pellets on ice for 30 sec. This step was 
repeated eight times. Pellets were centrifuged at 2,460 x g for 10 min and the
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resulting supernatant was transferred to a clean micro centrifuge tube. Analysis 
by SDS-PAGE could then proceed.
All gels were run at 25 mA for 1.5 hrs. Gels were stained overnight in 
coomassie blue stain, followed by destaining in 10% acetic acid, 40% methanol.
Western Blot Analysis
A western blot was carried out on all samples employing anti-His6 antibodies or 
mti-Schistosoma japonicum  cathepsin C (SjCC).
Reagents required for the Western Blot protocol are outlined in the table below: 
Table 18: Western Blot Reagents
10X Phosphate Buffered Saline 
(PBS) pH 7.0
80 g/L NaCl 
2 g/L KCL 
11.6 g/L Na2H P04
2 g/L KH2PO4, adjust to pH 7.0, 
dilute to IX
Transfer Buffer 3.03 g/L Tris
14.4 g/L Glycine
100 ml 100% Methanol
Adjust vol. to 500 ml with dH20, pH
to 8.1-8.5
SDS/PAGE was carried out as normal. Eight pieces of filter paper, cut to the 
size of the gel were soaked in transfer buffer. Nitrocellulose membrane was 
also soaked in transfer buffer for 15 min. When migration of the protein 
samples on the gel was sufficient, the gel was also soaked in transfer buffer for
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5-10 min. Four pieces of filter paper were first placed on the blotter followed 
by nitrocellulose membrane, followed by the gel and lastly by the remaining 
four pieces of filter paper. Transfer was carried out at 15 V for 20 min. After 
transfer was complete blocking was carried out with IX PBS, 5% Marvel for 1 
hr. This was followed by two five-minute washes of the membrane with 1 X 
PBS- 1% Tween. Between each stage of the western blot procedure three such 
five-minute washes were carried out on the membrane. The primary antibodies, 
namely the anti-His6 antibody or the anti-SjCC antibody were added to the 
membrane at a dilution of 1:3000 and 1:200 respectively in IX PBS-Tween-1% 
Marvel for 1 hr. Next, the secondary antibody was then added to the membrane 
for 1 hr. This was goat anti-mouse IgG (1:1000 dilution in PBS-Tween) when 
the His tag was been probed and anti-rabbit IgG (1:1000 dilution in PBS- 
Tween) when SjCC was been probed. Any binding that occurred was visualised 
with DAB peroxidase.
Colony Blot Procedure
The colony blot procedure was implemented to determine whether P. pastoris 
clones actually expressed SmCC by probing with antibodies to His6.
The solutions outlined in Table 19 were needed for the colony blot procedure.
77
Table 19: Colony Blot Solutions
SDS solution 10% (w/v) sodium dodecyl sulfate
Denaturing solution 0.5 MNaOH, 1.5 M NaCl
Neutralisation solution 1.5 M NaCl; 0.5 M Tris-CL, pH 7.4 
(25°C)
20X SSC 500 ml: 87.65 g NaCl, 50.25 g 
trisodium citrate.2H20
PBS buffer As for western blot procedure
PBS-Tween As for western blot procedure
YNB plates 134 g/L YNB, 15 g/L agar, 2% final 
vol. filter sterilised MeOH added 
after autoclaving
Colonies expected to express SmCC were dotted in duplicate onto a YPD plate, 
followed by incubation at 30°C overnight. The next day these colonies were 
blotted onto sterile nitrocellulose membrane, which was then transferred to a 
YNB plate containing 2% methanol. The plates were incubated at 30°C. After 
4-6 days the nitrocellulose membranes were incubated colony side up on filter 
paper in petri dishes in the following solutions:
Table 20: Incubation Times
SDS solution 10 min
Denaturing solution 5 min
Neutralisation solution (x 2) 5 min
SSC (x 2) 15 min
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Filters were washed twice in PBS-Tween for 10 min each between all stages. 
Blocking was carried out using PBS-Tween 5% Marvel for 1 hr. Next step was 
the addition of the primary antibody which was Anti-His6 at a 1:1000 dilution 
in PBS-Tween-1% Marvel for 1 hr. Afterwards the secondary antibody was 
applied. The secondary antibody was goat-anti-mouse IgG at a 1:1000 dilution 
in PBS-Tween-1% Marvel and incubation with this antibody proceeded for 1 hr. 
DAB Peroxidase substrate was then applied to the membrane enabling 
expressing colonies to be visualised on the membrane.
ELISA Technique
For the ELISA technique the following solutions were needed:
Table 21: ELISA Reagents
0.1 M sodium carbonate buffer, pH 9.6 8 ml ofN a2C 03 (21.6 g/L) 
17 ml of NaHC03 (16.8 g/L) 
Add 25 ml dH20
Blocking Solution 1% BSA
10% sucrose in carbonate buffer
50 [iL of the sample and 150 p,L of carbonate buffer were used to coat the plate, 
which was stored overnight at 4°C. The plate was washed four times with IX 
PBS-1% Tween, followed by application of 200 i^L of blocking solution/well. 
The plate was then incubated at 37°C for 2 hrs. The aforementioned washing 
step was carried out on completion of each stage of the ELISA protocol. The 
next stage was binding of the primary antibody. 100 |xL of the antibody/well, 
diluted in PBS-Tween-Marvel was added for 1 hr. After washing, the 
secondary antibody was applied, using 100 ¡xL of the diluted antibody/well as 
before for 1 hr. The primary and secondary antibodies were as for the western
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blot procedure. Lastly, 100 pL TMB substrate was added to each well for 10 
min. The reaction was stopped on addition of 100 pL of IN H2SO4. 
Absorbance was read at 450 nm and the result was compared to a set of positive 
and negative controls.
Ni-NTA Beads Gel
This technique was used to detect the presence of an intact His-tag in the 
rSmCC samples.
• 200 pL of sample and 800 pL lysis buffer were combined
• 100 pL of Ni-chelate beads (50% suspension) for each sample were washed 
twice with 1 ml of lysis buffer. After each wash, centrifugation at 2,460 x g 
for 5 min was carried out and the lysis buffer was removed from the beads 
before proceeding to the next step.
• The sample from the first step was added to the beads and incubation for 1 
hr with shaking followed.
• Beads were then spun at 2,460 x g for 5 min and the supernatant was 
removed.
• Washing of the beads with lysis buffer was carried out as before and the 
lysis buffer was subsequently removed from the beads.
• 10 pL of H20 and 5 pL 4X sample buffer was added to the beads. The 
resuspended beads were heated to 100°C for 3 min.
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• Beads were centrifuged as before and the supernatant was transferred to a 
fresh tube prior to analysis of a 15 pL sample of each supernatant by SDS- 
PAGE.
Affinity Chromatography on Ni-NTA Agarose
Before affinity chromatography could be carried out, the following solutions 
had to be prepared:
Table 22: Stock Solutions for Affinity Chromatography
5X Monobasic sodium phosphate 35.5 g/L monobasic sodium phosphate 
(250 mM) 87.66 g/L NaCl (1.5 M)
5X Dibasic sodium phosphate 35.5 g/L dibasic sodium phosphate (250 
mM), 87.66 g/L NaCl (1.5 M)
3 M Imidazole (store at 4UC) 5.106 g/25 ml dH20 imidazole
• The sample was centrifuged at 1,260 x g for 20 min. A 1:5 dilution of 
supernatant sample in lysis buffer was performed.
• 2 ml of Ni-NTA beads were poured onto the column, which was then 
equilibrated with 3 ml of lysis buffer.
• 150 ml of the sample was applied to the column over time and the run 
through was collected.
• 15 ml of wash solution was added to the column and collected.
• 5 ml of elution buffer was applied next and was collected.
• 5 ml of “flush” was then added to the column.
• The eluate was dialysed overnight in 2 L IX PBS. The next day the PBS 
solution was changed twice and dialysis proceeded for a further 4 hrs
• Collected samples from all stages of the process were analysed by SDS- 
PAGE and the protein concentration in all samples was determined.
Table 23: Affinity Chromatography Reagents
5X Sodium Phosphate Buffer, 
pH 6.0
Monobasic:Dibasic 
87.7:12.3 (need -  50 ml)
5X Sodium Phosphate Buffer, 
pH 7.0
Monobasic:Dibasic 
39:61 (need ~ 50 ml)
5X Sodium Phosphate Buffer, 
pH 8.0
Monobasic:Dibasic
2:98 (need ~ 100 ml)
Lysis Buffer, pH 8.0 (200 ml) 40 ml 5X sodium phosphate pH 8.0,
667 |xL of 3 M imidazole (final conc. 10 
mM), adjust vol. to 190 ml with dH20, pH 
to 8.0, final vol. of 200 ml
Wash Buffer, pH 8.0 (100 ml) 20 ml 5X sodium phosphate pH 8.0, 
667 ¡xL 3M imidazole (final conc. 20 
mM), bring to 99 ml with dH20, pH to 
8.0, adjust vol. to 100 ml
Elution Buffer, pH 7.0 (20 ml) 4 ml 5X sodium phosphate pH 7.0, 1.667 
ml imidazole (final conc. 250 mM), bring 
vol. to 19 ml, pH to 7.0, adjust, to 20 ml
Flush, pH 6.0 (20 ml) As for elution buffer except use 5X 
sodium phosphate buffer pH 6.0
10X PBS See western blot solutions
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2 .2 .7 : BIOCHEMICAL CHARACTERISATION OF FASCIOLA HEPATICA CATHEPSIN 
C (F H C C ), S. MANSONI CATHEPSIN C (S M C C ) AND RECOMBINANT S. MANSONI 
CATHEPSIN C  (R S M C C )
Enzyme assays had to be carried out to determine whether an active SmCC was 
produced by Pichia pastoris. Prior to performing any enzyme assays a set of 
suitable, accurate standards had to be prepared:
Preparation of 7-amino-4-methyl-coumarin (NHMec) standards
A 500 pM stock of NHMec was prepared. The stock was prepared in 2 ml of 
dimethylformamide (DMF) to dissolve the fluorogenic NHMec and the volume 
was adjusted accordingly with dH20. Dilutions of the stock NHMec were 
performed so that a set of standards were obtained with NHMec concentrations 
in the range of 50 pM-0.78 pM. 1 ml of each standard was incubated at 37°C 
along with enzyme assays and 2 0 0  of the stopping reagent, 1 0 % acetic acid 
was added to each standard after incubation. All standards were read on a 
fluorimeter at slit width 10:10 or 10:2.5 with an excitation wavelength of 370 
nm and an emission wavelength of 440 nm. A standard curve was prepared 
plotting average fluorescence units against NHMec concentration (pM).
Preparation of F.hepatica somatic extract
Fifteen ml of Tris-HCL pH 7.0 buffer was added to whole, intact liver flukes. 
The flukes were homogenised until they had sufficiently broken up. 
Homogenisation was performed on ice. Homogenate was frozen at -80°C 
followed by thawing on ice and brief sonication. This step was repeated three 
times. Centrifugation was carried out at l,260x g for 1 hr. The supernatant was 
removed and this somatic extract was used in all assays as a positive control. 
The remaining pellet was resuspended in 0.1% Tris-Triton X and was 
centrifuged for 1 hr. The resultant supernatant was removed and this was the
83
detergent extract. The pellet was discarded. The concentration of protein in the
somatic extract was estimated using the BCA protein assay procedure.
Standard Enzyme Assay
• The pH optimum of SmCC was reported as pH 5.5. Therefore, a sodium 
acetate buffer, pH 5.5 was employed in all assays unless stated otherwise. A 
series of pH profile assays were carried out to investigate the effect of pH 
on cathepsin C activity. A series of buffers were prepared namely, sodium 
citrate, pH 3.0, 4.0, 5.0, 6.0 and 7.0, sodium acetate pH 4.0, 4.5, 5.0, 5.5 and
6.0, sodium phosphate, pH 5.0, 5.5, 6.0, 6.5, 7.0 and 7.5, Tris-HCL pH 6.0,
7.0, 7.5, 8.0 and 8.5 and glycine pH 8.5, 9.0, 9.5, 10.0 and 10.5.
• DTT was known to increase the activity of cathepsin C so it was added to all 
assays to a final concentration of 2 mM in most assays. A 20 mM assay 
stock was prepared and 100 pL of this stock was used in an assay volume of 
lml for rSmCC assays. For FhCC assays 15-100 pL of 2 mM DTT was used.
• The fluorogenic cathepsin C substrate H-Gly-Arg-NHMec was used in all 
assays. A 10 mg/ml stock of this substrate was prepared in DMF. A 100 
pmolar working stock was prepared for all assays and this was prepared by 
adding 1 pL of the stock in DMF to 257.5 pL dH2 0 . In a 1 ml tube assay 
100 pL of this working stock was used so the final concentration of 
substrate in the assay was 10  pmolar.
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Table 24: Standard cathepsin C Assay
Component Cathepsin C 
assay
Positive control Background
control
Buffer 790 (iL 790 [iL 800
DTT 1 0 0  \iL 1 0 0  [¿L 1 0 0
Enzyme 10 (aL 10 N/A
Substrate 100 |o.L 1 0 0  \ÏL 1 0 0  |xL
Final volume 1 ml 1 ml 1 ml
For rSmCC assays the enzyme was the supernatant sample from the induction 
process in P. pastoris. For the positive control, the enzyme refers to the F. 
hepatica somatic extract. This somatic Fh extract was also used as the source 
of FhCC for biochemical characterisation studies. The background control 
contained all assay components except the enzyme and was used to zero the 
fluorimeter on reading the assays.
Assays were initially carried out at 37°C. However because rSmCC activity 
proved to be low it was necessary to perform overnight assays. The 
concentration of NHMec released during the assay could be determined from 
the standard curve. Enzyme activity was calculated in units (U). 1 U is defined 
as 1 nmol of NHMec released/min/ml of enzyme.
The enzyme reaction was stopped on addition of 200 jxL of 10% acetic acid. 
All assays were read as for the NHMec standards.
Enzyme Inhibition Assays
Inhibition assays were carried out on all samples to determine whether the 
enzyme produced was a cysteine protease that could be inhibited. Unlike 
proteases such as aminopeptidase, cathepsin C does not possess its own specific
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inhibitor so it was necessary to use a general cysteine protease inhibitor. 
Leupeptin was the inhibitor of choice in these inhibition assays and it was 
prepared at a stock concentration of 100 fxM. In each assay 100 |xL of inhibitor 
was used in a 1 ml assay volume giving a final inhibitor concentration of 10 
in the assay.
The assay procedure was carried as before except the inhibitor was incubated 
with the enzyme and assay components for 10 min prior to addition of the 
enzyme.
Table 25: Sample Inhibition Assay
Component Inhibition Assay Control Background
Buffer (pH 5.5) 690 ¡xL 690 ¡xL 700 |xL
DTT 1 0 0  txL 10 0 100 (xL
Enzyme 10 jxL 10 |xL N/A
Inhibitor 100 |xL 100 |xL 1 0 0  nL
Substrate 100 [xL 100 (xL 100
Final volume 1 ml 1 ml 1 ml
For the control, the enzyme refers to the F. hepatica somatic extract. A regular 
enzyme assay without inhibitor was carried out together with the inhibition 
assay to enable accurate comparisons to be made. Inhibition assays were 
performed overnight at 37°C unless stated otherwise.
The effect of different cysteine proteinase inhibitors on SmCC and rSmCC 
activity was investigated. Inhibitors used for this study included: 
iodoacetamide, leupeptin, N-ethyl-malelimide (NEM), trans-epoxysuccinyl-L- 
leucylamide (4-guanidinol)-butane (E-64).
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lodoacetamide Inhibition Assay
The assay protocol was as for leupeptin assay with the exception of the 
concentration of iodoacetamide used. A stock solution of 1 mM iodoacetamide 
was used and the final inhibitor concentration in the assay was varied. The 
amount of buffer used was adjusted accordingly to give a final assay volume of 
1 ml.
Table 26: Iodoacetamide Inhibition Assay
Component Assay 1 Assay 2
Buffer (pH 5.5) 690 nL 780 pL
DTT 100  p.L 1 0 0  (iL
Inhibitor 100 pL 10  (xL
Enzyme 10 |xL 10 pL
Substrate 100 (iL 100 pL
In assay 1 the final concentration of inhibitor in the assay was 100 whereas 
in assay 2 it was 10 |xM. Controls were prepared as for the leupeptin assay 
detailed in Table 25.
NEM Inhibition Assay
A 5 mM stock solution of NEM was prepared and 200 pL of this was used in 
the assay to give a final assay concentration of 1 mM.
E-64 Inhibition Assay
E-64 is considered a slow inhibitor of cathepsin C whereas it is an 
instantaneous inhibitor of cathepsin L. An E-64 time course assay was carried 
out. Cathepsin LI was used as a comparison using a 100 |j,M stock of Z-Phe-
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Arg-NHMec, the substrate for cathepsin LI. The enzyme preparation used for 
all assays was F. hepatica somatic extract. The time that 1 mM E-64 was 
incubated with the enzyme prior to the addition of the substrate varied.
Table 27: E-64 Assay Procedure
Sample Ctrl. 1 Ctrl. 2 0 5 10 20 40 80
Buffer, 
pH 5.5 
(m-L)
795 790 785 785 785 785 785 785
DTT
(|xL)
1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 100
Enzyme
(m-L)
N/A 10 10 10 10 10 10 10
1 mM E- 
64 (jj.L)
5 N/A 5 5 5 5 5 5
Substrate
(M-L)
1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 100
After incubation of E-64 with the enzyme for the desired time, substrate was 
added and incubation at 37°C for 30 min ensued. As always the reaction was 
stopped on addition of acetic acid and results were read on the fluorimeter.
Halide Enhancement Assays
Cathepsin C is enhanced in the presence of halide ions. Sodium iodide (Nal), 
sodium bromide (NaBr) and sodium fluoride (NaF) at a stock concentration of 
20 mM and sodium chloride (NaCl) at a stock concentration of 10 mM were 
used in the assay. A control assay that did not contain halides was set up for 
comparative purposes. The final assay volume was 1 ml in all instances.
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Final concentrations of halides in the assays were as follows: 
Table 28: Halide Enhancement Assays
Halide Concentration
NaCl 0.1 mM, 1 mM
Nal 0.1 mM, 1 mM, 10 mM
NaBr 0.1 mM, 1 mM, 10 mM
NaF 0.1 mM, 1 mM, 10 mM
Assays were carried out as normal using 10 |xL of undiluted enzyme in pH 5.5 
buffer, 100 |xL of 2 mM DTT, incubation as usual.
Determination of Protein Concentration-BCA Protein Assay
Prior to performing the assay, bovine serum albumen standards were prepared 
at the following concentrations: 2mg/ml, 1.75 mg/ml, 1.5 mg/ml, 1.25 mg/ml, 
0.75 mg/ml, 0.5 mg/ml and 0.25 mg/ml. 25 pL of each standard was plated in 
duplicate onto rows A and B of a 96 well microtilre plate. 25 pL of the protein 
sample whose concentration was to be determined was plated at different 
dilutions (e.g., neat, 1:2, 1:5, 1:10) in duplicate onto rows C and D of the plate. 
BCA working reagent was prepared in accordance with the protocol outlined by 
the manufacturer (Pierce) and 200 [xL of this working reagent was added to each 
well. Gentle shaking of the plate ensured adequate mixing of the assay 
constituents. The plate was incubated at 37°C for 30 min after which the 
absorbance at 570 nm was read. A BCA standard curve was prepared plotting 
A570 against protein concentration (mg/ml). The concentration of protein in the 
sample could be determined from this standard curve. The specific activity of 
SmCC could be determined by dividing the enzyme activity (U) by the total 
protein concentration (mg/ml).
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3: R esu lts
3 .1 : I s o l a t io n  a n d  a m p l if ic a t io n  b y  p o l y m e r a s e  c h a in
REACTION (PCR) OF SCHISTOSOMA MANSONICATHEPSIN C (SMCC) 
CDNA FROM A CDNA LIBRARY
3.1.1: E a r l y  A t te m p ts  a t  PCR A m p l i f i c a t io n  o f  t h e  1.3 k b  SmCC cDNA a n d  
THE DISCOVERY OF THE 450 BP FRAGMENT
A number o f primers were designed for the amplification o f SmCC cDNA from 
a cDNA library in pB42AD as outlined in Figure 7.
F2
F4 M F
Stop
Pre Prosegment M a tu re
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Figure 7: Diagram showing location of primers on the SmCC cDNA
For a detailed listing o f  all primer sequences and location on the SmCC cDNA 
refer to Tables 2 and 3 in the materials and methods section (section 2.2).
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Table 29: The primer pairs used in the amplification process
Primers Expected size o f 
P C R  product
Actual size of 
PC R  product
StnCCF & Sm CCR 1.353 kb 450  bp
Sm CCF2 & Sm CCR2 1.307  kb 450  bp
Sm CCF2 & 
Sm CCM R
601 bp 601 bp
S m C C R 2 & 
Sm CCM F
728 bp 728  bp
Sm CCF2 & SmCCR3 1.311 kb 450  bp
Sm CCF2 & 
pB 42A D F
1.35 kb none obtained
Sm CCF2 & 
p B 42A D R
1.35 kb 850 bp, 350  bp & 
150 bp
SmCCM F
& pB 42A D F
778 bp none obtained
SmCCM F
& pB 42A D R
778 bp none obtained
Sm CCM F & 
SmCCR3
731 bp 731 bp
Sm CCF4 & SmCCR3 1.366  kb 480  bp
Sm CCF4 & Sm CCR4 1.393 kb 480 bp
Sm CCF2 & Sm CCR5 1.298  kb 1.298  kb
Sm CCF4 & Sm CCR5 1.353 kb 1.353 kb
Sm CCF2 & Sm CCR6 1.304  kb 1.304  kb
SmCCF & Sm C C R 6 1.315 kb 1.351 kb
Sm CCF4 & Sm CCR6 1.359  kb 1.359 kb
Sm CCM F & 
Sm CCR5
718 bp 718 bp
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Initially when using most o f the primer sets a small band o f 450/480 bp was 
visible on the gel instead o f the 1.3 kb anticipated PCR product (see Table 29 
and Figure 8).
Figure 8: The 450 bp band (lane 2) as seen on a 1% agarose gel
Lane 1 contains the 1 kb molecular weight marker (M). The 450 bp band 
in L2 was amplified using the primers SmCCF2 and SmCCR2. The 
positive control (L3) was PH 1, a reverse transcriptase gene from S. 
mansoni in pBluescript amplified with M l3 F and R primers. The 
negative control (L4) consisted o f all reaction components except 
template DNA so no band is present in this lane as expected.
For the majority o f PCR reactions the following cycle was used:
Denaturing: 95°C for 5 min (1st cycle only) 
Denaturing: 95°C for 1 min 30 sec 
Annealing: 55°C for 1 min 30 sec 40 cycles
Extension: 72°C for 1 min 30 sec 
Extension: 72°C for 10 min (last cycle only)
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However, as successful amplification o f the full-length SmCC cDNA with 
initial primers did not occur it was necessary to vary the conditions o f the PCR 
reaction.
• Firstly the MgCl2 concentration was varied in 0.5 mM increments 
from 0.5 mM to 3 mM.
• Secondly, the concentration o f dNTPs and MgCl2 were varied, MgCl2 
as before and dNTPs in 0.1 mM increments from 0.1 mM to 0.5 mM.
• Annealing temperature was varied in 5°C increments from 35-65°C.
These variations did not result in the full-length cDNA being successfully 
amplified.
On one occasion the full 1.3 kb SmCC cDNA was faintly visible relative to the 
very bright 450 bp band after amplification with SmCCF2 and SmCCR2 (Figure 
9). However, re-amplification with gel purified SmCC and the same primer sets 
proved to be unsuccessful. Subsequent amplifications with the SmCCF2, 
SmCCR2 and cDNA template failed to amplify SmCC again.
M L2 L3 L4
lkb 
500 b
Figure 9: Faintly visible 1.3 kb SmCC cDNA relative to the 450 bp PCR 
product
The 1 kb molecular weight marker is depicted in LI. In L2 the PCR 
products at 450 bp and 1.3 kb of amplification with SmCCF2 and
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SmCCR2 are visible. The positive and negative controls (L3 and L4) 
were as before (Figure 8).
Primers, SmCCMF and SmCCMR were designed to amplify a region in the 
middle o f  SmCC to prove that the full cDNA was present in the library. The 
primer sets used for this reaction are depicted in Table 29.
M L2 L3 L4 L5 L6 L7
750 bp 
500 b p ----
Figure 10: PCR amplification using “middle” SmCC specific primers
L2 shows the 728 bp PCR product obtained when PCR with SmCCR2 
and SmCCMF was carried out. The 601 bp DNA in L3 was obtained 
using SmCCF2 and SmCCMR. In L4 and L5 SmCCF2 and SmCCR3 
amplified the usual 450 bp product using a 1:10 diluted and neat cDNA 
respectively. The usual PH 1 positive control (L6) and negative control 
(L7) illustrated that the PCR had worked.
A PCR reaction was set up using primers specific for pB42AD, pFor and pRev 
to amplify the full length SmCC cDNA. By virtue o f the fact that cloning of 
the cDNA library into pB42AD was non-directional pFor was used together 
with both forward and reverse SmCC specific primers.
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M L2 L 3L 4  L5 L6 L7 L8
1 kb 
250bp —
Figure 11: PCR using pFor and pRev plasmid-specific primers
The 1 kb marker is present in LI. In L2 the use o f pFor and SmCCF2 
failed to produce a clear product. In L3 bands at 900 bp, 350 bp and 150 
bp are clear. The 900 bp band is also visible in L7. The DNA in L7 was 
amplified using pRev primer only and cDNA template. No band is 
visible in L4 using SmCCMF and pFor primers. In L5 with SmCCMF 
and pRev a band is present at <200 bp but this is probably primer-dimers 
or unused primers. The presence of the usual PH 1 positive control (L6) 
and absence o f a product for the negative control (L8) proved that the 
PCR was working properly.
The 728 bp (SmCCMF and SmCCR2) and 601 bp (SmCCMR and SmCCF2) 
DNA was gel purified and sent as a probe to the Department of Tropical 
Medicine, Tulane University, New Orleans for the screening of an S. mansoni 
Bacterial Artificial Chromosome (BAC) library.
3.1.2: S u c c e s s f u l  I s o l a t i o n  o f  t h e  1.3 k b  SmCC cDNA
The full-length SmCC cDNA was successfully amplified from the cDNA library 
using SmCCF2 or SmCCF4 forward primers with the reverse primer SmCCR5. 
Amplification with SmCCMF and SmCCR5 produced a 718 bp product as 
expected (Figure 12). However, for cloning into the pPIC9K vector it was 
necessary to re-amplify the 1.3 kb cDNA with SmCCF and SmCCR that contain 
the SnaBI and A vrll recognition sites. Using gel purified SmCC DNA
« f
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amplified with SmCCF2 and SmCCR5 as template, PCR was carried out using 
SmCCF and SmCCR but successful amplification did not occur probably as a 
result o f  low concentration and poor quality o f  the template DNA.
1.5 kb 
1 kb
Figure 12: Successful amplification of SmCC using primers SmCCF2/F4 
and SmCCR5
The 1 kb ladder (M) is clear in lane 1. The 1.3 kb band in L2 was 
amplified with SmCCF2 and SmCCR5 using a 1:10 dilution o f cDNA 
template. The same reaction was carried out for the L3 sample except 
neat cDNA was used but no band is visible in L3. In L4 the 1.3 kb 
product o f the PCR using SmCCF4 and SmCCR5 and a 1:10 dilution of 
cDNA template can be seen clearly but when neat cDNA was used as 
template (L5) no product was seen on the gel. In L6 a 718 bp product 
was successfully amplified using SmCCMF and SmCCR5 primers. The 
negative and positive PCR controls in L7 and L8 respectively showed 
that the PCR worked effectively. The PCR positive control was a 1:10 
dilution o f cDNA amplified with SmCCMF and SmCCR2 whereas the 
negative control had no template but contained all other PCR 
components.
It was thought that a problem existed with the 3’ end of the SmCC cDNA 
making amplification o f the full-length product difficult. PCR was undertaken 
to illustrate this problem.
M L2 L3L 4 L5 L6 L7 L8
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M L2 L3 L4 L5 L6 L7 L8
1.5 kb 
1 kb 
500 bp
Figure 13a: PCR to prove that a problem existed with the 3 ’ end of SmCC 
A strong 1.35 kb band was amplified with SmCCF4 and SmCCR5 (L2). 
The usual 480 bp band appears with SmCCF4 and SmCCR2 (L3). In L4 
a faint band at 1.36 kb was seen but a very bright band was also seen of 
480 bp. In L5 a strong 1.3 kb band is visible with SmCCF2 and 
SmCCR5. The usual very bright 450 bp band and faint 1.3 kb band seen 
after PCR with SmCCF2 and SmCCR2 appears again in L6. PCR with 
SmCCF2 and SmCCR3 yielded no product (L7). In L8 the very bright 
718 bp band seen was obtained with SmCCMF and SmCCR5.
M L2 L3 L4 L5 L6
750 bp 
250 b
Figure 13b: PCR to prove that a problem existed with the 3’ end of SmCC
PCR with SmCCMF and SmCCR2 produced the usual 728 bp product 
(L2). The 731 bp band seen in L3 resulted from PCR with SmCCMF and 
SmCCR3. The 601 bp band in L4 was the product o f PCR with 
SmCCMR and SmCCF2. L5 depicts the very strong 450 bp band and
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faint 1.3 kb band amplified with SmCCF and SmCCR. L6 contains the 
negative control.
As SmCCR5 did not extend beyond the stop site o f SmCC, another primer 
SmCCR6 was designed which did (Figure 7).
1 kb 
500 bp 
250 bp
Figure 14: SmCC full-length cDNA
The usual 1 kb ladder (M) is depicted in lane 1. The 1.3 kb SmCC 
cDNA is visible in L2 as amplified with SmCCF2 and SmCCR6. In L3 
the 1.3 kb gene is also present, this time amplified with SmCCF and 
SmCCR6. The full-length SmCC cDNA can also be amplified with 
SmCCF4 and SmCCRÔ (L4).
The strong 1.3 kb band obtained as a result o f PCR with SmCCF2 and SmCCR6 
was gel purified and re-amplified by PCR using primers SmCCF and SmCCR, 
which contain the restriction sites for cloning into pPIC9K (refer to section 3.2).
However, after many unsuccessful attempts at amplification of the SmCC 
cDNA containing the necessary restriction sites it decided to clone the purified 
1.3 kb cDNA amplified using SmCCF2 and SmCCR6 into the pGEM-T vector.
M L2 L3 L4
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3.1.3: C l o n i n g  o f  1.3 k b  SmCC c D N A  i n t o  p G E M
Gel purified and concentrated 1.3 kb SmCC was cloned into the pGEM-T vector 
system (refer to 2.2.2).
M L2 L3 L4 L5
1.5kb 
750 bp
Figure 15: Gel purified 1.3 kb SmCC as seen on a 1% agarose gel
LI contains the 1 kb ladder (M). In L2-L5 the gel purified 1.3 kb SmCC 
amplified with SmCCF2 and SmCCR6 is clearly visible. All four 
purified DNA samples were pooled and concentrated by ethanol 
precipitation prior to ligation to the pGEM vector.
The concentration o f 1.3 kb DNA used in the ligation procedure was 395 ng/jxL.
Table 30: Ligation of 1.3 kb SmCC cDNA to pGEM
Component A B C Positive Background
2X Buffer 5 nL 5 nL- 5 fxL 5 |xL 5 nL
Vector 3 |uL 2 p.L 1 fiL 1 jj.L 1 p,L
1.3 kb gene 1 p,L 3 nL 3 \iL
Control
insert
2 p.L
Ligase 1 |iL 1 |xL 1 |xL 1 nL 1 nL
h 2o 1 |xL 1 \iL 3 p.L
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Overnight ligation and transformation was carried out (refer to Materials and 
Methods, Section 2.2.2).
Table 31: Results of transformation process
Plates A B C
White
Colonies
A l: 1 
A2: 1
B l: 0 
B2: 0
Cl: 10
C2: 9
White colonies were selected off plate C only and were cultured overnight in 
LB-Amp broth. Plasmids were subsequently purified by alkaline lysis (refer to 
2.2.2). The success o f  the purification procedure was determined by 
visualisation o f  the purified plasmids on a 1% agarose gel and was deemed to 
be successful.
Purified plasmid DNA was used as a template in a PCR reaction employing 
SmCC specific primers and restriction digest analysis with PstI proved that the 
SmCC cDNA was contained in pGEM.
The plasmid DNA served as a template in the PCR reaction using SmCCF and 
SmCCR primers to amplify the SmCC cDNA with SnaBI and A vril restriction 
sites.
M L2 L3 L 4L 5 L6 L7 L8 L9
1.5 kb___
1 kb ----
Figure 16: PCR amplification of SmCC containing restriction sites for 
cloning
- - ■ - I .
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The marker in lane 1 is the 1 kb DNA ladder. In L2-L6 purified plasmid 
served as the template for the re-amplification o f SmCC with primers 
SmCCF and SmCCR. L7 contains the PCR positive control, which is 
cDNA template amplified with SmCCMF and SmCCR2 and the bright 
band seen at 728 bp proves the PCR to be a success. In L8 pGEM vector 
was used as template for PCR with SmCCF and SmCCR. No band 
should be visible but faint band at 450 bp and stronger band at 150 bp 
indicate that non-specific binding o f primers to the pGEM vector 
occurred. The absence o f DNA in L9, the negative control shows that 
the PCR reaction components were not contaminated.
3.1.4: C l o n i n g ,  S e q u e n c i n g  a n d  A l i g n m e n t  o f  t h e  450 b p  P C R  p r o d u c t
To determine what the 450 bp fragment was that was repeatedly amplified with 
the SmCC specific primers as described earlier, it was decided to sequence this 
fragment. The 450 bp product was amplified using SmCCF2 and SmCCR2 
forward and reverse primers. A gel purified, concentrated 450 bp PCR product 
was cloned into the pGEM-Easy vector system. PCR analysis o f the purified 
plasmids using the pGEM specific primers pGEM F and pUC/M13 R 
demonstrated that the 450 bp product was contained in the pGEM vector 
(Figure 17).
M L2 L3 L4 L5 L6
1 kb ladder
622 bp band
ofpGEM-
450
172 bp band of 
pGEM alone
Figure 17: Bands showing the 450 bp band in the pGEM vector
101
The 1 kb ladder (M) is in lane 1. PCR amplification o f the pGEM-450 
construct with pGEM F and pUC/M13 R results in a 622 bp band (L2- 
L4) being produced. PCR o f pGEM vector alone gives a band at 172 bp 
(L6). The negative control, which contains all reaction components 
except template DNA did not produce any band proving that no 
contaminants were present (L5). Non-specific bands are also visible at 1 
kb and 2 kb in L2-L4.
Sequencing was carried out in the 3 ’->5’ direction using the pUC/M13 reverse 
primer (Figure 18).
1 pGEM forward primer
GGGCGAATTGGGCCCGACGTCGCATGCTCCCGGCCGCCATGGCGGCC
60
GCGGGAATTCGAT*ATCACTAGTGAATTCGCGGCCGCCTGCAGGTCGAC
CATATGGGAGAGCTCCCAACGCGTTGGATGCATAGCTTGAGTATTCTAT
PUC/M13 reverse primer
AGTGTCACCTAAATAGCTTGGCGTAATCATGGTCATAGCTGTTTCCTG
TGTGAAAT
200
* denotes the point where the pGEM vector was linearised with EcoR V and 
where a T-residue was added to both 3’ ends for ligation of the PCR product to 
the vector
Figure 18: Location of pGEM specific primers on pGEM-T Easy vector
pGEM-450 amino acid sequence aligned with 99.2% identity (129/130 amino 
acids) with the first 130 amino acids o f Sm procathepsin C. However, the last 9
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amino acids o f  pGEM-450 namely LGVRFDPVL had 100% identity with the 
last 9 amino acids o f SmCC. This indicated that the middle o f the SmCC cDNA 
was missing from the 450 bp product, giving rise to a shorter truncated SmCC.
10 20  30  40 50
I I I I I
SmCC ADTPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFGNRGHWTL 
450 ADTPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFGNRGHWTL 
Cns. ADTPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFGNRGHWTL
60 70  80  90  100  110
I I I I I I
SmCC IYNQGFEVAINHRKWLVIFAYKSNGEFNCHKSMPMWTHDTLIRQWKCFVAEKIGVHDKFH 
450 IYNQGFEVTINHRKWLVIFAYKSNGEFNCHKSMPMWTHDTLIRQWKCFVAEKIGVHDKFH 
Cns. IYNQGFEValNHRKWLVIFAYKSNGEFNCHKSMPMWTHDTLIRQWKCFVAEKIGVHDKFH
120  130
I I
SmCC INKLFGSKSFGRTLYHIN
pGEM4 5 0 INKLFGSKSLGVRFDPVL —
Cns. INKLFGSKSlGrrldh!n
Figure 19: Alignment of SmCC with pGEM-450
Note: The first amino acid (A) in figure 18 is actually the 20th amino acid of 
preprocathepsin C because a 19 amino acid signal sequence precedes 
procathepsin C. The consensus sequence is also shown (cns).
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3.2: C lo n in g  o f  t h e  Sm CC cDNA i n t o  pPIC9K v e c t o r  a n d
SEQUENCE ANALYSIS
3.2.1: C l o n in g  a n d  v e r i f i c a t i o n  o f  t h e  p r e s e n c e  o f  SmCC i n  pPIC9K
The SmCC cDNA and pPIC9K were successfully linearised with SnaBI and 
Avrll. An overnight ligation was then performed, using a 3:1 molar ratio o f  
vector:insert. Transformation o f E. coli with the vector/SmCC ensued the next 
day. Initially, transformation efficiency proved to be poor and PCR using 
purified plasmid DNA from an overnight bacterial culture o f the selected 
transformant with the pPIC9K specific primers AOX3’ and a-factor produced 
only the 195 bp band characteristic o f pPIC9K that does not contain an inserted 
gene (Figure 20). The presence o f the insert in the vector would be indicated 
by a band at 1.5 kb (195 bp o f pPIC9K + 1.3 kb o f SmCC). A PstI  digest was 
also performed to verify the presence o f  SmCC in the vector. The expected 
fragment sizes produced when vector alone and vector containing the SmCC 
cDNA were cut with PstI  are depicted in Table 32.
On one occasion, only 75 ng/j^L o f SmCC and 20 ng/pL o f vector were 
available. In this instance the usual 3:1 vector:insert ratio was not maintained 
in the subsequent ligation. 2\xL o f SmCC and lO^L o f vector were used. 
Transformation was carried out as usual. On analysis o f the purified plasmid 
DNA by PCR using AOX3’ and a-factor primers, the 195 bp band o f pPIC9K 
appeared on the gel together with a faint 1.5 kb band for two out o f  three of the 
plasmids. This could mean that contamination o f the purified plasmids with 
pPIC9K occurred, or that a mixed colony was used which had plasmids that 
contained SmCC but also those that did not (Figure 22). A double digest was 
performed on the samples using SnaBI and A vrll  to liberate the 1.3 kb SmCC 
cDNA from pPIC9K. However, the 1.3 kb band was not seen, only the
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characteristic 9.3 kb pPIC9K was visible on the gel o f this digest which showed 
that SmCC was not contained in the vector.
M L2 L3 L4L5L6L7L8L9L10L11
250 bp 195 bp
Figure 20: Screening of eight transformants by PCR using AOX3’ and a- 
factor primers
Lane 1 contains the 1 kb DNA ladder (M). In L2-L9 the eight 
transformants all produce the 195 bp band expected for pPIC9K without 
an insert. As a control pPIC9K vector was also amplified with the 
primers and the expected 195 bp band can be seen clearly (L10). A 
negative control was also included in the PCR that contained all 
components o f the reaction except template DNA. No band was 
expected but the amplification o f a 195 bp band in L ll  is suggestive o f  
pPIC9K contamination of the PCR.
Typically, prior to ligation, digested vector and plasmid DNA was cleaned up 
using a Wizard kit (Promega). However the transformation process was seen to 
be more efficient when DNA that had not been cleaned-up was used in the 
ligation process. After overnight ligation was performed ligation products were 
run on a gel (Figure 23). Ligation was deemed unsuccessful for those samples 
in which a distinct 1.3 kb band was visible on gel analysis as this indicated that 
the SmCC eDNA had not been ligated to the vector. Only samples that did not 
show the distinct 1.3 kb SmCC band on the gel were selected for the 
transformation process. Transformation efficiencies were high in this instance 
with hundreds o f colonies present on plates (plates B1 and B2). Nevertheless,
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screening with A 0X 3’ and a-factor primers amplified only the 195 bp band of 
pPIC9K.
M L2 L3L4L5L6L7L8L9L10L11
Figure 21: PstI digest of eight pPIC9K clones expected to contain SmCC
The usual 1 kb ladder is visible in lane 1 (M). Lane 2-9 contains the 
eight purified plasmids isolated from the selected transformants. The 
expected bands at 1.241 kb, 1.827 kb, 2.55 kb and 3.6 kb can be seen for 
all samples except 3 and 4 (L4 and L5). Also a very strong band at 5 kb 
is present for all samples except 3 and 4. If the plasmids prove positive 
for the presence o f SmCC it is expected that a band of 4.9 kb would be 
produced but the 3.6 kb band should be absent. In this case both the 4.9 
kb and 3.6 kb bands are present, which provides an inconclusive result. 
A control was included (LI 1) which was pPlC9K vector alone cut with 
PstI and bands produced are o f the expected sizes (refer to Table 32).
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M L2 L3 L4 L5 L6
1.5 kb
250 bp 195 bp
Figure 22: PCR amplification of three pPIC9K clones expected to contain 
SmCC using AOX3* and a-factor primers
The 1 kb DNA ladder is depicted in LI (M). In L2-L4 the 195 bp band 
o f pPIC9K is clear. However, a band is also visible -1 .5  kb which 
would indicate that pPIC9K does in fact contain the 1.3 kb SmCC cDNA. 
The control in L5 is pPIC9K vector amplified with AOX3’ and a-factor 
primers. The negative control in L6 has a distinct 195 bp band, which is 
indicative o f pPIC9K contamination o f the PCR as no template DNA was 
added in this reaction.
Figure 23: Gel of overnight ligation products
LI contains the 1 kb DNA ladder (M). In all lanes 9 jxL o f ligation mix 
was used. In L2-L6 pPIC9K 9.3 kb DNA is clearly visible but for 
samples 2 and 5 (L3 and L6) the 1.3 kb SmCC cDNA can also be seen
M L2 L3 L4 L5 L6 L7
1.3 kb
1.5 kb
1 kb
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which illustrates that ligation was not successful for these samples. L7 
contains pPIC9K as a control.
A series o f digests were performed to establish whether the insert was present 
in the vector (Table 32).
Table 32: Restriction digests performed to verify that pPIC9K contained 
the SmCC cDNA
Restriction
enzyme
Fragments
produced
(pPIC9K)
Fragments
produced
(pPIC9K
and
SmCC)
Result
Kpnl 612 bp 
8,683 bp
612 bp 
9,983 bp
Digestion
incomplete
PstI 1,241 bp 
1,827 bp 
2,555 bp 
3,677 bp
1,241 bp 
1,827 bp 
2,555 bp 
4,977 bp
Inconclusive
StuI 1,425 bp, 
7,870 bp
1,425 bp 
9,170 bp
Digestion
incomplete
Xbal 2,034 bp 
7,261 bp
1,935 bp 
2,583 bp 
6,712 bp 
6,729 bp
As above
Xhol 1,195 bp 
3,583 bp 
4,517 bp
1,195 bp 
3,583 bp 
4,517 bp
As above
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Double digests were also performed using SnaBI and AyrU  to liberate the 
SmCC cDNA from pPIC9K if  present. Digestion proved to be incomplete after 
numerous attempts.
Colonies were screened from the highly efficient transformation (plate B2). 
Plasmids were isolated from an overnight culture o f the selected transformant 
by the methods detailed in 2.2.2. Colonies used for screening were replica 
plated to enable further analysis o f  the same colonies. A new screening method 
was implemented using SmCC specific primers in conjunction with pPIC9K 
specific ones.
M L2 L3 L4 L5 L6 L7 L8 L9 L10 L l l  L12
1 kb 
500 bp
Figure 24a: PCR using SmCCF2 and SmCCMR primers for the detection of 
SmCC in pPIC9K in ten selected transformants from plate B2
LI contains the 1 kb DNA ladder (M). 10 \iL o f each PCR product and 2 
p.L o f loading dye was loaded into each well. A strong 601 bp band is 
visible in L2, L5, L7, L9 and L ll  for clones 1, 4, 6, 8 and 10, This band 
is faint in L4 and L10. L12 contains 5fiL o f pPIC9K and 2 pL o f loading 
dye
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M C l C2 C3 C4
750 bp 
250 bp
Figure 24 b: Controls for PCR (24a)
C l, which was purified SmCC template amplified with SmCCF2 and 
SmCCMR produced the expected 601 bp band. No band was visible for 
C2 as expected because only one primer was used in this PCR with 
SmCC purified template. A low band present for C3 could be as a result 
o f primer-dimer formation. The template for C3 PCR was pPIC9K and 
SmCCF2 and SmCCMR primers were used. No band is expected and 
none is seen. The last lane C4 contains 5|xL o f pPIC9K and 2 of 
loading dye.
N otl was used to linearise plasmid DNA from 6 clones (clones 1, 4, 6, 8, 9 and 
10), which appeared positive when screened with SmCCMF2 and SmCCMR 
(Figure 24a). All clones were originally from transformant plate B2. The 
linearised plasmids were then compared by size on a gel to both digested and 
undigested pPIC9K vector as an increase in size o f the vector would indicate 
that it contained SmCC.
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4 kb *
M L2 L3 L4 L5 L6 L7 L8 L9
10 kb
8 kb
Figure 25: N oti digest to linearise plasmid DNA
LI (M) contains the 1 kb ladder. Each lane contains 20 ¡¿L of plasmid 
DNA and 5 ^L o f  loading dye. The linearised plasmid DNA in L2-L8 
appears to run slightly higher than digested pPIC9K. However, this 
could be because the DNA in L2-L8 is more concentrated than that in L9,
Another screening strategy employed involved the use o f the A 0 X 3 ’ primer 
with SmCCMF and the a-factor primer with SmCCMR to screen for plasmids 
which contained SmCC (Table 33). The same isolated plasmids were screened 
as in the PCR in Figure 24a.
Table 33: Sizes expected for screening with SmCC and pPIC9K primers
Primer sets Product size
a-factor
SmCCMR
664 bp
AOX3’
SmCCMF
814 bp
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1 kb 
500bp
M L2 L3 L4 L5L6 L7 L8 L9 L10L11
Figure 26: Screening of transformants for SmCC using a-factor and 
SmCCMR
The 1 kb ladder is depicted in lane 1(M). The 664 bp band indicative o f  
a positive result for SmCC is seen in L5, L6 and L9 for clones 4, 5 and 8 
respectively. Only clones 4 and 8 were positive for SmCC when 
screening with SmCCF2 and SmCCMR primers.
Figure 27: Screening of plasmids for SmCC using AOX3’ and SmCCMF
The 1 kb ladder is clearly visible in lane 1(M). The band at 814 bp, 
which is indicative o f a positive result for SmCC is seen in L5, L6 and 
L9 for clones 4, 5 and 8. For those clones which do not appear to be 
positive for SmCC (clones 1, 2, 3, 6, 7, 9 and 10) a distinct band at 1.4 
kb is visible.
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Purified plasmid DNA was sent for sequencing. The resulting sequence data 
proved that the selected clones did not contain the SmCC cDNA (from 
transformation plate B2).
For further analysis transformation plate B l was used. A new SmCC specific 
primer, SmCCMF2 was designed, which when used along with SmCCMR would 
amplify a 200 bp SmCC band (Figure 28). PCR screening with a-factor and 
SmCCMR, and AOX3’ and SmCCMF revealed that 4 out o f 8 o f the selected 
colonies, namely transformants 2, 4, 6 and 8 appeared positive for SmCC.
M L2 L3 L 4L 5 L6 L7 L8 L 9L 10L 11L 12
250 bp
Figure 28: Screening of clones using primers SmCCMF2 and SmCCMR
The usual 1 kb ladder is depicted in lane 1 (M). The 200 bp band 
expected if  clones were positive for SmCC can be seen clearly in 6 o f the 
8 clones (L3-L7 and L9) and is faintly visible in the other two (L2 and 
L8). SmCC DNA was also amplified with the primers and the resultant 
200 bp band is visible in L10. PCR using the primers and pPIC9K 
template did not produce a 200 bp product as expected (L ll)  and the 
absence o f a band in L I2, the negative control, shows that no 
contaminants were present in the PCR.
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Plasmids that appeared positive for SmCC on PCR screening with SmCCMF2 
and SmCCMR (clone 2, 4 and 6) were used to transform E. coli cells. The 
transformation proved to be very efficient with ~200 colonies on each plate. 
One plate was selected to work with, the plate containing clone 2. However, 
although the previous PCR screenings revealed this clone to be positive for 
SmCC, subsequent screening failed to replicate this result. More colonies were 
selected o ff plate 2 and were screened. Further screening with SmCCMF2 and 
SmCCMR produced a positive result for all clones with a strong 200 bp PCR 
product visible on the gel. Screening with AOX3’ and SmCCMF produced a
1.4 kb band for all clones, which in previous PCRs was associated with a 
negative result (Figure 27). Plates 4 and 6 were also screened by PCR for 
SmCC but results proved inconclusive.
Restriction digests were performed on all potentially positive clones using 
SnaBJ and A vrll to liberate the 1.3 kb SmCC cDNA from the pPIC9K vector. 
However, for all clones analysed no 1.3 kb was seen when digested products 
were run on a gel which indicated that plasmids did not contain SmCC.
M L2 L4 L6
10 kb
Figure 29: Double digest of plasmids using SnaBI and A vrll
Lane 1 contains the 1 kb ladder (M). For all lanes 20 \iL o f digested 
plasmid was loaded. L2 contains the digested plasmid expected to 
contain SmCC. L4 contains digested pPIC9K known to contain F.
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hepatica cathepsin LI (FhCLl). Digested pPIC9K without an insert is 
depicted in lane 6. The band in L2 is o f a similar size to that in L6 so is 
pPIC9K DNA. The absence o f a 1.3 kb band proves that SmCC is not 
present in the vector. In L4 the high band o f pPIC9K is present but also 
a 1 kb band is visible which illustrates that pPIC9K contained FhCLl, 
which was released from the vector on digestion.
Purified SmCC cDNA with SnaBI and A vrll  restriction sites was digested as 
before prior cloning into pPIC9K. The DNA was cleaned-up after digestion 
was complete. The concentration o f DNA was 105 ng/jxL and 115 ng/jxL for 
vector and SmCC respectively. Two overnight ligations were performed using 
a 3:1 (ligation A) and 2:1 molar ratio o f vector:insert (ligation B). The results 
o f the subsequent transformation are outlined in Table 34.
Table 34: Results of transformation
Transformation No. of colonies
A A l: 20
A2: 23
B B l: 25
B2: 42
E. coli control No growth
pPIC9K +ve TNTC
control
Plate A1 only was selected for further analysis for simplicity.
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M L2 L3L 4 L5 L6 L7 L8
9 kb 
6 kb
2 kb 
1 kb
Figure 30: Gel of purified plasmid DNA (plate A l)
5 o f plasmid and 3 |j.L o f loaded dye were applied to each lane. 
All plasmids with the exception o f plasmid # 4 (L5) appear to be 
the same size as the pPIC9K vector without insert (L8). Plasmid 
4 appears to be larger than pPIC9K, which indicates that the 
SmCC cDNA is possibly contained in this plasmid.
PCR using SmCCF2 and SmCCMR (Figure 31) and a-factor and SmCCR 
primers (Figure 32) on all plamids (1-5) showed that SmCC was present in the 
vector.
M L2 L3 L4 L5 L6 L7 L8 L9
750 bp 
500 bp
Figure 31: PCR amplification of SmCC specific band using SmCCF2 and 
SmCCMR
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The SmCC 601 bp band can be clearly seen for all plasmids (L2-L6), 
which indicates that pPIC9K contains the SmCC cDNA. The positive 
control in L8 is a pure SmCC template amplified with SmCCF2 and 
SmCCMR. When pPIC9K was amplified with these primers (L9) a band 
at 601 bp can also be seen which indicates that contamination occurred 
in the PCR. However, this band does not appear as strong as the other 
601 bp bands visible on the gel.
M L2 L3 L4 L5 L6 L7 L8 L9
Figure 32: PCR amplification of SmCC specific band using a-factor and 
SmCCMR primers
The DNA o f the 1 kb ladder appears to have degraded somewhat 
although the bands are still distinct. The band o f 664 bp that is expected 
if  SmCC is contained in the vector is visible for all plasmids (L2-L6). 
Pure SmCC template amplified with a-factor and SmCCMR produced a 
faint band at 664 bp, which should not be the case (L8) and when 
pPIC9K served as a template this faint band can also be seen (L9).
A double digest with SnaBI and A vrll  was performed to prove conclusively 
whether plasmid # 4 contained SmCC (Figure 33). Plasmid 4 was chosen 
because o f all the plasmids it looked most likely to contain SmCC on gel 
analysis (Figure 30).
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M L2 L3 L4 L5 L6
10 kb
1.5 kb 
500 bp
Figure 33: Double digest with SnaB I  and A v r ll
The 1 kb ladder is depicted in lane 1 (M). 25 fiL o f three samples o f  
plasmid # 4 (4A, 4B and 4C) were loaded into each lane (L2*L4). In 
each o f  these lanes the 1.3 kb band is clearly visible having been 
released from the 9.3 kb pPIC9K plasmid. In L5 pPIC9K known to 
contain FhCLl was digested and the 1 kb FhCLl band was successfully 
Liberated from the plasmid thus proving the success o f  the digestion 
process. The pPIC9K vector was also digested as a control (L6).
PCR was carried out using plasmid # 4 (4A, 4B and 4C) and AOX3 ’ and a- 
factor primers as an additional verification o f the presence o f SmCC in the 
vector (Figure 34).
Using the plasmid # 4, E. coli cells were transformed and plasmids were 
isolated and confirmed to contain SmCC. This was done to provide a plentiful 
supply o f the plasmid DNA for sequencing.
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SnaBl Avril
pPIC9K Mature Enzyme pPIC9K
Figure 34a: Diagrammatic representation of SmCC/pPIC9K construct.
M L2 L3 L4
B
Figure 34 b: PCR with AOX3’ and a-factor primers to show that pPIC9K 
contained the SmCC cDNA
The 1.5 kb bands in L2-L4 (4A, 4B and 4C) show conclusively that 
SmCC is present in pPIC9K. Controls (not shown) were also included in 
the PCR one o f which was a pPIC9K template amplified with AOX3’ and 
a-factor primers producing the characteristic 195 bp band for pPIC9K. 
The other contained all PCR components except template DNA showed 
that contaminants were not present in the PCR.
3 .2 .2 :  S e q u e n c in g  o f  SmCC in  pPIC9K
Sequencing was carried out on purified plasmid DNA # 4 to verify that it 
contained SmCC and also to confirm that changes had not occurred in the 
cDNA sequence, particularly in the active site. Sequencing was carried out in 
the 3 ’—* 5 ’ direction using the following primers depicted in colour in Figure
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PRO REGION
Sna BI MR4 MR4
GYVADTPANCTYEDAHGRWKFHIGPYOSKCPEKLNSKQSVVISLLYPD
IA
IDEFGNRGHWTLIYNQGFEVTINHRKWLVIFAYKSNGEFNCHKSMPM
W
MR
THDTLIROWKCFVAEK1GVHDKFHINKLFGSKSFGRTLYHINPSFVPK1
N
AHOKSWRAElYPELSKYTrDELUNRAGGVKSMVTRPSVLNRKTPSKEL
MR MATURE REGION
ISLTGNLPLEFDWTSPPDGSRSPVTPIRNQGICGSCYAFASAAALEARIRLV
SNFS
MR5
EQPILSPQAVVDCSPYSEGCNGGFPFLIAGKYGEDFGFVSENCDPYTGEDT
GK
MRS
CTVSKNCTRYYTADYSYIGGYYGATNEKLMOLELISNGPFPVGFEVYEPF
QE
AOX3’
YKEGIYHHTTVQNDHYNFNPFELTNHAVLLVGYGVDKLSGEPYWKVK
NS
Avrll
WGVEWGEQGYFRILRGTDECGVESLGVRFD PVLHHHHHH STOP PRAAN
Figure 35: Location of the primers used to sequence the SmCC cDNA
• Pink: AOX 3 ’ primer, underlined pink region denotes overlap in the 
sequence obtained using AOX3 ’ with that using SmCCMR5
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• Green: SmCCMR5 primer, underlined green region denotes overlap in 
the sequence obtained using MR5 with SmCCMR primer
• Red: SmCCMR primer, underlined red region denotes overlap in the 
sequence using this primer with sequence obtained using MR4 primer
• Blue: SmCCMR4 primer which sequenced some pPIC9K amino acids 
(not shown) in addition to SmCC amino acids
The yellow highlighted regions indicate the primer binding sites on the cDNA.
DTPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFG
NRGHWTLIYNQGFEVTINHRKWLVIFAYKSNGEFNCHKSMPMWTHDTLIR
QWKCFVAEKIGVHDKFHINKLFGSKSFGR.TLYHINPSFVDKINAHQKSWR
AEIYPELSKYTIDELRNRAGGVKSMVTRPSVLNRKTPSKELISLTGNLPLEF
DWTSPPDGSRSPVTPIRNQGICGSCYAFASAAALEARIRLVSNFSEQPILSPQ
AVVDCSPYSEGCNGGFPFLIAGKYGEDFGFVSENCDPYTGEDTGKCTVSK
NCTRYYTADYSYIGGYYGATNEKLMQLELISNGPFPVGFEVYEDFQFYKE
GIYHHTTV QNDH YNFNPFELTNH AVLLV GY G VDKLS GEP YWKVKNS WG
VEWGEQGYFRILRGTDECGVESLGVRFDPVL
Figure 36: The full amino acid sequence of the SmCC cDNA
The 198 amino acid propeptide is shown in blue and the 237 mature region is 
shown in black. The active site residues Cys 30, His 181 and Asn 203 are 
shown in red.
3.2.3: Alignment of SmCC cDNA with the Genbank sequence and other 
cathepsin Cs
An alignment was performed aligning the deduced amino acid sequence of 
SmCC from the Genbank (Butler et al., 1995) with the SmCC sequence detailed 
in Figure 36.
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10 20  30  40  50  60
l i l i l í  
SmCC ADTPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFGNRGHWTLI 
GB ADTPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFGNRGHWTLI 
Cns. ADTPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFGNRGHWTLI
70 80  90 100  1 1 0  120
l i l i l í
SmCC YNQGFEVTINHRKWLVIFAYKSNGEFNCHKSMPMWTHDTLIRQWKCFVAEKIGVHDKFHI 
GB YNQGFEVTINHRKWLVIFAYKSNGEFNCHKSMPMWTHDTLIDSGSV-CSGKIGVHDKFHI
Cns. YNQGFEVTINHRKWLVIFAYKSNGEFNCHKSMPMWTHDTLIrqgkc caeKIGVHDKFHI
130  140  150  160  170  180
l i l i l í  
SmCC NKLFGSKSFGRTLYHINPSFVDKINAHQKSWRAEIYPELSKYTIDELRNRAGGVKSMVTR 
GB NKLFGSKS FGRTLYHINPSFVGKINAHQKSWRG51YPELSKYTIDELRNRAGGVKSMVTR 
Cns NKLFGSKSFGRTLYHINPSFVdKINAHQKSWRaEIYPELSKYTIDELRNRAGGVKSMVTR
190  2 0 0  21 0  2 2 0  2 3 0  240
l i l i l í
SmCC PSVLNRKTPSKELISLTGNLPLEFDWTSPPDGSRSPVTPIRNQGICGSCYAFASAAALEA 
GB PSVLNRKTPSKELISLTGNLPLEFDWTSPPDGSRSPVTPIRNQGICGSCYASPSAAALEA 
Cns. PSVLNRKTPSKELISLTGNLPLEFDWTSPPDGSRSPVTPIRNQGICGSCYAfaSAAALEA
250  2 6 0  27 0  2 8 0  2 9 0  300
l i l i l í  
SmCC RIRLVSNFSEQPILSPQAVVDCSPYSEGCNGGFPFLIAGKYGEDFGFVSENCDPYTGEDT 
GB RIRLVSNFSEQPILSPQTVVDCSPYSEGCNGGFPFLIAGKYGEDFGLPQKIVIPYTGEDT 
Cns RIRLVSNFSEQPILS PQaVVDCS PYSEGCNGGFPFLIAGKYGEDFGlpqencdPYTGEDT
310  3 20  330  3 4 0  3 50  360
l i l i l í
SmCC GKCTVSKNCTRYYTADYSYIGGYYGATNEKLMQLELISNGPFPVGFEVYEDFQFYKEGIY 
GB GKCTVSKNCTRYYTTDYSYIGGYYGATNEKLMQLELISNGPFPVGFEVYEDFQFYKEGIY
Cns. GKCTVSKNCTRYYTaDYSYIGGYYGATNEKLMQLELISNGPFPVGFEVYEDFQFYKEGIY
3 70  3 8 0  390  40 0  4 1 0  420
l i l i l í  
SmCC HHTTVQNDHYNFNPFELTNHAVLLVGYGVDKLSGEPYWKVKNSWGVEWGEQGYFRILRGT 
GB HHTTVQTDHYNFNPFELTNHAVLLVGYGVDKLSGEPYWKVKNSWGVEWGEQGYFRILRGT 
Cns. HHTTVQnDHYNFNPFELTNHAVLLVGYGVDKLSGEPYWKVKNSWGVEWGEQGYFRILRGT
430
I
SmCC DECGVESLGVRFDPVL 
GB DECGVESLGVRFDPVL 
Cns. DECGVESLGVRFDPVL
Figure 37: Amino acid alignment of SmCC with the Genbank SmCC (GB), 
(accession no: Z32531). The consensus sequence is also shown (Cns)
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The results o f  the alignm ents perform ed on SmCC are discussed in detail in 
Section 4.3. A lthough SmCC cDNA was seen to be 94.5%  identical to that in 
the Genbank some differences w ere apparent (Figure 37). SmCC cDNA was 
aligned w ith rat, m ouse, hum an and S. japonicum  cathepsin  Cs and significant 
changes in am ino acid sequence am ong the species w ere noted (Figure 38 and 
39).
Rat CC RN W ACFVGK
M ouse CC RN W ACFVGK
Hum an CC RNW ACFTGK
SmCC RQW KCFVAE
SmCC (G enbank) D S G _ S V C S G  
SjCC CQW HCFTAT
Figure 38: Amino acid differences between SmCC and Genbank SmCC 
proregions and the conservation of these changes among different species
R at CC 
M ouse CC 
H um an CC 
SmCC
Genbank SmCC 
SjCC
VVEENCF
VVEESCF
LVEEACF
FVSENCD
LPQKIVI
FVEEKCN
Figure 39: Amino acid differences between SmCC and Genbank SmCC 
mature enzymes and the conservation of these changes among different 
species
Am ino acid identities o f  SmCC w ith the S. japonicum  cathepsin C (SjCC) and 
m am m alian cathepsin  Cs are shown in  Table 35.
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Table 35: Amino acid identities of aligned sequences
A lignm en t (p ro  an d  m a tu re  reg ions) %  am ino  ac id  id en tity
SmCC and G enbank SmCC 94.5%  (412/436)
SmCC and SjCC 60.78%  (265/436)
SmCC and H um an 47.99%  (215/448)
SmCC and R at 48.2%  (216/448)
SmCC and M ouse 48.44%  (217/448)
As the am ino acid changes tha t occurred did no t affect the key sites in 
particu lar the active site on SmCC it was possib le to proceed w ith the 
functional expression o f  th is fragm ent in P ichia  pastoris .
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3.3: F u n c t i o n a l  e x p r e s s i o n  o f  SmCC i n  P ic h ia  p a s t o r is
3.3.1: T r a n s f o r m a t i o n  o f  P ic h ia  p a s t o r is  w i t h  SmCC
The restric tion  enzym e B glH  was used to linearise the pPIC9K/SmCC 
expression cassette p rio r to  transform ation o f  P. pasto ris . B g lll  stim ulates gene 
replacem ent at the AOX1 loci in  P. pastoris. This restric tion  enzyme was 
selected because it did not cut SmCC w hereas the other two enzym es that could 
be used, S a il  and Sac I  cut w ithin the SmCC cDNA.
Figure 40: B glll restriction digest of pPIC9K/SmCC expression cassette
The 1 kb m arker is depicted in lane 1 (M). The two d istinct bands at 8.2 
kb and 2.4 kb in  L2 show that pPIC9K /Sm CC digestion w ith B g lll  was 
successfully  com pleted. As a  control pPIC9K  alone was digested w ith 
B g lll and the expected bands at 6.8 kb and 2.4 kb are clearly v isible in 
L 3 . U ndigested pPIC9K  was included in L4 fo r com parative purposes.
For the first transform ation  carried out, 1.8 |ng o f  digested pPIC9K/Sm CC was 
used to  transform  P  p a sto ris  GS115 cells. A fter 5 days incubation at 30°C the 
confluent growth o f  spheroplasts on RDBH and no grow th on RDB was 
observed. Tiny colonies appeared on the transform ed P. pastoris  plates. A cell
M L2 L3L4
2 kb
10 kb 
6 kb
125
count revealed that 3 x 105 and 1 x  105 cells/m l w ere present in the top agar o f  
each duplicate plate. As a cell count o f  5 x 105 cells/m l is recom m ended for 
p lating onto G418, each cell suspension (200 jiL) was p lated neat onto each 
G418 plate. A fter 6 days incubation no grow th was observed on any o f  the 
plates. H ow ever, P. pastoris  grew  well on YPD, indicating that yeast cells 
w ere viable.
For the second transform ation, 5 (j,g o f  pPIC9K /Sm CC w as used. As a control,
2.4 ng o f  B g lll  d igested pPIC9K  w as used to transform  P. pastoris.
Table 36: Results of P. pastoris transformation # 2
Plate Days incubation Cell count
A(Sm CC/pPIC9K) 7 5.45 x 10 / cells/m l
B (pPIC9K) 10 3 x 106 cells/m l
W hen plating on G418, yeast cell suspensions were diluted to 5 x 105 cells/ml. 
N eat cell suspension was also p la ted  (plate C).
Table 37: Results of G418 plating
Plate Days
incubation
Colonies
(duplicate
plates)
A l 10 2
A2 11
B1 7 150
B2 147
C l 4 C onfluent
C2 growth
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The above results are for 0.25 m g/m l G418 plates only as no growth was 
observed at h igher G418 concentrations. A fter single colony purification on 
YPD p lates, re-plating onto 0.25 m g/m l G418 ensued. Single colonies from 
these p la tes w ere blotted onto M M /M D plates for phenotypic analysis. 
Colonies grew  w ell on MD but no t on MM and so w ere deem ed to be o f  the 
M uts phenotype. Colonies on the  MD plates were single colony purified on 
YPD p rio r to com m encing the induction  protocol.
PCR Analysis of P. pas tor is Integrants
PCR w as carried  out using 5 ’A O X l and 3 ’A O X l prim ers to determ ine w hether 
SmCC had  been integrated  into the P. p a sto ris  genom e. PC R  o f  pPIC9K  alone 
using 5 ’A O X l and 3 ’A O X l resu lts in  a 492 bp PC R  product. Therefore, a 1.8 
kb PCR product is indicative o f  the presence o f SmCC in  the P. pastoris  
genom e (492 bp + 1,300 bp).
M L2 L3 L 4 L 5 L 6 L 7  L8 M
2 kb
1 kb
Figure 41: PCR screening of P. pastoris clones using 5’AOXl and 3’AOXl 
primers
The 1 kb ladder is depicted in lanes 1 and 9. In lane 2 a band is visible 
at 1.8 kb w hich illustrates tha t SmCC has been successfully  integrated 
into the P. p a sto ris  genom e for transform ants A2. The same is true for 
transform ants from  plate C2, w ith  the appearance o f  a 1.8 kb band in L3.
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In L4, PCR w ith P. pastoris  strain  GS115 results in a product at 2.1 kb 
as expected. F. hepatica  CL1 (F h C L l) in P. pastoris  was included as a 
control in the PCR (L5). For clone B2 (pPIC9K), only the characteristic 
2.1 kb band o f  P. pastoris is seen as expected. (L6). In L7 the 492 bp 
product expected when pPIC9K  is am plified w ith 5 ’A O X l and 3 ’A O X l 
prim ers is clearly  visible. The absence o f a band in L8, the negative 
control shows that no contam inants w ere present in the PCR.
3.3.2: M e t h a n o l  i n d u c t i o n  o f  SmCC i n  P . p a s t o r i s  a n d  a n a l y s i s  o f  
e x p r e s s e d  p r o t e i n
A series o f  inductions were carried out, each one varying param eters o f  the 
protocol so as to optim ise the expression o f  an active, functional SmCC enzyme.
3 .3 .2 .1 :  In d u c t i o n #  1
Culture Conditions
100 ml o f  BMGY w ere inoculated w ith a single colony from  the following 
plates:
•  P late A1 (SmCC and pPIC9K )
•  Plate A2 (SmCC and pPIC9K )
• Plate B2 (pPIC9K  background control)
• Plate C2 (Sm CC)
•  A14 clones (FhC L l in  P .pastoris)
An OD o f 2.7 w as reached by all cultures after 41 hours incubation. Induction 
began after resuspension o f  each culture in  20 ml o f  BM M Y, pH 6.0. M ethanol 
was added to culture flasks to a final volum e o f  1 % daily  for six days. Samples 
were taken each day, from  day 0-day 6 (D0-D6).
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C ulture supernatants w ere analysed by SDS-PAGE.
M L3 L5 L7 L9 LH
175 kDa
47.5 kDa 
25 kDa
Figure 42: SDS-PAGE of D3 supernatants from induction # 1
10 p.L pro te in  and 5 |iL 4 X  reducing buffer were applied to each well. 
The m olecular w eight m arker (M) is depicted in L I . M any bands can be 
seen in L3 fo r A1 but are no t significant as they are due to  cell debris. 
L5 contains A2 supernatant and a  fain t band at ~  22 kD a is visible. C2 
supernatant also shows th is 22 kD a band in  L7.
M L3 L4 L 6L 7 L9 L10
83 kDa
47.5 kDa
25 kDa
SDS-PAGE Analysis
Figure 43: SDS-PAGE of D4-D6 supernatants for B2 and C2 clones
Lane 1 contains the m olecular w eight m arker (M ). C2 D4 supernatant in 
L3 has a  band at 22kD a, w hich is not seen for B2 D4 (L4). This 22kDa 
band is also v isib le  for C2 D5 in  L6 along w ith an additional band at 83
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kDa, both o f  w hich are absent for B2 D5. The 22 kD a and 83 kDa bands 
are v isible again on analysis o f  C2 D6 supernatant along w ith a band at ~ 
40 kD a w hich was not previously seen (L9). All three bands are absent 
from  B2 D6 (L10).
SDS-PAGE was carried out using D6 supernatants and N i-NTA beads. Bands 
w ere seen on the gel at 22 kDa for A l, A2 and C2 but not fo r B2, as expected. 
Pellets w ere disrupted for D1-D6 sam ples and were analysed by SDS-PAGE.
As no DO sam ple had been taken for th is induction in error, it was im possible to 
ascertain  w hich resolved bands w ere indicative o f  induced protein.
Western Blot
A w estern blot probing the D3 supernatants (A2, B2 and C2) w ith Anti-His6 
antibody did not show  any binding. B inding was observed using FhC L l and 
Sm cathepsin B (SmCB) sam ples as expected. A w estern blot was also carried 
out on D1-D6 d isrupted pellets but the Anti-His6 antibody did not bind to any 
o f  them  (data not shown).
Enzyme Activity Assays
Enzym e activ ity  assays were carried out for A2, B2 and C2 D1-D6 supernatants 
to detect i f  rSm CC was present using the cathepsin C specific substrate H-Gly- 
A rg-NHM ec. A ll assays were read at s lit w idth  10, 2.5. A ll assays were 
perform ed overnight ( - 1 8  hrs) at 37°C unless stated otherw ise.
An NHM ec standard curve was prepared for each enzyme assay that was carried 
out in this p ro ject (data not shown). The standard curves prepared are shown in 
the A ppendix.
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Table 38: Enzyme activity assay using supernatants from induction # 1
Day A2 B2 C2
D1 0.91 0.58 0.77
D2 0.98 1.12 0.77
D3 1.01 1.30 0.47
D4 1.01 1.01 0.96
D5 1.06 0.95 1.21
D6 1.21 1.17 1.55
The positive control contained all the usual reaction com ponents except the 
enzym e was F. hepatica  som atic extract. The average fluorescence o f this 
positive control was 192.9 fluorescence units.
1.8
JS 1 6  
c  1 .4
o 1-2
2 1
8 0.8
®  0.6
|  0 .4
u- 0.2 
0
A 2  B 2  C 2
C u ltu r e  s u p e r n a ta n t
Figure 44: Enzyme activity assay for rSmCC from induction # 1
Enzym e activ ity  o f  D 1-D6 supernatants using the cathepsin C specific substrate 
H -G ly-A rg-N H M ec is depicted in the graph above. For both A2 and C2 
supernatants, w hich are expected to exhibit rSm CC activity, activity  increases 
reaching a m axim um  at D6. However, cleavage o f  the SmCC specific substrate 
also occured for B2, and this should not be the case as SmCC cDNA w as not 
present in B2 transform ants.
■  D1
■  D 2
□  D 3
□  D 4
■  D 5  
HD6
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Enzyme activity assays were also carried out on D6 pellets from culture 
supernatants A2, B2 and C2 (Table 39).
Table 39: Enzyme activity assay using D6 pellets from induction # 1
Pellet Average fluorescence
D6  A2 7.09
D6  B2 3.99
D6  C2 8 . 6 6
Background control 0.957
Positive control 180.43
A2 B2 C2
culture supernatant
Figure 45; Enzyme assay using D6 pellets from induction # 1
For B2, which should not contain SmCC, non-specific cleavage of the substrate 
occurred. D l, D3 and D5 pellets were also assayed. A DO control from a later 
induction was used but on average five times more substrate was cleaved for DO 
control sample than for the pellet samples, which reinforces the notion that 
yeast proteases capable o f hydrolysing the SmCC substrate were produced.
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3.3.2.2: In d u c t io n  # 2 (s c a le -u p )
Culture Conditions
Using the YPD replica plate o f C2 transformants, 2 colonies were selected and 
were used to inoculate 250 ml o f BMGY. Resupsended pellets were combined, 
giving a final volume o f 100 ml BMMY, pH 6.0 in the culture flask. Methanol 
was added daily to a final concentration o f 1% for six days as before.
SDS-PAGE Analysis
SDS-PAGE analysis on D0-D6 supernatants did not reveal any significant 
bands. The numerous bands present on the gels were attributed to yeast cell 
debris. SDS-PAGE was also carried out after addition o f Ni-NTA beads to the 
supernatants as before. A weak band was seen at 22 kDa for the D6 supernatant 
sample but not for any o f  the others. The D0-D6 pellets from this induction 
were resupsended in dH20 and were applied to the gel as usual (Figure 46).
M DO D1 D 2D 3 D4 D5 D6
Figure 46: SDS-PAGE analysis of D0-D6 pellets from induction # 2
The molecular weight marker is depicted in lane 1 (M). It is clear to see 
that most o f the bands present in D1-D6 pellets are also found in DO, 
which indicates that they do not represent induced protein. However, a
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band is visible in D1-D6 at ~ 40 kDa that is not present in the DO pellet 
sample, which indicates that this band could be expressed SmCC.
Western Blot
A western blot was carried out using the D0-D6 pellets and Anti-His6 
antibodies. No binding was observed except for SmCB purified protein 
included as a control.
Affinity Chromatography on a Ni-NTA column
The D6 sample from induction # 2 was diluted in a 1:5 sample:lysis buffer ratio 
before it was applied to the column. SDS-PAGE o f column fractions did not 
reveal the presence o f any protein except for the dialysed sample, which 
showed a faint band at 62 kDa. A BCA assay was carried to determine the 
protein concentration o f all column fractions (Table 40). As is clear from the 
BCA assay results, the protein concentration o f the sample before it was applied 
to the column (0.89582 mg/ml) was practically the same as that o f the run 
through sample (0.884099 mg/ml), which illustrates that very little, if  any 
protein was bound to the Ni-NTA beads in the column.
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Table 40: BCA assay of Ni-NTA affinity column fractions
Averag
e
BSA
mg/ml Lysis Wash Elution Flush PBS
0 0.099 0.114 0.127 0.123 0.0875
0.2 0.539 0.241 0.2065 0.195 0.2175
0.4 0.734 0.3415 0.279 0.252 0.357
0.6 0.4225 0.81 0.357 0.3325 0.5865
0.8 0.5105 0.495 0.4235 0.3945 0.76
1 0.619 0.598 0.512 0.4695 0.895
1.2 0.6425 0.6775 0.57 0.5005 0.864
1.4 1.0325 0.6765 0.5955 0.5565 1.049
1.6 1.1355 0.686 0.6725 0.5965 1.1335
1.8 1.3115 0.8425 0.706 0.6525 1.2095
2 2.3485 1.006 0.821 0.6985 1.332
Pre
Run
Thru Wash Eluate Flush
Post
Dialysis Day 6
0.797 0.762 0.21 0.139 0.134 0.101 2.027
0.751 0.768 0.213 0.137 0.136 0.107 2.027
Averag
e 0.774 0.765 0.2115 0.138 0.135 0.104 2.027
Cone.
Mg/ml 0.89582
0.88409
9 0.06503 0.00605 -0.04404 -0.08459
3.03766
8
Lysis
y = 0.7679x + 
0.0861
Wash
y = 0.3552x + 
0.2346 Flush
y = 0.2861x 
+ 0.1476
Elution
y = 0.3305x + 
0.14 PBS
y = 0.6159x 
+ 0.1561
135
Enzyme Activity Assays
A regular enzyme assay and a leupeptin inhibition assay were performed on DO, 
D4, D5 and D6 culture supernatants (Table 41). Leupeptin was used at a 
concentration o f 10 |xM and this was observed to be insufficient to cause 
inhibition of SmCC. Higher leupeptin concentrations were employed in later 
assays, it was seen that a 0.5 mM final concentration o f leupeptin was necessary 
to result in at least 55% inhibition o f SmCC.
Table 41a: Results of enzyme activity assays of induction # 2 supernatants
Day Average
Fluorescene
DO 0.71
D4 0.743
D5 0.892
D6 0.786
Table 41b: Controls for induction # 2 assays
Control Average
Fluorescence
Positive (Fh 
somatic 
extract)
205.7
Background 0.643
As is evident from the results above, no specific SmCC activity was present as 
the fluorescence detected for DO culture supernatant was only slightly lower to 
that for D6 supernatant.
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Assays were carried out in sodium citrate (SC), sodium acetate (SA), sodium 
phosphate (SP) and Tris-HCL (T) buffers at different pHs to determine whether 
rSmCC had a different pH optimum to o f pH 5.5 reported in the literature 
(Table 42). Day 6 culture supernatant was used for all pH profile assays. The 
average fluorescence read for each pH was plotted against pH (Figure 47).
Table 42a: Controls for pH profile assay
C o n tro ls A verage
F luorescence
Positive control 
(Fh somatic 
extract)
216
Background 0.603
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Table 42b: pH profile assays for SmCC, induction # 2
B u ffe r A verage  fluo rescence  
un its
SC pH 3.0 0.97
SC pH 4.0 0.59
SC pH  5.0 1.0
SC pH  6.0 1.49
SC pH  7.0 1.74
SA pH  4.0 0.66
SA pH 4.5 0.71
SA pH  5.0 0.72
SA pH  5.5 1.22
SA pH 6.0 1.02
SP pH  5.0 1.78
SP pH  5.5 3.46
SP pH  6.0 6.28
SP pH 6.5 9.6
SP pH  7.0 13.04
SP pH 7.5 15.43
T pH 6.0 0.96
T pH 7.5 4.73
T pH  8.0 2.94
T pH 8.5 6.11
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Figure 47: Graph of pH profile assays using the SmCC substrate H-Gly- 
Arg-NHMec and D6 culture supernatants from induction # 2
Disrupted D6 peliets from C2, induction # 2 were assayed for SmCC activity at 
pH 5.5 but activity was seen to be less than that o f the B2 control. This would 
suggest that the enzyme activity seen was not due to rSmCC.
3.3.2.3: I n d u c t i o n  # 3
C u ltu re  C o n d itio n s
For this induction A2, B2 and C2 clones were used to inoculate 100 ml of 
BMGY each. After 41 hrs incubation an OD600 o f  2.6 was reached for all 
cultures. Induction was initiated by resupsension o f each culture in 20 ml o f 
BMMY pH 6.0.
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SDS-PAGE Analysis
On SDS-PAGE analysis o f  D0-D7 supernatant sam ples, the only bands seen for 
C2 were bands o f  approxim ately 200 kDa. N o significant bands were seen for 
any o f  the others. A nalysis o f  disrupted D0-D7 pellets by SDS-PAGE did not 
reveal the presence o f  any induced bands. Bands observed at D1-D7 were also 
present in DO pellets.
Western Blot and ELISA
A w estern  blot and an ELISA (Table 43) were perform ed on D0-D7 
supernatants and disrupted pellets. Positive controls w orked w ell for both 
procedures but no binding o f  Anti-His6 antibody to  the SmCC hexahistidine tag 
was observed for any o f  the D0-D7 supernatants or pellets.
Table 43: ELISA results for D0-D7 supernatants (average A450 nm of 
duplicate wells)
1 2 3 4 5
A F hC L l
0.190
SmCB
0.655
SmCB
(dialysed)
0.0765
Blank
0.030
B DO C2 
0.046
B lank
0.047
D3 C2 
0.048
D6 C2 
0.049
D7 C2 
0.051
C DO A2 
0.042
D1 A2 
0.0505
D3 A2 
0.074
D6 A2 
0.058
D7 A2 
0.058
D DO B2 
0.043
D1 B2 
0.044
D3 B2 
0.048
D6 B2 
0.045
D7 B2 
0.045
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Enzyme Assays
Enzym e assays w ere perform ed on DO, D l, D3, D6 and D7 supernatants from 
cultures A 2, B2 and C2. A ssays were carried out in  a sodium  acetate pH 5.5 
buffer and a bar chart w as p lo tted  depicting the average fluorescence obtained 
using each supernatant (Table 44a below  and Figure 48).
Table 44a: Enzyme Assay of culture supernatants, induction # 3
Supernatant Average fluorescence
A2 DO 0 . 6
A2 Dl 0.52
A2 D3 0.48
A2 D6 0.59
A2 D7 0.48
B2 DO 0.46
B2 Dl 0.60
B2 D3 0.55
B2 D6 0 . 6 6
B2 D7 0 . 6 6
C2 DO 0 . 6 6
C2 Dl 0.57
C2 D3 0.50
C2 D6 0.53
C2 D7 0 . 6 6
Table 44b: Controls used in the enzyme assay
Control Average fluorescence
Background 1.011
Positive 163.03
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Figure 48: Bar chart depicting the results of the enzyme assay for D0-D7 
supernatants, induction 3
Enzyme assays were also performed on disrupted cell pellets (Table 45). 
Assays were performed in sodium acetate pH 5.5 and a bar chart was prepared 
showing the average fluorescence (NHMec released) for pellets from each day 
o f the induction (Figure 49).
Table 45a: Controls used in the enzyme assay
Control Average fluorescence
Background 0.60
Positive 177.05
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Table 45a: Enzyme Assay of pellets, induction # 3
Pellet Average fluorcsccncc
DO 5.60
Dl A2 1.63
D3 A2 3.07
D6  A2 11.92
D7 A2 7.91
D l B2 4.47
D3 B2 4.81
D6  B2 10.89
D7 B2 5.96
Dl C2 7.19
D3 C2 7.95
D6  C2 9.61
D7 C2 4.25
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Figure 49: Bar chart of enzyme assay of D0-D7 pellets, induction # 3
3 .3 .2 .4 :  I n d u c t io n  #  4 
Culture Conditions
Colonies from B2 and C2 replica p lates were used to inoculate 500 mis o f 
BM GY, w hich was then split into 2 x 250 ml cultures. An ODeoo o f 2.2 was 
reached by both cultures after 23 hours incubation. Each duplicate 250 ml 
culture pe lle t was pooled after resuspension in 50 ml BMMY to give a final 
culture volum e o f  100 ml. M ethanol was added tw ice daily for 7 days to a final 
concentration o f  1.5% in the culture medium.
SDS-PAGE Analysis
Culture supernatants w ere analysed by SDS-PAGE. Pellets were disrupted by 
the usual m ethod but recovery proved insufficient to perm it further analysis to 
be undertaken.
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62 kDa
47.5 kDa
32.5 kDa
25 kDa
6.5 kDa
Figure 50: SDS-PAGE of D0-D7 supernatants from C2, induction # 4
The usual m olecular w eight m arkers (M) are depicted in the first and last 
lanes. The DO supernatant displays a band at ~ 40 kDa. D1 supernatant 
shows a band at 47kD a, w hich is also present for D2-D7 samples. A 
band at ~ 58 kD a is v isib le  for D2-D7 that is only faintly  visible at D l. 
A t D4 a band appears o f  55 kDa, w hich was absent from  previous days 
but present in  la ter ones. As the predicted  m olecular size o f  the pro- 
m ature SmCC is 49.5 kDa, these bands at > 50 kD a could be indicative 
o f  d ifferentially  glycosylated form s o f  pro-m ature SmCC. The 
appearance o f a fa in t 25 kD a band in D2-D7 sam ples could indicate that 
the m ature enzym e is being produced. The fact that enzym e activity  was 
detected for these sam ples supports this notion. For D1-D7 supernatants 
the bands < 6.5 kD a th a t appear on the gel could be breakdown products 
that arose from  proteolysis o f  the pro-m ature SmCC.
Supernatants bound to N i-N T A  beads w ere resolved by SDS-PAGE and the 
same bands were seen fo r th is gel as for regular SDS-PAGE.
M DO D l D2 D3 D4 D5 D6 D7 M
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Western Blot and ELISA
Two w estern blots w ere carried  out on D0-D6 supernatants using the usual anti- 
H is6 antibody and anti-schistosom e m ouse sera. The secondary antibody in 
each case was goat anti-m ouse IgG. In both cases binding occurred to SmCB 
but not SmCC protein. A n ELISA  was perform ed using both  sets o f  antibodies 
and although binding occurred for SmCB and FhC L l controls, none was 
observed for SmCC.
A w estern  b lo t was perform ed using anti-5, japonicum  cathepsin  C rabbit sera. 
Purified  baculovirus expressed rS jCC  was included as a control.
Day
M 0 1 3 5 6 7 SjCC
47.5 kDa
Figure 51a: Western Blot using anti-SjCC rabbit sera
No binding is seen for DO or D1 supernatants. W ith D3 and D5 
supernatants antibodies bound to a  band a t 47 kDa. Binding was not 
observed for any other supernatants or for the SjCC postive control. 
Figure 51b shows the supernatants used in  th is  b lo t resolved by SDS- 
PAGE. For D3 and D5 supernatants the band at 47 kD a to w hich binding 
occurred in the w estern  b lo t can be clearly seen. This band is also 
v isible at D l, D6 and D7 despite the fact th a t binding did not occur for 
these. SjCC resolves as a band at ~ 150 kDa.
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Day
M 0 1 3 5 6 7 SjCC
62 kDa 
47.5 kDa
32 kDa
Figure 51 b: Samples used for western blot as resolved by SDS-PAGE
An ELISA  w as carried out using anti-S jCC  rabbit sera. As depicted in Table 46, 
b inding o f  the antibody to  SmCC w as m inim al. N eat and diluted SjCC and S. 
m ansoni som atic extract w ere included as controls but only w eak binding was 
observed for these controls.
Table 46: ELISA results (average A450 nm of duplicate wells)
1 2 3 4
A SjCC
(dilute)
0.068
SjCC
(neat)
0.049
Sm
somatic
extract
0.084
Blank
0.030
B DO C2 
0.048
D1 C2 
0.0445
D2 C2 
0.044
D3 C2 
0.046
C D4 C2 
0.047
D5 C2 
0.0435
D6  C2 
0.045
D7 C2 
0.044
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Enzyme Assays
Enzym e assays were perform ed on B2 and C2 D0-D5 culture supernatants 
(Table 47a and b). The buffer used in  the assays was sodium  acetate pH  5.5. A 
standard curve was prepared as usual (refer to A ppendix). A bar chart was 
prepared depicting average fluorescence (NHM ec liberated) for B2 and C2 for 
each day o f  the induction (Figure 52).
Table 47a: Controls used in the enzyme assay
Control Average fluorescence
B ackground 0.675
Positive 169.85
Table 47b: Enzyme Assay of induction # 4 culture supernatants
Supernatant Average fluorescence
DO B2 0.93
D l B2 0.49
D2 B2 0.48
D3 B2 0.91
D4 B2 0.53
D5 B2 0.57
DO C2 0.53
D l C2 0.77
D2 C2 1.69
D3 C2 4.38
D4 C2 10.77
D5 C2 30.21
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Figure 52: Bar chart of enzyme activity assay for B2 and C2 (D0-D7), 
induction # 4
An enzyme assay at pH 5.5 was set up to determine the difference in enzyme 
activity over a 4 hr. and 20 hr. incubation period using D5 supernatants (Table 
48). The difference in fluorescence o f duplicate assays over the seven-day 
period o f  both the 4 hr and 20 hr assays is detailed in Figure 53.
Table 48: Enzyme assay of C2 culture supernatants over a 4hr. and 20 hr. 
induction period
Day 4 hrs 20 hrs
DO 0.73 0.26
D1 0.81 0.41
D2 1.81 1.45
D3 2.38 3.80
D4 3.91 9.91
D5 9.01 31.43
D6 8.87 30.47
D7 9.24 28.46
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The usual controls were included which proved that the assay was working 
properly (data not shown).
d, 40 
o
§ 30 
$ 20|  10 
u_ o
DO D1 D2 D3 D4 D5 D6 D7 
Day
Figure 53: Bar chart showing the effect of a 4 hr. and 20 hr. incubation 
period on enzyme activity
An inhibition assay was performed using the D5 supernatant from induction # 4 
and leupeptin to a final concentration o f 0.5 mM (Table 49). The bar chart in 
Figure 54 clearly shows the inhibitory effect leupeptin had on rSmCC activity. 
Three controls were included in this assay as follows:
•  Control 1 contained 10 |aL o f D5 supernatant and no leupeptin.
• Control 2 contained 10 jiL o f F. hepatica somatic extract and 0.5 mM 
leupeptin.
•  Control 3 contained 10 of F. hepatica somatic extract and no 
leupeptin.
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Table 49: Leupeptin inhibition assay using D5 supernatant induction # 4
Assay Average fluorescence
B ackground control 0.55
Leupeptin  + rSm CC 2.73
C ontrol 1 (rSm CC) 29.13
Control 2 (Fh + leupeptin) 92.57
C ontrol 3 (Fh alone) 159.9
D 5  Fh
Source of enzyme
Figure 54: Bar chart of leupeptin inhibition assay using D5 supernatant, 
induction # 4
Leupeptin  inhibited  the  rSm CC activity by 90.6% . The cathepsin C activity  in 
the F, hepatica  som atic ex tract exhibited 42% inh ib ition  in the presence o f 
leupeptin.
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A similar assay was set up using iodoacetamide to a final concentration o f 1 
mM in the assay instead of leupeptin, to study its effect on rSmCC activity. 
Using the same D5 supernatant, only 9.32% inhibition o f rSmCC activity was 
observed. Using F, hepatica somatic extract 94.6% inhibition o f cathepsin C 
was observed with iodoacetamide.
An assay was set up to investigate i f  the cathepsin C specific substrate H-Gly- 
Arg-NHMec could be non-specifically cleaved by recombinant FhCLl (Table 
50). The bar chart in Figure 55 shows the cleavage o f the substrate by rFhCLl 
was low relative to that observed for rSmCC.
Table 50: Assay to determine whether rFhC Ll can cleave H-GIy-Arg- 
NHMec
rSmCC rFhCLl
DO 0.76 0.99
D1 0.97 1.65
D3 4.35 3.612
D6 26.77 4.58
Background 0.57 0.57
Positive control 156.3 329.4
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Figure 55: Bar chart depicting the cleavage of cathepsin C specific 
substrate by rSmCC and rFhCLl
3,3.2.5: I n d u c t io n  # 5
Culture Conditions
To investigate the effect o f pH on expression o f SmCC, three separate 
inductions were carried out at pH 5.0, 6.0 and 7.0. The culture conditions were 
as before (refer to 3.3.2.4), using C2 transformants, the only difference being 
the pH of the induction media. After initial growth in BMGY pH 6.0, each 
culture was brought to an OD^oo of 20 prior to initiation of induction. The final 
pH o f the BMMY in each flask was determined at the end o f the 6 -day 
induction period (Table51).
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Table 51: pH of BMMY culture media after 6 days induction
pH 5.0 6.5
pH 6.0 7.5
pH 7.0 8.5
SDS-PAGE Analysis
Figure 56 shows the supernatants from the 6-day induction period as resolved 
by SDS-PAGE.
DO D1
Figure 56a: pH optimum studies on the expression of SmCC (DO and D l)
The usual molecular weight marker is shown in lane 1(M). No bands are 
visible for DO supernatants at any pH. A single band appears at ~ 42 
kDa for the D l pH 7.0 supernatant but not for any o f the other D l 
samples.
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Figure 56b: pH optimum studies on the expression of SmCC (D3, D5, D6)
N o band is apparent for D3 pH 5.0 supernatants. A single band at ~  55 
kD a can be see for D3 pH  6.0. Three distinct bands are visible for D3, 
pH  7.0, one at 60 kD a, a  faint one a t 55 kD a and one at 47 kDa. 
D egradation products can be clearly  seen at the bottom  o f  the gel. The 
sam e bands are seen fo r D5 and D6 supernatants.
Western Blot and ELISA
A w estern  blot w as perform ed using DO pH 5.0, 6.0 and 7.0 and D4, pH 5.0, 6.0 
and 7.0 supernatants and anti-S', japon icum  cathepsin C antibodies (Figure 57). 
A w estern blot was also  carried  using the anti-His6 antibody and although the 
SmCB positive control w orked w ell, no binding o f  the antibodies to rSmCC his- 
tag was observed.
In  order to  determ ine w hether C2 clones actually  expressed rSm CC, a colony 
b lo t was perform ed (refer to 2.2.6). Probing o f  the colony blot w ith  anti-His6 
antibodies failed  to reveal any significant binding. Binding o f  anti-His6
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antibody to the His-tag o f rFhCLl, the positive control in this experiment 
occurred. This indicated that rSmCC was not expressed in the C2 clones.
DO D4
M X 5 6 7 X 5  6 7
62 kDa ------------ ' I'1 !
32 kDa --------—
Figure 57: Western Blot of DO and D4 pH 5.0, 6.0 and 7.0 supernatants 
using anti-SjCC antibodies
Binding occurred to a 62 kDa and 28 kDa band using D4 pH 6.0 
supernatant. Binding to the 28 kDa band was also observed for D4 pH 
7.0 supernatants.
Enzyme Assays
Enzyme assays were carried out to determine whether culturing at different pHs 
had an effect on the activity o f rSmCC. All assays were performed at pH 5.5 
(Table 52). A bar chart was prepared showing the average fluorescence 
obtained using D0-D6 supernatants from inductions performed at pH 5.0, 6.0 
and 7.0.
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Table 52a: Enzyme assays using D0-D6 supernatants at pH 5.0-7.0 (average 
fluorescence of duplicate assays)
pH 5.0 pH 6.0 pH 7.0
DO 0.63 0.58 0.88
D1 3.58 0.46 0.76
D3 4.91 2.35 1.34
D4 4.75 3.01 1.42
D5 4.89 2.27 1.45
D6 4.46 1.78 1.43
Table 52b: Controls for the assay
Control Average fluorescence
Background 0.69
Positive 154.37
■  DO
■  D1
□  D3
□  D4
■  D5 
OD6
Figure 58: Bar chart depicting the enzyme activity of rSmCC of 
supernatants induced at pH 5.0, 6.0 and 7.0
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3.3.2.6: Inductio n  #6
Culture Conditions
Culture conditions were exactly as for 3.3.2.4. Incubation for 18 hrs was 
sufficient for an OD600 3.0 to be attained for both cultures. Resupsended pellets 
in BMMY pH 6.0 were combined and upon initiation o f  induction the culture 
volume was 100 ml. Methanol was added to a final concentration o f 1.5% twice 
daily for 5 days.
SDS-PAGE
D0-D5 supernatant samples were resolved by SDS-PAGE
62 kDa 
47.5 kDa
Figure 59: SDS-PAGE of D0-D5 supernatants from induction # 6
The usual molecular weight marker is depicted in lane 1 (M). 
bands at ~ 47 kDa are visible for D3 and D4 supernatants only, 
at ~ 70 kDa can be seen for SmCB in the final lane.
Single 
A band
M X DO D1 D2 D3 D4 D5 X CB
158
Western Blot
A w estern  blot was carried out on D0-D5 sam ples using anti-His6 antibodies 
and anti-S jCC sera. N o binding w as observed for e ither w estern  blot, although 
the positive control SmCB reacted  w ith  anti-His6 and anti-S jCC. This was a 
surprising resu lt w ith anti-S jCC as it was not expected that SmCB would cross- 
react w ith anti-S jCC  antibodies.
Enzyme Assays
An overnight enzym e assay w as perform ed at pH 5.5 on D0-D5 culture 
supernatants to ascertain  w hether active rSm CC was produced (Table 53). A 
bar chart was prepared p lo tting  the average fluorescence o f  duplicate assays 
perform ed over 4 and 20 hrs using D0-D5 culture supernatants (Figure 60).
Table 53: Enzyme assays using D0-D5 culture supernatants, induction # 6
Supernatant Average fluorescence
DO 0.32
D1 0.15
D2 5.01
D3 6.65
D4 9.28
D5 9.09
B ackground 1.88
Fh som atic extract positive 
control
142.55
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Figure 60: Bar chart of enzyme activity assay using D0-D5 supernatants 
from induction # 6
A 4 hr. and 20 hr. assay was perform ed to assess the effect o f  incubation tim e 
on the activ ity  o f  the recom binant enzym e. The bar chart in  Figure 61 depicts 
the average fluorescence obtained (NHM ec released) after the assay was carried 
out for 4 hrs and 20 hrs.
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Figure 61: Bar chart showing rSmCC activity (fluorescence) after 4 hrs and 
20 hrs incubation
The increase in rSmCC activity over time is non-linear. Maximum activity was 
observed at D4 for both the 4 hr. and 20 hr. assay.
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Cathepsin C from F. hepatica somatic extract (FhCC) was characterised to 
ascertain whether FhCC shared the following biochemical characteristics 
displayed by other cathepsin Cs, in particular SmCC:
• Enhancement o f enzyme activity in the presence o f the reducing agent 
DTT.
• Optimum enzyme activity at pH 5.5.
• Inhibition by the general cysteine protease inhibitors leupeptin, 
iodoacetamide and NEM and slow inibition by E-64.
• Enhancement by halide ions.
3.4.1: E n h a n c e m e n t  o f  e n z y m e  a c t i v i t y  b y  DTT
A series o f enzyme assays were performed in the presence and absence of the 
reducing agent DTT in order to determine its effect on FhCC activity.
• Addition of 5 ^L of 2 mM DTT to the assay resulted in a five-fold 
increase in fluorescence (NHMec liberated) from 16.72 nm in the 
absence o f DTT to 84.8 nm when DTT was added. The enzyme activity 
for the DTT assay was calculated to be 0.67 U (refer to Section 2.2.7). 
The enzyme activity could not be determined for the assay without DTT 
owing to the fact that the fluorescence value did not fall within the area 
o f the NHMec standard curve (see Appendix for standard curves) but the 
enhancing effect o f  DTT on FhCC activity was evident.
• An assay was carried out using 15 pL DTT at pH 5.5 and 8.5 and all 
assays were read on the fluorimeter (slit width: 10, 10) (see Figure 62).
3 .4 :  B i o c h e m i c a l  C h a r a c t e r i s a t i o n  o f  F. h e p a t ic a  c a t h e p s i n
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The addition o f DTT resu lted  in 67% enhancem ent o f  FhCC activity  at 
pH 5.5 and 50% enhancem ent at pH 8.5.
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Figure 62: Bar chart showing the enhancing effect of DTT on FhCC activity
• In assays carried out for rSm CC activity, 100 ^iL o f  20 mM DTT was 
used in  a 1 ml assay to tal assay volum e. A t slit w idth 10, 10 on the 
fluorim eter FhCC activ ity  proved to be off-scale giving a result o f  1000. 
A t 10, 2.5 an average read ing  o f  180 was obtained. This DTT 
concentration w as em ployed in all assays fo r rSm CC.
3.4.2: p H  p r o f i l e  a s s a y s  o f  FhCC
In order to determ ine the pH  optim um  o f  FhCC, a series o f  pH  profile assays 
w ere perform ed. A ll assays w ere prepared as usual except 150 fxL o f  DTT was 
added to all assays (Table 55).
Table 54: Buffers used in the pH profile assays
Buffer pH
Sodium  acetate (SA) 4.0, 4.5, 5.0, 5.5
Sodium  phosphate (SP) 5.5, 6.0, 6.5, 7, 7.5, 8.0
Tris-H C l (T) 7.5, 8.0, 8.5, 9.0
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Table 55: pH profile assay results (average fluorescence at 10,10)
Buffer Result Control
SA pH 4.0 6.85 14.36
SA pH 4.5 21.51 14.0
SA pH 5.0 83.18 17.73
SA pH 5.5 138.03 16.87
SP pH 5.5 34.47 15.44
SP pH 6.0 43.96 16.14
SP pH 6.5 47.02 19.28
SP pH 7.0 60.25 22.86
SP pH 7.5 75.98 25.51
SP pH 8.0 91.68 26.57
T pH 7.5 106.45 14.8
T pH 8.0 137.45 13.37
T pH 8.5 205.45 17.06
T pH 9.0 11.84 18.75
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Figure 63: Graph depicting the results o f the pH profile assay of FhCC
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A pH profile assay was carried out following incubation o f the enzyme with the 
cathepsin-L inhibitors Z-Phe-Ala-NH 2 and Z-Phe-Phe-OH to investigate 
whether the peak o f activity observed at pH 8.5 was due to the presence of 
another cysteine pro tease, such as cathepsin L.
Table 56: Results of pH profile assay using Z-Phe-Ala-NH2 inhibitor
Buffer Average fluorescence
SA, pH 4.0 10.73
SA, pH 4.5 65.53
SA, pH 5.0 150.83
SA, pH 5.5 193.40
SP, pH 5.5 109.46
SP, pH 6.0 130.27
SP, pH 6.5 116.12
SP, pH 7.0 152.70
SP, pH 7.5 195.97
SP, pH 8.0 281
T, pH 7.5 418.63
T, pH 8.0 662.10
T, pH 8.5 782.73
T, pH 9.0 2 1 2 . 2 0
As is evident from Figure 64, the two peaks o f activity at pH 5.5 and 8.5 that 
were previously observed (Figure 63) are present again.
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Figure 64: Graph of enzyme assay containing Z-Phe-Ala-NH2
The assay using Z-Phe-Phe-OH was carried out at pH 5.5 and 8.5 only as they 
represented the pH at which highest FhCC activity was observed.
Table 57: Results of pH profile assay using Z-Phe-Phe-OH inhibitor
Buffer Average fluorescence
SA, pH 5.5 (+ inhibitor) 599.50
SA, pH 5.5 (no inhibitor) 690.23
SP, pH 5.5 (+ inhibitor) 198.47
SP, pH 5.5 (no inhibitor) 198.27
T, pH 8.5 (+ inhibitor) 575.63
T, pH 8.5 (no inhibitor) 659.67
As Figure 65 illustrates, only a slight decrease in enzyme activity is observed in 
those assays that contain the inhibitor (refer to Discussion 4.5). Therefore, the 
enzyme with peak activity at pH 8.5 is not cathepsin L.
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Figure 65: Bar chart of the assay carried with and without Z-Phe-Phe-OH
3.4.3: E n z y m e  a s s a y s  u s i n g  c y s t e i n e  p r o t e a s e  i n h i b i t o r s
Assays were performed with the general cysteine protease inhibitors 
Iodoacetamide (Table 58), Leupeptin (Table 59) and NEM (Table 60) to 
examine the effect o f  these inhibitors on FhCC. Controls were included for 
comparative purposes, which were standard enzyme assays without inhibitor.
Table 58: Iodoacetamide inhibition assay results
Iodoacetamide (mM) Fluorescence units % inhibition
0 79.61
0.01 76.58 3.8
0.1 68.15 14.4
1 47.56 40.3
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Table 59: Leupeptin inhibition assay results
Leupeptin (mM) Fluorescence units % inhibition
0 605.75
0.01 515.15 15
0.1 335.50 44.6
Table 60: NEM inhibition assay results
NEM (mM) Fluorescence units % inhibition
0 295.8
1 198.33 33
Slow inhibition by the cysteine protease inhibitor E-64 is another feature o f  all 
cathepsin Cs. Other cathepsins such as cathepsin L are inhibited almost 
instantaneously by E-64. To investigate this enzyme assays were performed for 
cathepsin C and L in the presence and in the absence o f 5 jxM E-64. For the E- 
64 assays activity was expressed as a % o f  the total activity o f  the enzyme 
determined in the absence o f  the inhibitor (Table 61, Figure 66).
Table 61: E-64 inhibition assay of FhCC and FhCL
Time FhCC% activity FhCL% activity
0 89.58 8.87
5 90.33 8.06
10 81.35 7.84
20 74 6.89
40 62.47 6.84
80 62.13 6.11
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Figure 66: Graph showing £-64 inhibition assay of FhCC and FhCL
The slow  inhibition o f  FhCC by E-64 is clearly depicted in the bar chart in 
Figure 66 whereas it can be seen that inhibition o f cathepsin L by E-64 occurs 
almost instantaneously.
3.4.4: A c t i v a t i o n  o f  FhCC b y  h a l i d e s
Cathepsin C activity is enhanced in the presence o f  halide ions. To investigate 
the effect o f  halides on the activity o f  FhCC, a series o f  assays were performed 
using halides at the concentrations outlined in Tables 62-65 below. Activity is 
expressed as a percentage o f the activity o f  FhCC in the absence o f  halide ions.
Table 62: Results o f activation of FhCC with NaCl
NaCl conc. (mM) Fluorescence units % activation
0 38.94
0.1 39.18 0.6
1 51.45 32.12
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Table 63: Results of activation of FhCC with NaBr
NaBr conc. (mM) Fluorescence units % activation
0 23.9
0.1 26.97 12.8
1 27.08 13.32
10 28.55 19.44
Table 64: Results of activation of FhCC with Nal
Nal conc. (mM) Fluorescence units % activation
0 21.79
0.1 25.03 14.87
1 29.72 36.36
10 31.43 44.21
Table 65: Results of activation of FhCC with NaF
NaF conc. 
(mM)
Fluorescence units % activation
0 22.51
0.1 22.20 -1.37
1 22.24 -1.18
10 21.59 -4.04
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3.4.5: BCA P r o t e i n  A s s a y s
BCA protein assays were carried out on the F. hepatica  somatic extract in order 
to determine the protein concentration o f  the extract so that the specific activity 
o f FhCC can be calculated. A standard curve was prepared using known 
concentrations o f  BSA and the protein concentration o f  the somatic extract was 
determined from the graph using the A 570 value obtained for the extract in the 
assay (Table 66, Figure 67).
Table 66: BCA Protein Assay
Name A5 7 onm of duplicates
H2O control 0.128
0.2 mg/ml BSA standard 0.482
0.4 mg/ml BSA standard 0.761
0.6 mg/ml BSA standard 1.049
0.8 mg/ml BSA standard 1.294
1.0 mg/ml BSA standard 1.915
1.5 mg/ml BSA standard 2.151
2.0 mg/ml BSA standard 2.667
Neat somatic extract Off-scale
1 /5 dilution o f  somatic extract 1.778
1/10 dilution o f  somatic extract 0.854
1/100 dilution o f somatic 
extract
0.180
From the BSA standard curve (Figure 67):
• The 1/5 dilution o f somatic extract had an A570 o f  1.778 nm. From the 
standard curve the protein concentration in this sample was 0.945 mg/ml. 
This represented a 1/5 dilution o f the extract so the total protein 
concentration was 4.725 mg/ml.
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• The 1/10 diltuion o f  somatic extract had an A 570 o f  0.854 nm. From the 
standard curve the protein concentration was determined to be 0.56 
mg/ml. Taking the dilution factor into account, the overall protein 
concentration was 5.6 mg/ml.
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Figure 67: BSA Standard Curve
The protein concentration was used to determine the specific activity o f  FhCC 
in the somatic extract. Using the result from the DTT assay performed in 
Section 3.4.1, the activity o f  FhCC was 0.67 U. The protein concentration is 
4.725 mg/ml determined from the 1/5 dilution o f  somatic extract. The specific 
activity was determined to be 0.142 U/mg o f protein.
When somatic extract was prepared again from homogenised flukes it was 
necessary to carry out a BCA assay in order to determine the total protein 
concentration. The protein concentration o f  a somatic liver fluke extract was 
determined to be 16.2 mg/ml o f  protein.
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4: D iscussion
4: Discussion
Proteases undoubtedly play an indispensable role in the biology of parasitic 
organisms, playing a pivotal role in tissue penetration, digestion of host 
tissue for nutrition and evasion of immune responses (Tort et al., 1999; Sajid 
and McKerrow, 2002). A number of proteinases have been implicated in Hb 
digestion by schistosomes including the exopeptidase cathepsin C, which is 
the focus of this project (refer to 1.2.6). It has been suggested that any 
immune response directed against the Hb digesting enzymes of schistosomes 
could block the digestive process and deliver a detrimental effect on the 
parasite (Dalton et a l,  1995; Brindley et al., 1997).
Because of the widespread applications of gene cloning technologies, 
including the reliability of PCR it has been possible to clone and produce by 
recombinant means many of the important proteases of parasites, many of 
which have potential as vaccine candidates (Tort et a l, 1999). These 
technologies were exploited to the full in this project, in order to isolate, 
clone and express recombinant SmCC.
Schistosome cathepsin C shares many characteristics with those of mammals 
in that it is a lysosomal cysteine protease belonging to the papain 
superfamily, active at acid pH and containing an unusually long propeptide 
(Hola-Jamriska et a l ,  1998; Tort et a l, 1999; Turk et a l,  2001). The full- 
length cDNA of S. mansoni cathepsin C was cloned by Butler et a l, 1995 
and can be retrieved from the public database (accession no: Z32531). 
Proenzyme cathepsin C from S. japonicum  was previously expressed in a 
baculovirus expression system utilising Trichoplusia ni (High-Five) strain 
host insect cells. Approximately 1 mg/L of recombinant enzyme was 
purified by affinity chromatography per litre of cell culture supernatant 
(Hola-Jamriska et a l,  2000). The rat cathepsin C precursor was also 
expressed in a baculovirus system and the yield of mature enzyme produced
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by this system was 50 mg/L (Lauritzen et al., 1998). S. mansoni cathepsin C 
has not been expressed in any system to date.
4.1: I s o l a t i o n  a n d  PCR a m p l i f i c a t i o n  o f  S. m a n s o n i  c a t h e p s i n  C 
(SmCC) CDNA
Prior to cloning of the SmCC cDNA into the pPIC9K vector for expression in 
Pichia pastoris, the cDNA had to be isolated from the cDNA library. 
Initially primers were designed based on the Genbank cDNA sequence to 
amplify the pro and mature regions of SmCC, which contained the SnaBI and 
A vrll restriction sites for cloning into the pPIC9K vector. In initial PCRs 
using the SmCCF and SmCCR primers, a strong 450 bp band was seen on gel 
analysis of the amplified products instead of the expected 1.3 kb SmCC 
cDNA. This could be explained by the fact that the primers contained
additional bases not specific to SmCC cDNA, such as the aforementioned
restriction sites and the hexahistidine tag at the 3’ end. These extra
sequences could not anneal specifically to the cDNA template in the PCR
and this could explain why PCR with SmCCF and SmCCR did not amplify 
the 1.3 kb cDNA.
“Faithful” primers were designed based solely on the Genbank sequence i.e., 
no recognition sites or hexahistidine tail was present. However, the 450 bp 
band was seen again using the new SmCCF2 and SmCCR2 primers. In order 
to increase the specificity of the PCR reaction various parameters of the 
reaction were manipulated such as the annealing temperature and MgCh 
concentration but the 1.3 kb cDNA was not isolated. On one occasion a faint
1.3 kb band was visible on the gel after amplification with SmCCF2 and 
SmCCR2 but a very bright 450 bp band was also present (Figure 9). When 
this faint 1.3 kb band was gel purified and used as template in the re­
amplification of the fragment with the same primers no PCR product was 
obtained which would indicate that the concentration and quality of the 
purified DNA was not conducive to the successful re-amplification of SmCC. 
It is inevitable that some DNA is lost during the purification process and if
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the DNA concentration was low prior to purification this could explain why 
the expected 1.3 kb cDNA was not amplified. Another explanation is that 
inhibitory reagents of PCR may have been introduced during the purification 
process thus inhibiting the action of Taq polymerase.
It was thought that perhaps the cDNA library was degraded or defective or 
that the end of the cDNA was folded in such a manner that it was impossible 
for the reverse primer to anneal. Alternatively, perhaps the full-length 
SmCC cDNA was absent from the library. To investigate whether this was 
the case a set of primers, SmCCMF and SmCCMR were designed, based on 
the sequence from the middle of the SmCC cDNA, which when used with 
SmCCR2 and SmCCF2 respectively, would amplify cDNA fragments of 728 
bp and 601 bp (refer to Figure 7). Gel analysis of the PCR products from 
amplification with these primers showed that these fragments were produced, 
each comprising “half5 of the SmCC cDNA, thereby verifying the presence 
of the full-length cDNA in the library (Figure 10). A new reverse primer, 
SmCCR3, was designed that was moved down several bases past the SmCC 
stop site towards the 3’ end of the cDNA (Figure 7, Table 2 and 3). PCR 
using this primer along with SmCCF2 still resulted in the amplification of 
the small, 450 bp product.
Another strategy employed involved the use of a primer specific for the 
plasmid pB42AD together with an SmCC specific primer as this was the 
vector used in the construction of the cDNA library. As the exact orientation 
of the library in the vector was unknown SmCCF2 was used with both pFor 
and pRev primers. The “middle” primer SmCCMF was also used with both 
vector specific primers (Figure 11). Gel analysis of PCR products revealed 
the presence of bands at 900 bp, 350 bp and 150 bp on amplification with 
pRev and SmCCF2. The 900 bp band was discovered to be a vector specific 
band. The 1.3 kb SmCC cDNA was not amplified.
New primers were designed, called SmCCF4 and SmCCR4. The forward 
primer was designed to anneal to a region of the signal peptide of SmCC
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cDNA, whereas the reverse primer was designed to anneal to the 3’ end 
twenty bases past the stop site. PCR amplification with these primers 
produced a 480 bp product only.
The obstacle to the successful amplification of the full length SmCC cDNA 
appeared to be the reverse primer. A convoluted secondary structure, or 
missing bases at the 3’end could have been an obstacle to the reverse primer 
annealing. Alternatively, it was possible that the reverse primer annealed 
properly to its complementary sequence on the template cDNA but was 
unable to complete the synthesis of the full-length cDNA, thus giving rise to 
a truncated smaller product.
To investigate this possibility it was necessary to design another reverse 
primer, SmCCR5. This primer was designed to anneal at bases 1351-1380 on 
the cDNA sequence, which was 5’ to the stop site. The stop site (base 1382) 
was not amplified. PCR amplification with either SmCCF2 or SmCCF4 with 
this reverse primer resulted in the full-length SmCC cDNA being produced. 
This indicated that a problem had indeed existed with the 3’ end of the 
SmCC cDNA past the stop site. This was demonstrated by PCR. It was seen 
that when the reverse primer was designed to anneal seven bases past the 
stop site of SmCC, as is the case for SmCCR and SmCCR2, the full-length 
cDNA could not be amplified. The same was true when SmCCF4 was used 
which annealed eighteen bases after the stop site (3’ end). However, by 
designing the primer to anneal before the stop site as a result of moving the 
primer closer to the 5 ’ end of the cDNA, the full-length product was 
amplified. Because it was vital that the stop site was present in the amplified 
cDNA, it was necessary to design another primer, SmCCR6, which annealed 
just four bases past the stop site. Amplification with this primer proved 
successful and also illustrated that whatever problem occurred at the 3’end of 
the SmCC cDNA occurred after base 1386. The 1.3 kb PCR product 
amplified with SmCCF2 and SmCCR6 was gel purified and concentrated.
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To increase the concentration of DNA present to facilitate the successful re­
amplification of SmCCF with SmCCR primers, the purified SmCC cDNA 
was cloned into the pGEM vector. After successful transformation of E. coli 
cells with the vector, the presence of the insert in isolated, purified pGEM 
was confirmed by size comparison between the vector containing the insert 
and pGEM vector alone, by performing a PstI digest on the clones, and by 
PCR analysis using both pGEM and SmCC specific primers. Isolated 
plasmid DNA confirmed to contain SmCC was used as template for the 
amplification of the cDNA using SmCCF and SmCCR primers containing 
SnaBI and A vrll restriction sites for cloning. The resultant 1.3 kb product 
was purified for use in the next cloning step into the pPIC9K vector.
4.2: The 450 bp fragment
Owing to the fact that the 450 bp PCR product appeared so frequently with 
so many different primers during the amplification process, much curiosity 
existed about it. It was decided to sequence this fragment after it was 
successfully cloned into pGEM to determine whether it was an artifact of the 
cDNA library, a smaller, truncated version of SmCC, or perhaps another 
previously undiscovered or related gene with sequence similarity to SmCC. 
Subsequent alignment of the amino acid sequence of the 450 bp fragment 
with that of SmCC revealed a 99.2% identity of this sequence with amino 
acids 20-148 of SmCC. Also the last nine amino acids of the 450 bp 
fragment were 100% identical to the last nine bases of SmCC. This proved 
conclusively that the 450 bp fragment was a smaller, truncated version of the 
SmCC DNA. The region of SmCC from amino acids 128-447 was missing 
from the 450 bp fragment. A BLAST was performed using all reverse 
primers against SmCC cDNA to investigate whether these primers bound to 
any other region of the SmCC cDNA but no alternative binding sites were 
revealed for any of the reverse primers (Atschul et ah, 1990). It is possible 
that non-specific binding of the reverse primer to another site on the SmCC 
cDNA did occur but this is unlikely because of the fact that the 450 bp 
fragment was seen to contain 9 amino acids from the end of SmCC, which is
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indicative of the reverse primer successfully binding to the end of the cDNA. 
Another theory is that the primer could be defective and may not be able to 
amplify the full-length cDNA. The probability that a primer will not be fully 
extended is dependent on distance, secondary structure, the extent of DNA 
degradation in the template, enzyme limitation and the time allowed for 
polymerase extension (Ehrlich et al., 1991). Any of these factors could 
explain why the truncated SmCC 450 bp fragment was produced. In 
conclusion, the 450 bp product was probably produced together with the full- 
length cDNA but because of the increased sensitivity of PCR to the 
amplification of smaller fragments, the 450 bp fragment appeared as a strong 
band on gel analysis, whereas the 1.3 kb band was faint (Figure 9).
4.3: C l o n i n g  o f  t h e  SmCC cDNA i n t o  PPIC9K v e c t o r  a n d  s e q u e n c e  
a n a l y s i s
The next stage in this project involved cloning the SmCC fragment into the 
pPIC9K vector. Initial transformation efficiencies proved low, and analysis 
of transformants by PCR using the pPIC9K specific AOX3’ and a-factor 
primers revealed that the 1.3 kb insert was not contained in the vector. Only 
the 195 bp band characteristic of pPIC9K was visible on gel analysis of the 
PCR products instead of the 1.5 kb band expected if pPIC9K contained the 
insert. A confirmatory PstI digest did not reveal the presence of the 1.3 kb 
cDNA in the vector (Figure 21). It was expected that if SmCC was contained 
in pPIC9K, a larger fragment of 4.9 kb would replace the 3.6 kb fragment 
expected when the enzyme cuts pPIC9K. For 6 of the 8 clones analysed in 
this manner, the aforementioned 3.6 kb fragment was produced on digestion 
in addition to the 4.9 kb fragment. This could be indicative of the presence 
of mixed plasmids i.e., some plasmids contained the SmCC cDNA while 
others did not. Further evidence for the mixed plasmid theory came from 
PCR analysis of plasmids isolated from a different transformation (Figure 
22). Gel analysis of a PCR using A 0X 3’ and a-factor primers revealed the 
presence of a 1.5 kb band for 2 of the 3 clones analysed, which suggests that 
the plasmid contained the insert. However, the 195 bp band of pPIC9K alone
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was also visible, which should not be the case. These conflicting results 
could be explained by the mixed population theory or alternatively could 
indicate that the PCR was contaminated with pPIC9K. The later is likely 
because the negative control for this PCR, which contained no template DNA 
revealed pPIC9K contamination. A double digest with SnaBI and Avrll was 
performed on these clones to liberate the 1.3 kb cDNA from the vector but on 
gel analysis only the 9.3 kb pPIC9K band was seen.
Prior to initiating any further transformations the efficiency of the overnight 
ligation step was ascertained. Only those ligation reactions that did not show 
a 1.3 kb SmCC band on gel analysis were used for transformation because 
the absence of this insert suggested that it had been successfully ligated to 
the vector (Figure 23). It was decided to screen the subsequent 
transformants by restriction digestion because PCR preferentially amplifies 
smaller pieces of DNA, and if a mixed colony was used, it was thought that 
the smaller 195 bp DNA would be always preferentially amplified at the 
expense of the larger SmCC cDNA. However, restriction enzyme digests 
performed using Kpnl, StuI, Xbal and Xhol were incomplete even after 3 hrs, 
at 37°C (Table 32). Plasmid DNA wasn’t cut either, which indicates that the 
problem lay with the enzymes themselves. An explanation for this could be 
that traces of phenol, chloroform, detergents or other inhibitory agents 
remained after isolation of the plasmid DNA by alkaline lysis. Methylation 
of plasmid DNA could also account for the inactivity of the enzymes. 
Additionally, compared to linear DNA, intact bacterial plasmids often 
require a higher unit quantity of restriction enzyme in order to cut the DNA 
owing to the fact that it is in a supercoiled, covalently closed circular form. 
Perhaps the activity of the enzymes employed had declined over time so that 
the activity stated by the manufacturer did not represent the true activity of 
the enzyme and consequently was not sufficient to complete the digestion 
(New England Biolabs and Promega manuals).
Transformants from plate B2 were selected for PCR analysis using the SmCC 
specific SmCCF2 and SmCCMR primers (Figure 24a and b). PCR analysis
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of eleven isolated plasmids revealed that five contained SmCC cDNA. 
However, gel analysis also revealed the presence of bands < 250 bp, which 
could represent the 195 bp bands of pPIC9K even for those plasmids shown 
to contain SmCC cDNA. This finding provides further support for the mixed 
population theory. These small bands appeared brighter for those plasmids 
that did not have SmCC cDNA.
Size comparison of Notl linearised plasmids on a gel with pPIC9K alone 
proved inconclusive (Figure 25). It was difficult to ascertain precisely from 
the gel whether the plasmids contained the insert because although on 
inspection it appeared that some plasmids were larger than pPIC9K alone this 
could be attributed to the fact that may have contained more concentrated 
DNA than pPIC9K and thus produced stronger, brighter bands.
Another detection strategy employed involved carrying out PCR using an 
SmCC specific primer in conjunction with a pPIC9K specific one. This 
would determine whether the SmCC cDNA detected in the previous PCR was 
actually contained in the vector and not the result of insert carry-over from 
the ligation procedure. Three out of ten clones, namely clones 4, 5 and 8 
produced the anticipated 664 bp product when screened with a-factor and 
SmCCMR primers (Figure 26). Only clones 4 and 8 proved positive for 
SmCC when screened with SmCCF2 and SmCCMR primers. The same 
clones produced the expected 814 bp product when they were screened with 
AOX3’ and SmCCMF primers (Figure 27). For those clones which did not 
reveal the 814 bp band on gel analysis a band at 1.4 kb was visible, which 
arose as a result of the SmCCMF binding non-specifically to a site on the 
vector. Plate B1 was screened with SmCCMF2 and SmCCMR. The presence 
of a 200 bp band was indicative of a positive result for SmCC and half of the 
clones screened were seen to be positive (Figure 28). The SmCC positive 
plasmids from this PCR were used to transform E. coli. Transformation 
proved very efficient in this instance and clones transformed with plasmid # 
2 were selected for further analysis. On PCR analysis some isolated 
plasmids proved positive for SmCC while others did not which reinforces the
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mixed population theory. Restriction digestion with SnaBI and Avrll showed 
that the plasmids originating from transformation plates B1 and B2 did not 
contain the 1.3 kb SmCC cDNA.
All the evidence supported the notion that a mixed plasmid population was 
present.
Because of the difficulties experienced in obtaining a pure culture, 
containing plasmids with SmCC, it was decided to transform again with 
SmCC cDNA. Transformation efficiencies proved high in this instance 
(Table 34). Purified plasmids from the transformation were analysed on a 
gel. One of the plasmids on size comparison, referred to as plasmid # 4 , 
proved to be larger than the other plasmids and the pPIC9K control (Figure 
30). Further analysis of this plasmid by PCR using the SmCCF2, SmCCMR 
(Figure 31) and a-factor, SmCCMR (Figure 32) primers confirmed the 
SmCC cDNA to be present in the vector. Restriction digestion with SnaBI 
and A vrll liberated the 1.3 kb SmCC cDNA from the 9.3 kb pPIC9K (Figure 
33). The appearance of a distinct 1.5 kb band upon gel analysis of the 
products of a PCR carried out with AOX3’ and a-factor primers proved 
conclusively that SmCC was contained in pPIC9K (Figure 34b). No pPIC9K 
195 bp band was visible as was expected if the vector contained the SmCC 
fragment.
Sequence Analysis
Sequencing was carried out on plasmid # 4 using the sequencing primers 
detailed in 3.2.2 (Figure 35). The deduced amino acid sequence of this 
SmCC consisted of a propeptide of 198 residues and a mature enzyme 
sequence of 237 residues. The signal peptide of 19 amino acids was not 
cloned. When the SmCC amino acid sequence of the propeptide and mature 
regions were aligned with SmCC from the Genbank 412 amino acids out of 
436 were seen to be 94.5% identical.
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Using BLAST, SmCC (pro and mature) was found to 47.99% identical to 
human dipeptidyl peptidase I (DPPI), 48.44% identical to mouse DPPI and 
48.2% identical to rat DPPI (Table 35). The deduced SmCC sequence 
exhibited 21.34% identity with SmCB and 21.87% identity with SmCL at the 
amino acid level. As anticipated active site residues Cys 30, His 181 and 
Asn 203 were conserved among species, as were the residues in proximity to 
the active site.
When SmCC was aligned with three mammalian cathepsin Cs from human, 
mouse and rat, Genbank SmCC and SjCC (see Appendix) the following 
points were noted:
• The nine amino acid residues RQWKCFVAE, (residues 102-110 in 
Figure 37), which are not found in the Genbank SmCC are found in 
other species. For instance, arginine (R) is conserved in rat, mouse 
and human cathepsin C, glutamine (Q) is conserved in SjCC, while 
tryptophan (W), cysteine (C) and phenylalanine (F) are all found in 
rat, mouse, human and SjCCs. Valine (V) is conserved in rat and 
mouse CC only. Alanine (A) is found in SjCC and the additional 
glutamic acid (E) appears to be unique to the sequenced SmCC, it is 
not conserved in any other species examined (Figure 38).
• The amino acid sequence FVSENCD, located at position 287-293 
(Figure 37) in SmCC was different to that in the Genbank (Figure 39). 
E was the only residue that was conserved in all species but not the 
Genbank SmCC.
Since the publication of the SmCC sequence in 1995, advances have been 
made which improve the efficiency and accuracy of DNA sequencing. The 
amino acid differences between the SmCC used in this project and that in the 
Genbank are conserved among many species so it is likely that the sequence 
of the SmCC used in this project represents the correct sequence of SmCC.
1 8 2
Only 60.78% identity was observed on alignment of the pro and mature 
regions of SmCC with that of SjCC. On alignment of the Genbank SmCC 
with SjCC, 56% identity was seen. It was expected that SmCC would exhibit 
a higher identity with SjCC and this implies that SmCC and SjCC may be 
discrete enzymes rather than species homologues (Hola-Jamriska et ah,
1998).
The tyrosine residue adjacent to the active site Cys 30, which is unique to all 
cathepsin C members of the papain superfamily, was conserved in SmCC. It 
is believed that this acidic residue may play an important role in determining 
substrate specificity by being involved in the binding of the amino-terminus 
of the peptide substrate and an isoleucine at the P2 side chain binding cleft 
(McGuire et al., 1997; Hola-Jamriska et ah, 1998).
At position 71 in the mature enzyme, an uncharged polar amino acid, 
asparagine (N) is found in SmCC and its Genbank counterpart. Mouse, rat 
and SjCCs all possess an acidic residue, aspartic acid (D) at this position. 
Additionally, an isoleucine (I) residue at position 229 in the mature enzyme, 
found in all mammalian cathepsin Cs and SjCC was replaced by a leucine (L) 
in SmCC. This isoleucine residue is believed to interact with the side group 
of the P2 residue of the substrate. These key differences between SmCC and 
SjCC and mammalian cathepsin Cs could be indicative of differences in 
substrate specificity and function (Hola-Jamriska et ah, 1998).
In mammalian cathepsin Cs it is thought that a conserved sequence of the 
prosegment, TA/DEIQQQ/KIL, situated in proximity to the cleavage site of 
the pro and mature regions, regulates the processing of the mature enzyme 
from the inactive zymogen. This sequence is not conserved in cathepsin C 
from schistosomes (Hola-Jamriska et ah, 1998). Also, a conserved sequence 
in mammalian cathepsin Cs, GLS/RD adjacent to the site where the enzyme 
is cleaved during conversion to the two-chain form was not conserved in 
schistosomes (Dolenc et al., 1995; McGuire et ah, 1997). A unique insert 
was seen in schistosomes at this site; NNH in SjCC and TDH in the Genbank
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SmCC. For the SmCC used in this project, the sequence at this location was 
NDH.
N-Glycosylation
The four potential N-glycosylation sites, two in the proregion and two in the 
mature enzyme region of the Genbank sequence are conserved in the deduced 
SmCC (Butler et al., 1995). Three potential N-glycosylation sites are present 
in the three reported mammalian cathepsin Cs, one in the mature enzyme and 
the other two in the prosegment. The glycosylation site in the mature region 
is conserved in SmCC but is absent from SjCC. Because the recognition 
sites for targeting molecules to the lysosome are present on the carbohydrate 
moieties it is believed that SmCC and SjCC may have different cellular 
locations with Sj being secreted (Hola-Jamriska et al., 1998).
Disulfide Bonds
As for the Genbank SmCC, Cys 27 is capable of forming a disulfide bond 
with Cys 70 and Cys 63 can form a bond with Cys 104. Cys 109 is unpaired 
as is the active site Cys.
Prosegment
Owing to the fact that cysteine proteases are initially synthesised as inactive 
zymogens, the proregion plays a number of vital roles. It can serves as a 
signal sequence, an endogenous inhibitor and also an intramolecular 
chaperone (Sajid and McKerrow, 2002). The unusually long prosegment 
characteristic of cathepsin C members of the papain superfamily was evident 
in SmCC. Alignment of the prosegments of the schistosome and mammalian 
cathepsin Cs revealed a high level of conservation; of 209 residues 49 were 
absolutely conserved and 68 were >50% conserved. The long prosegment 
was attributed to an extension at the NH2 terminus. This extension contained
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two blocks of residues highly conserved among the cathepsin Cs. These two 
blocks were conserved within the SmCC used in this project. At the COOH 
terminus of the proregion two conserved blocks are present which share 
structural similarity with cathepsins B and L. The prosegment of SmCC 
contained ERFNIN-like motifs, which are characteristic of cathepsin L. This 
was also observed for SjCC (Hola-Jamriska et al., 1998).
Phylogenetic Analysis
Phylogenetic analysis of all the genes of members of the papain superfamily 
in the public database revealed that the cathepsin C genes cluster with the 
cathepsin Bs (Hola-Jamriska et al., 1998), Controversy exists with regards 
to the ancestry of cathepsin C. Due to the fact that cathepsin C possesses a 
simple exon/intron structure in comparison to the complex genes of cathepsin
B, H and L, it has been suggested that cathepsin C may not share a common 
ancestry with cathepsin B but instead perhaps arose through convergent 
evolution (Rao et al., 1997). However, murine DPPI was demonstrated to 
have a complex genomic structure. It contains seven exons and spans more 
than 20 kb. Cathepsin B and H also span more than 20 kb, comprising 10 
and 12 exons respectively. Cathepsins C, H and L all share a common 
insertion position that isolates the exon containing the active site residue. In 
cathepsins B, C, H and L the active site histidine and asparagines residues 
are found within one exon although the exon on which they reside and the 
positions of the intron-exon insertion sites differ from gene to gene. These 
similarities indicate that the four proteases arose from a common ancestral 
gene, but that their structures have evolved to include intron losses and 
insertions (Pham et al., 1997). Phylogenetic analysis of SmCC and SjCC and 
three mammalian species placed cathepsin C firmly on a clade with the 
cathepsin B group. Given the common ancestry of cathepsin C and B it is 
unusual that SmCC and SjCC contain the ERFNIN motifs mentioned earlier 
in their prosegments as they are characteristic of cathepsin L proteases 
(Hola-Jamriska et al., 1998).
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Restriction Sites
Prior to transformation of P. pastor is with SmCC, one of the restriction 
enzymes Sail, SacI or BgUI must be used to linearise pPIC9K containing the 
insert. The enzyme of choice should cut pPIC9K but not SmCC. Restriction 
site analysis was performed on the Genbank SmCC and none of the enzymes 
were shown to cut the cDNA. However, restriction site analysis of the 
sequenced SmCC revealed that base changes had occurred within the 
sequence, which resulted in the production of both a Sail and a S a d  site. 
This meant that only BgUI could be used to linearise the expression vector 
prior to transformation of pPIC9K.
TIGR Gene Indices
The TIGR gene indices represent a public database of Expressed Sequence 
Tags (EST). ESTs have provided a first glimpse of the collection of 
transcribed genes for a variety of organisms. Through careful analysis of 
this sequence data additional functional, structural and evolutionary 
information can be provided. Gene indices are constructed for selected 
organisms by first clustering, then assembling ESTs and annotated gene 
sequences from the Genbank, thereby producing a set of unique high fidelity 
virtual transcripts or tentative consensus sequences (Quackenbush et al., 
2000). TC 4520 from the TIGR database revealed 97.48% identity to the 
Genbank SmCC and 96.58% identity to the SmCC used in this project at 
amino acid level (http://www.tigr.org').
Secondary Structure Prediction
A predicted secondary structure scan was carried out on the deduced SmCC 
protein sequence (refer to Appendix). It was predicted that 42.5% of the 
amino acids of SmCC could assume a random coil conformation, while 
19.31% of amino acids are likely adopt alpha helical structures. A further
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26.9% of the amino acids were expected to form extended strands and
11.26% of the amino acids were predicted to form beta turns.
4.4: F u n c t i o n a l  E x p r e s s io n  o f  Sm C C  in  P i c h i a  p a s t o r i s
Transformation of P. pastoris was carried out by spheroplasting instead of 
the electroporation method because it is considered the most effective 
technique for the generation of multi-copy inserts. Transformation proved 
successful when 5(j,g of SmCC/pPIC9K DNA was used. Transformants grew 
only on 0.25 mg/ml G418, which means that it is likely that only one copy of 
SmCC was integrated into the P. pastoris genome as the level of G418 
resistance is proportional to the number of plasmids integrated. PCR using 
AOX5’ and AOX3’ primers showed that the SmCC cDNA was successfully 
integrated into the P. pastoris genome for clones A2 and C2 as the
anticipated band at 1.8 kb was present for these clones (Figure 41). Clone
B2, which represents P. pastoris transformed with pPIC9K reveals the 2.1 kb 
band characteristic of the GS115 P. pastoris strain as expected.
Induction # 1
An initial 16-18 hr growth period was recommended to achieve an OD6oo 2.0-
6.0 prior to induction. However, it was found that this could only be reached 
after 41 hrs incubation. It was later discovered that the spectrophotometer 
used was inaccurate which explained why such a long growth period was 
required to attain the recommended cell density. This error was not 
discovered until induction # 5. Therefore, for all inductions prior to this an
accurate determination of cell density could not be made.
On SDS-PAGE analysis of D3-D6 supernatants from this induction a distinct 
22 kDa band was visible, which was not seen for the pPIC9K control samples 
(B2). This 22 kDa could be representative of the mature enzyme as the 
predicted molecular size of the mature enzyme is 26.5 kDa. This band also 
appeared on SDS-PAGE of D6 supernatants after incubation on Ni-NTA
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beads. This indicated that an intact hexahistidine tag was present on the 
recombinant protein. If this 22 kDa protein was a yeast protein it would not 
possess this tag. However, no hexahistidine tag was detected by western blot 
analysis.
Enzyme activity assays were performed which revealed that the SmCC 
specific substrate H-Gly-Arg-NHMec was cleaved using A2 and B2 
supernatants. However, using B2 supernatants, the substrate was also 
cleaved. This should not be the case as this is the control containing P. 
pastoris transformed with pPIC9K without SmCC cDNA. This activity was 
attributed to non-specific cleavage by yeast proteases. Enzyme assays 
carried out using culture pellets revealed low SmCC specific activity. Due to 
the fact that no DO sample was available for this induction it was impossible 
to determine whether this activity was due to non-specific substrate cleavage 
by yeast proteases or whether it was due to SmCC.
Induction # 2
Although this was a scale-up of induction # 1, the 22kDa band from the 
previous induction was not seen. Western blot analysis did not detect the 
hexahistidine tag. Affinity chromatography was carried out on the D6 
supernatant. Determination of the protein concentration of the column 
fraction revealed that the protein concentration of the supernatant before 
application to the column (0.896 mg/ml) was virtually the same as that of the 
run through sample (0.884 mg/ml), which indicated that very little, if any 
protein bound to the column. This means that either the hexahistidine tag is 
not present, i.e., the protein detected was not SmCC or alternatively, it may 
mean that the tag was degraded or folded in such a manner that it was not 
exposed and therefore could not bind to the Ni-NTA beads or the anti-His6 
antibodies.
Enzyme activity for the culture supernatants was the same as that detected 
for the DO sample, which indicates non-specific hydrolysis of the substrate
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(Table 41a). A pH profile assay was employed to investigate activity at pH 
3.0-8.5. Highest activity was observed at pH 7.5 (Table 42c, Figure 46). 
However, the background control used for this assay was prepared in sodium 
acetate pH 5.5. When this control was prepared in sodium phosphate at pH
7.5 unusually high levels of substrate hydrolysis were observed relative to 
that of the control prepared in sodium acetate. As a result the high activity 
observed at pH 7.5 cannot be attributed to the change in pH but was a result 
of intrinsic properties of the buffer, which lead to non-specific cleavage of 
the substrate.
Pellets were disrupted and were analysed by SDS-PAGE to detect any 
intracellular SmCC that may not have been secreted (Figure 45). A band was 
observed at 40 kDa in D1-D6 pellets that was not present at DO. Therefore 
this band represented an induced protein, which could be SmCC. However, 
the enzyme activity observed using the pellets was the result of non-specific 
cleavage of H-Gly-Arg-NHMec and not due to rSmCC activity.
Induction # 3
Induction # 3 was performed as for # 1 for seven days. SDS-PAGE analysis 
of supernatants revealed the presence of bands at 200 kDa and analysis of 
disrupted pellets did not reveal the presence of any induced bands. Western 
blot and ELISA analysis of supernatants and pellets did not reveal any 
binding (Table 43). Enzyme activity assays were carried out using D0-D7 
supernatants and no increase in activity was observed between the D0-D7 
assays (Table 44a, Figure 47). B2 control supernatants exhibited similar 
activity to A2 and C2, which proves that the low activity observed was not 
due to rSmCC activity. A similar assay was performed using disrupted 
pellets (Table 45a, Figure 48). Using A2, B2 and C2, activity was seen to 
decline after DO, but increased after D3, reaching a peak at D6. Activity 
declined after D6. However, the observed activity could not be accredited to 
rSmCC because similar levels of substrate hydrolysis were seen for B2 
controls as for A2 and C2.
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Induction # 4
Initial growth was performed in a 500 ml volume for this scale-up induction. 
Although an accurate determination of cell density could not be made for 
reasons mentioned previously, the cell density was, by inspection, very high. 
The effect of feeding methanol twice daily to a final concentration of 1.5% 
was investigated. Culture supernatants were initially analysed by SDS- 
PAGE (Figure 49). A non-specific 40 kDa band was seen at DO. A strong 
band at 47 kDa was seen at D1-D7. A band at 58 kDa was visible at D1-D7 
but became fainter after D3. Incidentally, at D4 a band appeared at 55 kDa 
that was absent at D0-D3 but present at D5-D7. As the predicted molecular 
size of the SmCC proenzyme is 49.5 kDa, it is likely that these bands >50 
kDa could represent differentially glycosylated forms of the enzyme. These 
bands resolved by SDS-PAGE even after the supernatants had been incubated 
with Ni-NTA beads, which indicated an intact hexahistidine tag. Purified 
baculovirus expressed SjCC resolved as three forms in SDS-PAGE gels, of 
55, 39 and 38 kDa. It was thought that the 39 and 3 8 kDa polypeptides were 
derived from the larger 55 kDa polypeptide by differential processing of the 
NH2 -terminus during expression of the proenzmye or during purification 
(Hola-Jamriska et al., 2000). The mature enzyme has a predicted molecular 
mass of 25 kDa. Faint bands were visible at ~ 25 kDa on the gel, which 
could account for some of the SmCC specific activity observed. Degradation 
products were visible for all supernatants at < 6.5 kDa on the gel. These 
degradation products could indicate that processing of the proenzyme 
occurred or could demonstrate that yeast proteases were active in the media.
In mammalian cathepsin Cs part of the N-terminal portion of the propeptide 
is retained in the mature enzyme (Dolenc et al., 1995; Turk et al., 2001; 
Horn et al., 2002). Referred to as the residual propart, this unique peptide 
contributes to the tetrahedral structure and creates an extension of the active 
site cleft, providing features that endow cathepsin C with dipeptidyl 
aminopeptidase activity (Turk et al., 2001). The fact that insect-cell 
expressed SjCC was functionally active while retaining part of its proregion
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provides proof that this residual propart is also retained in schistosomes 
(Hola-Jamriska et ah, 2000). In that case, the mature enzyme would be 
expected to have a larger molecular mass than the predicted mass of 25 kDa. 
Therefore, the bands seen at >47 kDa on the gel could be representative of 
the mature enzyme. For example, in human cathepsin C, the monomeric 
proenzyme of 55 kDa was discovered to be only slightly larger than the 53 
kDa monomeric form of the mature enzyme (Dolenc et ah, 1995).
Two western blots were performed using anti-His6 and anti-Schistosome 
mouse sera as the primary antibodies. Despite the promising result obtained 
using the Ni-NTA beads, the hexahistidine tag was not detected for any of 
the supernatants analysed. No binding was observed with the anti­
schistosome mouse sera. The positive controls worked well for both cases. 
A western blot and an ELISA were performed using anti-SjCC rabbit sera 
(Figure 51a , Table 46). Using D3 and D5 supernatants, antibodies bound to 
a band at 47 kDa. This shows that Sj antibodies cross-react with SmCC. The 
ELISA showed that binding to the purified SjCC controls was minimal and 
no binding was observed with D0-D7 supernatants. This could indicate that 
the 47 kDa band seen for the western blot could possibly be due to non­
specific binding but the fact that a band of similar size appears on SDS- 
PAGE of D1-D7 supernatants increases the likelihood of this band being 
rSmCC.
Enzyme assays were performed on the D0-D5 supernatants (Table 47b, 
Figure 52). B2 supernatants served as a control in this assay. Low levels of 
non-specific substrate cleavage were observed for B2 supernatants. Using 
D0-D5 C2 supernatants, activity was detected, increasing steadily from D0- 
D5. The increase in enzyme activity after D4 coincides with the appearance 
of the aforementioned 55 kDa band at D4 on SDS-PAGE. However, activity 
was still low, D4 supernatants possessed 0.6 U of enzyme activity whereas 
D5 supernatants had 1.5 U of activity, which is low considering that the 
assay was performed overnight. Time was not taken into account when 
calculating enzyme activity in this instance. The positive control, FhCC had
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9 U of activity for the overnight assay. The change in activity over a 4 hr 
and 20 hr period was investigated. For the 4 hr assay activity peaked at D5 
(0.5 U), then declined slightly at D6, and then peaked again at D7. For the 
20 hr assay activity was seen to peak at D5 (1.7 U) and declined for 
subsequent days. As 1 U of enzyme activity is a function of time (min), 
although an increase in the amount of NHMec liberated over time was 
observed, this does not represent an increase in activity of the enzyme 
because the assay was performed over a longer time-scale.
A leupeptin inhibition assay was carried out using the D5 supernatant (Table 
49, Figure 54). A 90.4% decline in enzyme activity was observed in assays 
performed in the presence of leupeptin. For the positive control, leupeptin 
inhibited FhCC in somatic extract by only 42%. A similar assay performed 
using iodoacetamide revealed it to be only a weak inhibitor of rSmCC, 
inhibiting the enzyme by only 9.32%. Iodoacetamide inhibited FhCC by 
94.6%. Since F. hepatica somatic extract was used as the source of FhCC 
instead of purified enzyme and because iodoacetamide is a general cysteine 
protease inhibitor, it is likely that other cysteine proteases, capable of 
cleaving the cathepsin C substrate were also inhibited in the extract. This 
finding questions the reliability of using F. hepatica somatic extract as a 
positive control.
Another assay was undertaken, to discover the extent to which rFhCLl 
cleaves the cathepsin C substrate H-Gly-Arg-NHMec (Table 50). As the bar 
chart in Figure 55 illustrates, although some non-specific cleavage occurs, 
the activity of FhCLl towards H-Gly-Arg-NHMec is low relative to that of 
rSmCC.
These findings for induction # 4 indicate that although rSmCC appeared to 
be produced, production was by no means optimal. By increasing the cell 
density of the starting culture and by increasing the concentration of 
methanol in the induction flasks, the production of rSmCC was enhanced. 
As the cells are all of the slow-growing Muts phenotype, such a high cell
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density may be a necessity in order for a recombinant protein such as SmCC 
to be functionally expressed.
Induction # 5
Induction was performed at pH 6.0, 7.0 and 8.0 to investigate the effect of 
pH on rSmCC expression. Cultures were grown to an OD of 20.0 prior to 
induction. The pH in the induction flasks was monitored over the 6-day 
induction period and it was observed that pH increased by 1.5 pH units over 
the course of the induction (Table 51). Resolution of D0-D6 supernatants by 
SDS-PAGE revealed the presence of a single band for pH 6.0 supernatants 
from D3-D6 at 55 kDa. It is possible that this single band represents the 
mature enzyme with the residual prosegment attached For D3-D6 pH 7.0 
supernatants, three distinct bands are resolved at 60 kDa, 55 kDa and 47 
kDa, which are similar to those bands observed on analysis of induction # 4 
supernatants. Low molecular mass degradation products can be seen at pH
7.0 but not pH 6.0. No bands were visible for any of the supernatants prior 
to D3.
Western blot analysis using the anti-His6 antibodies did not detect the 
presence of the his tag. This provides further evidence that the his tag is 
damaged or that the secondary structure of the protein obscures the his tag. 
This will add to the complexity of subsequent purification steps. A western 
blot employing the anti-SjCC sera revealed that binding occurred to a 62 kDa 
and 28 kDa polypeptide for D4 pH 6.0 and D4 pH 7.0 supernatants. As these 
bands are not visible following resolution by SDS-PAGE for either sample, it 
is likely that they are due to non-specific antibody binding.
Enzyme activity assays were carried out on all supernatants (Table 52, 
Figure 58). Activity was low in all cases compared to that observed for 
supernatants from previous inductions, peaking at D3 for pH 5.0 
supernatants, D4 for pH 6.0 and D5 for pH 7.0. Surprisingly, pH 5.0
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supernatants exhibited the highest activity of the three. This is unusual 
because no bands were visible on SDS gel analysis of these supernatants.
Induction # 6
Cells were grown to an O D 6oo of 3.0 prior to induction. This induction 
served as a comparison to induction # 4, in which cells were initially grown 
to a very high density. All other conditions were as for induction #4. After 
5 days induction, supernatants were resolved by SDS-PAGE. A single band 
of 47 kDa was observed at D3 and D4 (Figure 59). This is an encouraging 
result, because it signifies that the pro-mature enzyme is being produced and 
no degradation of the product occurs. Perhaps this band represents the 
mature enzyme with the residual propart. This can only be proven by N- 
terminal sequencing of the protein.
Western blot analysis revealed no binding with anti-His6 and anti-SjCC sera. 
Surprising^, the positive control for the blot, SmCB was shown to cross- 
react with SjCC.
Activity in the supernatants was low in all instances (Table 53, Figure 60). 
Activity peaked at D4 and when results from an overnight assay were 
compared with an assay carried out over a 4hr period very little difference in 
activity between the two was seen (Figure 61).
4 .5 :  B i o c h e m i c a l  C h a r a c t e r i s a t i o n  o f  F. h e p a t i c a  C a t h e p s i n  C
Schistosome dipeptidyl peptidase I (DPPI) or cathepsin C was characterised 
by Flola-Jamriska et al., 1999. In this study, the optimum pH for cathepsin C 
activity was discovered to be pH 5.5. Activity was enhanced by reducing 
conditions and by addition of the halide ions Cl', Br' and I'. Schistosome 
cathepsin C was only slowly inhibited by E-64. Iodoacetamide, leupeptin 
and NEM, general cysteine protease inhibitors, which as thiol blockers
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inhibit the highly reactive thiol group that characterises the cysteine 
protease, rapidly blocked the schistosome’s DPPI activity. Therefore, 
schistosome DPPI exhibited similar characteristics to mammalian cathepsins 
(refer to Section 3.4).
Most of the enzymes characterised from F. hepatica have been 
endoproteinases. Previously, a dipeptidyl peptidase was characterised from
F. hepatica but it did not cleave the DPPI substrate H-Gly-Arg-NHMec. 
This enzyme cleaved DPPII and DPPIV substrates but their respective 
inhibitors, puromycin and bactitracin did not have any effect on the activity 
of the enzyme (Carmona et al., 1993).
Given the biochemical characteristics of schistosome DPPI, a series of 
enzyme assays were performed to determine if FhCC shared these 
characteristics and to investigate if FhCC possessed any novel or original 
attributes.
Initial assays were carried out to investigate whether FhCC, like its 
schistosome counterpart, was enhanced in the presence of DTT. DTT is a 
reducing agent that reduces the cysteines in the enzyme and aids in substrate 
binding by changing the enzyme conformation. The addition of even 5 .^L of 
2 mM DTT was seen to have a marked effect on enzyme activity. Addition 
of 15 (xL of 2 mM DTT resulted in a 67% enhancement of FhCC activity at 
pH 5.5 and a 50% enhancement at pH 8.5 (Figure 62). Addition of 100 |iL of 
20 mM DTT was recommended for optimal activity (Hola-Jamriska et al., 
1999). This resulted in a 524% enhancement of activity. Therefore, 100 [iL 
of 20 mM DTT was used in all assays to detect the presence of recombinant 
protein.
A series of pH profile assays were undertaken to investigate the pH optimum 
of FhCC. The graph in Figure 63 illustrates that two definite peaks of 
enzyme activity occurred, one at pH 5.5 and the other at pH 8.5. In this 
assay 1.5 times more NHMec was liberated from the fluorogenic substrate at
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pH 8.5 than at pH 5.5. Activity at pH 5.5 was 67% of that at pH 8.5. 
However, other assays revealed that the activity at pH 5.5 was greater than at 
8.5. When the buffer was changed from sodium acetate pH 5.5 to a sodium 
phosphate buffer of the same pH, a four-fold decline in FhCC activity 
resulted. This decline in activity did not occur on changing the buffer from 
sodium phosphate pH 7.5 to Tris-HCl, pH 7.5. The peak at pH 5.5 using the 
sodium acetate buffer was consistent with the pH optimum of schistosome 
cathepsin C using the same H-Gly-Arg-NHMec substrate. Optimum DPP III 
activity was previously reported at pH 8.5 but this does not explain the peak 
observed using H-Gly-Arg-NHMec as the substrate for DPP III is H-Arg- 
Arg-NHMec and DPP III does not cleave H-Gly-Arg-NHMec at pH 8.5 
(Hola-Jamriska et ah, 1999). In another study carried out in our laboratory, 
the peak at pH 8.5 was suggested to represent a second pH preference for
cathepsin C. Alternatively, another enzyme could be present in the somatic
extract capable of cleaving the cathepsin C substrate.
Cathepsin LI and L2 are the dominant proteases present in F. hepatica 
(Spithill et ah, 1999; Dalton and Mulcahy, 2001). To investigate if the peak 
at pH 8.5 was due to the activity of cathepsin L, the cathepsin L inhibitors Z- 
Phe-Ala-NH2 and Z-Phe-Phe-OH were incubated with the enzyme for 10 min 
before addition of the substrate (Table 56 and 57). For the assay performed 
with Z-Phe-Ala-NH2 highest activity was observed at pH 8.5 as before and 
the smaller peak at pH 5.5 was also present (Figure 64). Four times more 
NHMec was released at pH 8.5 than at pH 5.5. For the assay using Z-Phe- 
Phe-OH, assays were performed at pH 5.5 and pH 8.5 (Table 57). Only a 
slight decrease in enzyme activity was observed in assays containing the
inhibitor. The FhCC activity for the assay carried out at pH 5.5 in the
absence of inhibitor was 5 U. When inhibitor was present, activity was 4.1 
U, which represents a modest decline in activity of only 8%. At pH 8.5 3.67 
U of enzyme activity was observed in the presence of inhibitor, which 
represents a 30% decline in activity relative to the assay performed without 
inhibitor, which had 5.27 U of activity. When assays were performed in 
sodium phosphate buffer, pH 5.5, no decline in activity was observed on
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addition of inhibitor. Therefore, it is unlikely that the peak of activity at pH
8.5 is due to the action of a cathepsin L-like enzyme but could perhaps be 
due to the action of a previously uncharacterised enzyme. Alternatively, this 
could signify another pH preference of FhCC not evident in its schistosome 
counterpart.
Inhibition studies were carried out to further characterise the activity 
responsible for the hydrolysis of H-Gly-Arg-NHMec. In the study of 
schistosome DPP I iodoacetamide (1 mM) was the most potent inhibitor of 
DPP I resulting in 99% inhibition of the enzyme. NEM (1 mM) caused 95% 
inhibition of DPP I activity and leupeptin (10 p.M) inhibited the enzyme by 
72% (Hola-Jamriska et al., 1999). Iodoacetamide (ImM) inhibited FhCC by 
40.3% (Table 58), 0.1 mM leupeptin inhibited the enzyme by 44.6 % (Table 
59) and 1 mM NEM led to 33% inhibition of FhCC (Table 60). As previous 
studies carried out on schistosome cathepsin C showed leupeptin to be a less 
potent inhibitor than iodoacetamide and NEM, it is surprising that it was the 
most potent inhibitor of FhCC activity of the three. Inhibition of FhCC was 
low in all assays relative to the levels obtained for schistosome cathepsin C. 
Perhaps a higher concentration of inhibitor is needed to inhibit FhCC activity 
than is the case for schistosomes.
Mammalian cathepsin Cs are more slowly inhibited by E-64 relative to other 
cysteine proteases such as cathepsin B, H and L (Barrett et al., 1982). A 
time course study was performed on FhCC using the inhibitor E-64 to 
investigate if this was the case for FhCC. An assay was carried out with and 
without E-64 for cathepsin C and cathepsin LI using their respective 
substrates. The time for which FhCC and FhCLlin the somatic extract were 
incubated with E-64 before the addition of substrate was varied (Table 61). 
As depicted in Figure 66, for the FhCC assay with E-64 only slight inhibition 
was evident. After 10 min 81.3% of the activity remained, whereas after 80 
min incubation FhCC retained 62.13% of its activity. By contrast, hydrolysis 
of Z-Phe-Arg-NHMec by cathepsin L was blocked by 91% almost 
immediately. In schistosomes, SjCC was only slightly inhibited by E-64
197
after 10 min. More than 70% of the activity remained after 40 min and only 
50% of the activity was blocked after 80 min. Cathepsin L activity was 
immediately blocked in the presence of E-64 (Hola-Jamriska et al., 1999). 
The results demonstrate the slow inhibition by E-64 observed for mammalian 
and schistosome cathepsin C is also a characteristic of FhCC.
Mammalian cathepsin C is enhanced in the presence of chloride ions (Butler 
et al., 1969). It was later discovered that the location of the chloride ion in 
the S2 subsite of cathepsin C directed the interaction between the ion and the 
substrate and therefore enhanced cathepsin C activity. The activation of Cl' 
is pH dependent, being stronger at pH values below 7.0 (Cigic and Pain, 
1999). In studies of schistosome cathepsin C it was found that H-Gly-Arg- 
NHMec hydrolysis was increasingly enhanced in the presence of NaCl and 
NaBr in the range 0.1-10.0 mM. Activity was enhanced by Nal ions at a 
concentration of 1.0 mM but was slightly reduced at 10.0 mM. Fluoride ions 
at 0.1-10.0 mM did not enhance activity (Hola-Jamriska et al., 1999).
Halide enhancement assays performed on somatic extract using cathepsin C 
specific substrate revealed that 1.0 mM NaCl enhanced activity by 32.12% 
(Table 62). NaBr was a weaker enhancer than NaCl; 1.0 mM and 10.0 mM 
NaBr led to a 13.32% and 19.44% enhancement in activity respectively 
(Table 63). 1.0 mM Nal activated FhCC by 36.36%, whereas 10.0 mM Nal 
resulted in 44.21% activation (Table 64). This finding does not concur with 
that obtained for SjCC in the presence of Nal, which showed a slight 
reduction in activity at a higher iodide concentration (Hola-Jamriska et al.,
1999). As anticipated, NaF did not enhance activity. In fact, it had an 
inhibitory effect (Table 65).
It is possible that like mammalian cathepsin C, FhCC has an absolute 
requirement for chloride ions. The fact that activity was observed even in 
the absence of exogenous halides could be due to the presence of endogenous 
halides in the somatic extract.
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A BCA protein assay was carried out to determine the protein concentration 
of the extract in order to calculate the specific activity of FhCC. The 
specific activity was calculated to be 0.142 U/mg of protein. Another 
preparation of somatic extract was shown to have a specific activity of 
0.0414 U/mg of protein, which represents a very low activity.
In conclusion, FhCC was biochemically characterised and was seen to 
exhibit similar characteristics to its schistosome counterpart. Some 
differences exist but overall the biochemical properties of cathepsin C from 
the two different helminths were similar.
4 .6 :  C o n c l u s i o n
The cDNA encoding SmCC was successfully amplified from a cDNA library 
using specific primers containing sites for SnaBI and A vrll digestion. This 
facilitated cloning of the cDNA into the Pichia pastoris expression vector, 
pPIC9K in frame with the initiation codon of the yeast a-factor secretion 
signal. P. pastoris was transformed with the SmCC cDNA and transformants 
were selected on the basis of G418 resistance.
Protein expression was initially induced with BMMY media supplemented 
with 1% methanol. A 22kDa band was visible on resolution of culture 
supernatants by SDS-PAGE. This polypeptide was not reactive against anti- 
His6 antibodies and affinity chromatography on Ni-NTA using the D6 
supernatant revealed the absence of the his tag as no protein bound to the 
column. An induced band of 40 kDa appeared on SDS-PAGE analysis of 
culture pellets but further investigation did not prove this band to be SmCC.
When a twice-daily feed of methanol to a final concentration of 1.5% was 
employed, SDS-PAGE analysis of culture supernatants revealed the presence 
of distinct bands at 58, 55 and 47 kDa that were absent from DO samples. It 
is highly likely that these bands represented differentially glycosylated forms 
of the proenzyme since P. pastoris is capable of adding both O-and N-linked
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carbohydrate moieties to secreted proteins (Cereghino and Cregg, 2000). 
Enzyme activity was observed and although low, this indicated that the 
mature enzyme was produced. Due to the fact that mammalian cathepsin Cs 
retain part of their proregion in the mature enzyme any of aforementioned 
bands could represent the mature enzyme with this residual propart attached 
(Dolenc et al., 1 9 9 5 ;  Turk et al., 2001; Horn et al., 2002). Degradation 
products at <6.5 kDa were visible for all supernatant samples analysed which 
indicates that proteolysis occurred, possibly due to the action of yeast 
proteases. When this induction was repeated using BMMY media at pH 5.0,
6.0 and 7.0, no protein was produced at pH 5.0, a single protein of 55 kDa 
was expressed at pH 6.0 and at pH 7.0 the bands previously observed at 58, 
55 and 47 kDa were produced.
Despite the fact that an intact his tag could not be detected for any of the 
culture supernatants that showed potential cathepsin C bands when resolved 
by SDS-PAGE, SjC antisera bound to a protein of 47 kDa, which implies that 
this is SmCC. Perhaps secondary folding at the COOH terminus obscured 
the his tag or perhaps it was degraded by yeast pro teases. A colony blot was 
performed and revealed that the protein was not being expressed. N-terminal 
sequencing is the only way to conclusively prove that the proteins produced 
are SmCC but before this is carried out different parameters of the 
fermentation process need to be manipulated to optimise the production of 
the recombinant protein.
4 .7 :  R e c o m m e n d a t i o n s
When future research on the expression of SmCC by Pichia pastoris is 
carried out, it may be useful to implement some of the following strategies, 
which could have an effect on the expression levels of the recombinant 
protein:
• Although BgUI linearised plasmids are more likely to generate high 
copy number transformants than Sail or SacI, all transformants used in 
this project to initiate transformation were single copy. Generally the
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use of multi-copy inserts has improved yield. For instance, the 
production of tetanus toxin fragment C was related to the plasmid 
copy number (Clare et al., 1991b). Another transformation could be 
performed using a higher concentration of DNA, in an attempt to 
obtain multi-copy transformants. Alternatively, a vector could be 
constructed with multiple head to tail copies of the expression cassette 
in order to increase the copy-number and improve yield (Cereghino 
and Cregg, 2000).
• Expression levels in shake flasks are low relative to those obtained 
with fermenters (Higgins and Cregg, 1998). It is only in the 
controlled environment of a fermenter that it is possible to grow P. 
pastoris to high cell densities and as the concentration of product is 
roughly proportional to the concentration of cells in culture, this is an 
important factor. It has been demonstrated that by switching from a 
shake flask to a fermenter protein production in P. pastoris has 
increased by 140% (Cino, 1999). Aeration is a critical factor for the 
expression of a protein and Muts strains are more likely to become O2 
limited (Sreekrishna et al., 1997). In fermenters dissolved oxygen 
level is strictly monitored so that oxygen limitation does not occur. 
Studies have shown that a continuous fermentation process can result 
in a 5.0-6.0 fold higher productivity than a fed-batch system so 
perhaps when a fermentation is being carried out in future, it might be 
worth considering the possibility of operating it in a continuous mode 
(Goodrick et al., 2001).
• It has been suggested that for Muts strains, addition of glycerol 
together with methanol during the induction phase may increase the 
growth rate of the cells, which could increase the production rate of 
the recombinant protein (Files et al., 2001). This could be 
investigated for rSmCC production.
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• The level of expression at pH 5.0, 6.0 and 7.0 was investigated in this 
project. Although no protein was produced at pH 5.0, the effect of 
low pH on SmCC expression should be determined. The 
recommended pH range for expression in P. pastoris was between pH 
2.8-6.5 (Thiry and Cingolani, 2001). Media manipulation and pH 
changes can significantly alter the profile of protein components and 
can result in proteins that were previously unnoticed becoming 
evident.
• All inductions carried out in this project were performed at 30°C. 
Protein expression ceases at 32°C. High heat loads can result when P. 
pastoris is actively growing or expressing high levels of protein. In 
shake flasks, temperatures can increase by 25°C if left uncontrolled 
(Cino et al., 1999). Therefore, temperature should be monitored 
strictly for all future inductions. In one study, lowering the induction 
temperature from 30°C to 25°C resulted in a four-fold increase in 
yield of galactose oxidase in P. pastoris (Whittaker, 2000). On the 
basis of these findings, the effect of lowering the temperature on 
rSmCC expression should be investigated.
• Proteolysis represents the most common reason for failure of an 
expression process (Romanos, 1995). Proteolytic degradation 
occurred in induction # 4 as many low bands at < 6.5 kDa were visible 
on SDS-PAGE analysis of supernatants. To minimise proteolysis, 
amino acid or peptide supplements or EDTA should be added to the 
growth media. The media could also be buffered to pH 3.0, which 
would be unfavourable for the production of the harmful proteases 
(Sreekrishna et al., 1997). If proteolysis was discovered to be a major 
obstacle to the production of functional SmCC perhaps protease 
deficient P. pastoris strains could be utilised.
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An NHMec standard curve representative o f those used for all 
enzyme assays performed in this project is shown below:
NHMec uM Fluorescence
50 982.4
25 542.2
12.5 258.8
6.25 128.4
3.125 58.67
1.5 29.97
0.78 13.42
0 0.31
NHMec Standard Curve
0 10 20 30 40 50 60
y = 19.956X+ 4.429 
NHMec Cone. (uM) r 2 = 0.9975
VJk) i n i ;  I l  i l l J l \J I « |I IU M  I -------X-'  ---1-------I--------------------C
% ill*Network Protein Sequence Analysis
NPS@ is the IBCP contribution to PBIL in Lyon, France
[MOMEl [NPS@1 rSRSl flIELPl [REFERENCES1 fNEWSl [MPSA1 ÎANTHEPROTI fGeno3Dl
TPBILI
Monday, October 7th 2002 : InterProScan is available (see news)
Job CLUSTALW  (ID: 5518) is running on NPS@ server (started on Tue Feb 11 08:54:52 CET 2003). 
Results will be shown below. Please wait and don’t go back.
n your publication cite : 
fPS@: Network Protein Sequence Analysis 
IBS 2000 March Vol. 25, No 3 [291]: 147-150 
iombet C., Blanchet C., Geourjon C. and Deleage G.
"LUSTALW multiple alignment
Abstract Thompson, J.D., Higgins, D.G. and Gibson, T.J. CLUSTAL W: improving the sensitivity o f  progressive multiple 
equence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. (1994) Nucleic 
tcids Research, 22, 4673-4680 [HELP]
ESPript (Toulouse, FR) [ Residues repertoire
SHOW alignment with width : 60
all [▼" residues.
Conservation level of _o__% (works with "using conservation level o f’ option in list above).
All prediction methods and secondary consenus p ]  _ | with percentage of secondary structure.
_] DSC (King and Sternberg, 1996) (Do it alone) [HELP]
_ | DPM (Deleage and Roux, 1987) rHELPI
_ | GORI (Garnier et al., 1978) Choose parameters [HELP]
J  GOR m  (Gibrat et al., 1987) rHELPI 
J  GOR IV (Gamier et al., 1996) rHELPI 
_ | I INN (Guermeur, 1997) [HELP]
J  SIMPA96 (Levin et al., 1996) rHELPI
_ | PHD (Rost et al., 1994) (Do it alone) rHELPI
_ | PREDATOR (Argos et al., 1996) Choose parameters [HELP]
_ | SOPM (Geouijon and Deleage, 1994) (Do it alone) rChoose parameters] [HELP]
\  prediction method with the Do it alone sentence must be the only newly selected one between two 
dicks on SHOW button. The other methods can be kept if they have been computed or can be added 
ifter. All methods can be displayed at the same time in the alignement.
2/11/2003 8:06 AM
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^iew CLUSTALW in: rMPSA (Mac. UNIX), About...1 [AnThcProt (lJ< | , Download...1 [HELPI
10 20 30 40 50 60
I I I I I I
,atxxx4 DTPANCT^P LLGT VFQVGPRHPRSHINCSVMEPTEEKVVIHLKKLDTAY EVGNS YF
:ousex5 DTPANCT'í PDLL ÍTWVFQVGPRSSRSDINCSVMEATEEKWVHLKKLDTAYDELGNSGHF
umanx3 DTPANCTYLDLLGT V ’QVGSSGSQRDVNCSVMGPQEKKWVYLQKLDTAYDDLGNS HF
eqxxxO DTPANCTYEDAHGR KFHIG--- DYQSKCPEKLNSKQSWISLLYPDIAIDEFGNR HW
IBxxxxl DTPANCT E AH R K rHIG--- DYQSKCPEKLNSKQSWISLLYPDIAIDF.F 3NR HW
jCCxx2 DTPANCSYMDAIGH I -HVS--- RYKTKCTKQLDVSQTFSMNVQYPNIVTDSYC MGKW
■k-k-Jc-k-k'k‘ - k ' k  k  -k -k • • « k  • • •  ■ ~k -k -k -k «
rim.cons. DTPANCTY2D2LGTWVF2VGPR3SRY222CSVML22EQKVVI2L322D2AYDE2GNSGH2
70 80 90 100 110 120
l i l i l í  
:atxxx4 TLIYNQGFEIVLNDYKWFAFFKYEVKGSRAISYCHETMTGWVHDVLGRNWACFVGKKMAN
[ousex5 TLIYNQGFEIVLNDYKWFAFFKYEVRGHTAISYCHETMTGWVHDVLGRNWACFVGKKVES
:umanx3 TIIYNQGFEIVLNDYKWFAFFKYKEEGSKVTTYCNETMTGWVHDVLGRNWACFTGKKVGT
:eqxxx0 TLIYNQGFEVTINHRKWLVIFAYKSNGE---- FNCHKSMPMWTHDTLIRQWKCFVAEKIGV
IBxxxxl TLIYNQGFEVTINHRKWLVIFAYKSNGE---- FNCHKSMPMWTHDTLIDSG-SVCSGKIGV
:jCCxx2 TLIYNQGFEITMNHRKWLIMFAYGPNNT---- YTCNKSMPMWTHDTLICQWHCFTATKVNH
* . * * * * * * * .  . * **•  . * * * . . .  -k * _ * * _ *  _ *-
’rim.cons. TLIYNQGFEI2LN22KW2AFF2YK2NG23AI2YCH22M22W2HD2L2RNWACFVGKKVGV
130 140 150 160 170 180
l i l i l í  
:.atxxx4 HSEKVYVNVAHLGGLQEKYSERLYSHNHNFVKAINSVQKSWTATTYEEYEKLSIRDLIRR
[ousex5 HIEKVNMNAAHLGGLQERYSERLYTHNHNFVKAINTVQKSWTATAYKEYEKMSLRDLIRR
(umanx3 ASENVYVNTAHLKNSQEKYSNRLYKYDHNFVKAINAIQKSWTATTYMEYETLTLGDMIRR
1 eqxxxO HDKFHINKLFGS---- KSFGRTLYHINPSFVDKINAHQKSWRAEIYPELSKYTIDELRNR
IBxxxxl HDKFHINKLFGS---- KSFGRTLYHINPSFVGKINAHQKSWRGEIYPELSKYTIDELRNR
1 j CCxx2 FQRMIEYKSPVL---- QLDGNQLYKVDTKFIKAINAKQNSWKATIYPEYSKYTIKEMRRR
• • k  ~k • -k • ~k ~k * -k • -k -k -k k  . . . .  -k
■rim.cons. H2E2V222LAHLGGLQE2Y23RLY22NHNFVKAINA2QKSWTATIYPEY2KYTI22L2RR
190 200 210 220 230 240
l i l i l í
latxxx4 SG-HSGRILRPKPAP---- ITDEIQQQILSLPESWDWRN-VRGIN-FVSPVRNQESCGSC
Iousex5 SG-HSQRIPRPKPAP---- MTDEIQQQILNLPESWDWRN-VQGVN-YVSPVRNQESCGSC
Iumanx3 SGGHSRKIPRPKPAP---- LTAEIQQKILHLPTSWDWRN-VHGIN-FVSPVRNQASCGSC
leqxxxO AGGVKSMVTRPSVLN-RKTPSKELISLTGNLPLEFDWTSPPDGSRSPVTPIRNQGICGSC
IBxxxxl AGGVKSMVTRPSVLN-RKTPSKELISLTGNLPLEFDWTSPPDGSRSPVTPIRNQGICGSC
:jCCxx2 AGGSRSAFKRQNVQLPKKNLTSAMMLELLALPKEFDWVNRPEGLRSPVTPVRNQKTCGSC
• -k k  • • -k ~k • -k -k ~k 'k»-k*'k'k-k'k'k-k'k
’rim.cons. 2GGHSS2I2RPK2APPRKT2T2EIQQ2ILNLP222DWRNP2DG22SPV2PVRNQ2SCGSC
250 260 270 280 290 300
l i l i l í
latxxx4 YSFA LGMLEARIRILTNNSQT ’ILSPQEWSC PYAQGCDGGFPYLIAGKYAQDFGWE
Iousex5 YSFASMGMLEARIRILTNNSQTPILSPQEWSCSPYAQGCDGGFPYLIAGKYAQDFGWE
lumanx3 YSFASMGMLEARIRILTNNSQTPILSPQEWSCSQYAQGCEGGFPYLIAGKYAQDFGLVE
JeqxxxO YAFASAAALEARIRLVSNFSEQ ’ILSPQAWDCSPYSEGCNGGFPFLIAGKYGEDFGFVS
íBxxxxl YASPSAAALEARIRLVSNFSEQPILSPQTWDCSPYSEGCNGGFPFLIAGKYGEDFGLPQ
;jCCxx2 YAFASTAAIEARIRLASRFRLQPILSPQDIIDCSPYSEGCDGGFPYLVAGKHGEDFGFVE
* . -k • * * * * * •  • * * * * * *  . .  ** * • • * * • * * * * ' * . * * * •  • ** *
)rim.cons. Y2FAS222LEARIR2L2N2SQ2PILSPQEW2CSPY22GCDGGFPYLIAGKY22DFG3VE
310 320 330 340 350 360
l i l i l í
latxxx4 ENCFPYTATDA-PCKPKENCLRYYSSEYYYVGGFYGGCNEALMKLELVKHGPMAVAFEVH
Iousex5 ESCFPYTAKDS-PCKPRENCLRYYSSDYYYVGGFYGGCNEALMKLELVKHGPMAVAFEVH
Iumanx3 EACFPYTGTDS-PCKMKEDCFRYYSSEYHYVGGFYGGCNEALMKLELVHHGPMAVAFEVY
¡eqxxxO ENCDPYTGEDTGKCTVSKNCTRYYTADYSYIGGYYGATNEKLMQLELISNGPFPVGFEVY
ÍBxxxxl KIVIPYTGEDTGKCTVSKNCTRYYTTDYSYIGGYYGATNEKLMQLELISNGPFPVGFEVY
JjCCxx2 EKCNPYTGVKSGTCNKLLGCTRYYTTDYHYIGGYYGATNEDLMKLELVKNGPFPVGFEVY
• ~k ~k -k ♦ ~k ~k -k -k -k • • • -k ~k m k  ~k • -k -k 'k -k -k k  • -k -k -k « • •k -k » k  -k -k -k •
2/11/2003 8:06 AM
rim.cons. ENCFPYTG2DSGPCK2 2ENCTRYY2 SDY3Y2 GG2YG2 2NEALMKLELVK2GP2 2V2 FEVY
370 380 390 400 410 420
atxxx4 
ousex5 
:umanx3 
eqxxxO 
Bxxxxl 
j CCxx2
DDFLHYHSGIYHHTGLS-- DPFNPFELTNHAVLLVGYGKDPVTGLDYWIVKNSWGSQWG
DDFLHYHSGIYHHTGLS-- DPFNPFELTNHAVLLVGYGRDPVTGIEYWIIKNSWGSNWG
DDFLHYKKGIYHHTGLR-- DPFNPFELTNHAVLLVGYGTDSASGMDYWIVKNSWGTGWG
EDFQFYKEGIYHHTTVQNDHYNFNPFELTNHAVLLVGYGVDKLSGEPYWKVKNSWGVEWG
EDFQFYKEGIYHHTTVQTDHYNFNPFELTNHAVLLVGYGVDKLSGEPYWKVKNSWGVEWG
GDFLQYKSGVYSHTDIINNHHPFNPFELTNHAVLLVGYGIDNSSNLPYWKIKNSWGQYWG
DDFLHYKSGIYHHTGL2NDHDPFNPFELTNHAVLLVGYGVD22SG2PYW2VKNSWG2EWG’rim. cons.
430 440
;atxxx4 
[ousex5 
umanx3 
^eqxxxO 
IBxxxxl 
: j CCxx2
E2GYFRI2RGTDEC22ESIAVA2DP22KL'rim. cons .
Alignment data :
Alignment length : 449 
dentity (* ): 165 is 36.75 %
Strongly similar (:) : 70 is 15.59 %
Veakly similar (.): 51 is 11.36 %
A fferent: 163 is 36.30 % 
iequence 0001 : Ratxxx4 ( 438 residues). 
Sequence 0002 : Mousex5 ( 438 residues). 
Sequence 0003 : Humanx3 (439 residues). 
Sequence 0004 : SeqxxxO ( 435 residues). 
Sequence 0005 : GBxxxxl ( 434 residues). 
Sequence 0006 : SjCCxx2 (436  residues).
"LIJSTALW options used :
;ndgaps=l
;apdist=8
;apext=0.2
;apopen=10.0
igapresidues=GPSNDQERK
:tuple=l
natrix=gonnet
naxdiv=30
*utorder=aligned
>airgap=3
core=percent
opdiags=5
ype=PROTEIN
vindow=5
lesult files (text):
XUSTALW
jarn ier  param eters
2/11/2003 8:06 AM
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Network Protein Sequence Analysis
NPS@, is the IBCP contribution to PBIL in Lyon, France
[JJOME] [NPS@,1 rSRSI fHELPl fREFERENCESl [NEWS] [MPSA1 IANTHEPROT1 IGcno3Dl
TPBIL1
Monday, October 7th 2002 : InterProScan is available (see new s)
Job SO PM  (ID: 6412) is running on NPS@ server (started on Tue Feb 11 09:08:30 CET 2003). 
Results will be shown below. Please w ait and don't go back.
l your publication cite :
PS@: Network Protein Sequence Analysis 
IBS 2000 March Vol. 25, No 3 [291]: 147-150 
ombet C., Blanchet C., Geourjon C. and Deleage G.
>OPM result for : SmCCxxO
a b s tra c t Geourjon, C. & Deléage, G., SOPM: a self-optimised method for protein secondary structure prediction., Protein 
ngineering (1994) 7, 157-164
; iew SOPM in: [MPSA (Mac. U NI X) , About.„1 [AnTheProt (P C ), Download...] fHELPl
10 20 30 40 50 60 70
I I I I I I I
TPANCTYEDAHGRWKFHIGDYQSKCPEKLNSKQSVVISLLYPDIAIDEFGNRGHWTLIYNQGFEVTINH
ee ■ :eeeeee ■ ;:eeeeee‘ “ tttttt eeeee tt eeeett
KWLVIFAYKSNGEFNCHKSMPMWTHDTLIRQWKCFVAEKIGVHDKFHINKLFGSKSFGRTLYHINPSFV 
eeeeeee tt hhhhhhhhhhhhht heehhhhet eeee thh
'KINAHQKSWRAEIYPELSKYTIDELRNRAGGVKSMVTRPSVLNRKTPSKELISLTGNLPLEFDWTSPPD 
hhhhhhhhhhhhhhhhhhhhhhhhhhhhtt heee hh _■ heee ■ eeeee : . 
SRSPVTPIRNQGICGSCYAFASAAALEARIRLVSNFSEQPILSPQAVVDCSPYSEGCNGGFPFLIAGKY 
ttt hhhhhhhhhhhhhhhhhhh _eee ttttt 1 eeeeettt
EDFGFVSENCDPYTGEDTGKCTVSKNCTRYYTADYSYIGGYYGATNEKLMQLELISNGPFPVGFEVYED 
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equence length : 435
;OPM :
Alpha helix (Hh) 84 is 19.31%
310 helix (Gg) : 0 is 0.00%
Pi helix (ID 0 is 0 . 00%
Beta bridge (Bb) 0 is 0.00%
Extended strand (Ee) 117 is 26.90%
Beta turn (Tt) 49 is 11.26%
Bend region (- ) 0 is 0.00%
Random coil ( ) 185 is 42.53%
Ambigous states (?) 0 is 0.00%
Other states 0 is 0.00%
2/11/2003 8:10 AM
arameters :
Window width : 17
Similarity threshold : 8
Number of states : 4
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